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Prologue 
 
 
This thesis consists of four different chapters. Each chapter is written in a full-
paper style. When data from a previous chapter has been used, it appears mentioned 
in the text.  All chapters share and differ in the approaches and the systems to which 
they are addressed. Two different traditional medicinal chemistry approaches, 
bioisosterism and conformational restriction, have provided novel ligands for two 
different systems, melatoninergic and cholinergic system. Preliminar studies on their 
pharmacological mechanism and potential as novel tools for neurodegenerative 
diseases have been initiated for some of them. Since each chapter contains its own 
introduction, specific approach, methodologies, results, discussion and conclusions, in 
the epilogue of this thesis work general concluding remarks are made in order to 
provide a general overview of the whole work. 
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Chapter 1 
 
Design, synthesis and pharmacological 
characterization of novel melatonin analogues 
based on the bioisosteric replacement of its  
N-acetyl moiety for azoles and retroamides 
 
Introduction 
Melatonin receptors MT1 and MT2 lack a crystalized structure that 
would permit the characterization of the tertiary structure of these G protein-
coupled receptors (GPCRs) and of the pattern of interactions undertaken with 
their ligands. The structural knowledge gained along the years emerges from 
homology models based on other crystalized transmembrane-receptors 
structure and site directed-mutagenesis studies. Unlike other GPCRs that lack 
a crystal structure, melatonergic receptors MT1 and MT2 have some additional 
limitations: lack of a reliable template to build the homologous constructs, and 
the elusive ligand-receptor interactions1,2. Rhodopsin and more recently 
aminergic GPCRs are the most common templates used in melatonin receptor 
homology modeling3. However, sequence alignments are rather poor, 
 4 
 
providing structural models whose reliability has still to be proven. The low 
identity of the sequences increases the degree of speculation, and the poor 
usefulness of these models for drug design purposes4. Additionally, the nature 
of the endogenous ligand limits the identification of important ligand-receptor 
interactions. Melatonin lacks a charged group at physiological pH that would 
facilitate the identification of ionic interactions, like in the case of its parent 
amino-compound, the neurotransmitter serotonin1. As abovementioned, 
mutagenesis studies have provided some insights into the putative binding 
mode of melatonin5. In the case of MT1 receptor three amino acids have been 
identified as key contacts for ligand binding Ser110, Ser114 and His1956,7. In 
the case of MT2 several amino acids were identified as important for molecular 
recognition: Asn175, Val204, Asn268, Leu272, Ala275, Val291, Leu295, Tyr298 
and Tyr1888,9. In the case of MT2, consistent with the physicochemical 
properties of the natural ligand, the number and the lipophilicity of the amino 
acids involved in melatonin binding suggest the presence of a network of 
contacts characterized by the lack of strong polar interactions. This structural 
feature complicates the identification of an unambiguous binding pose for 
melatonin or synthetic analogues. Therefore, till now, structure-based design 
has not been a suitable approach for the design of novel melatonin ligands.  
Ligand-based drug design has been widely exploited and has provided 
two marketed drugs: agomelatine (Valdoxan®) for major depression and 
ramelteon (Rozerem®) for sleeping disorders, and other ligands are in 
development stages10. Subtle and major changes on melatonin structure have 
provided a plethora of ligands, in many cases able to beat the picomolar 
affinity of melatonin for its receptors, and several pharmacophoric models 
have been proposed4,11,12. Among the different pharmacophores there is a 
wide consensus on the necessity of the oxygen of the methoxy group for 
agonists, attached to an aromatic or heteroaromatic core connected to the 
acetamido side chain. Suppression of the methoxy group generally leads to an 
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inversion of the activity profile, like the antagonist luzindole (figure 1). This 
methylether has also been bioisosterically replaced for bromine (1.1)13, and its 
oxygen employed as the anchoring point for the linker in MT1-selective dimers 
and related structures (1.2)14. With respect to the indole nucleus, there are 
numerous successful examples of scaffold hopping of the aromatic core that 
demonstrate that the hydrogen held in position N1 of melatonin is not 
necessary for melatonergic receptor recognition15,16. The exploitation of a 
putative lipophilic pocket close to the binding site of melatonin has also been a 
successful approach, especially in the development of nonselective and MT2-
selective ligands17. This approach has provided synthetic ligands like the 
antagonist luzindole or the radioligand 2-[125I]iodomelatonin, which have 
been key pharmacological tools in the understanding of the melatonergic 
system18–20. Both the replacement of the indole ring for other aromatic and 
more lipophilic heterocycles or carbocycles, and the exploitation of this 
putative non-polar cavity have proven to be successful approaches. 
Nevertheless its application represents an increase in the overall lipophilicity 
of the potential drug candidates, what can in turn bring associated certain 
limitations in their development in more advanced stages. A high lipophilicity 
translates into poor water solubility what limits the pharmacokinetic 
properties of the developmental molecule. A gain in lipophilicity generally 
leads also to an increase of the hydrophobic effect, a non-specific component 
of the binding thermodynamics21. This effect might in turn translate into off-
target binding and increased likeliness of adverse interactions like hERG 
inhibition or toxicity associated to its metabolism and/or accumulation22–24. 
Therefore, at early development stages it is more desirable to exploit the 
ligand-receptor specific polar interactions in order to optimize the specific 
intermolecular contacts that have a greater enthalpic contribution to the free 
energy of the binding (i.e. hydrogen bonds, multipolar interactions, cation-
π)21. Melatonin has good water solubility but limited oral bioavailability. 
Attempts to introduce polar groups on the indole ring or on the scaffold of 
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other melatonergic ligands invariably led to a decrease of receptor binding 
affinity25,26. 
 
Figure 1. Selected melatonergic ligands. 
 
In the case of the acetamido moiety, the design and synthesis of 
melatonergic ligands also tend to be very conservative maintaining this group 
unmodified, with the exception of few bioisosteric replacements and 
elongation of the acyl group27. Bioisosterism is a classic ligand-based drug 
design strategy founded on the assumption that distinct molecular structures 
can be recognized in a similar manner by biological systems regardless of their 
structural or physicochemical similarity28. That is, bioisosterism is not defined 
by structural or physicochemical features, but by the ability of the bioisostere 
to mimic the biochemical recognition in a certain biological context. The 
mimicry does not imply that identical properties are retained by the 
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bioisosteres, conversely they normally modulate the properties of the original 
pattern. This approach is commonly used in the practice of medicinal 
chemistry in the development of new drug candidates and pharmacological 
tools29–31. The structural and physicochemical changes present in bioisosteres 
can translate into changes in pharmacological and pharmacodynamic 
properties such as selectivity, metabolic stability, permeability, solubility, 
synthetic ease, etc. and also permit acquiring additional intellectual property. 
Modifications performed on the acetamido group of melatonin were 
discouraging since its replacement by other moieties generally led to loss in 
binding affinity and potency at MT1 and MT2. As abovementioned, there are 
few reported cases of bioisosterism applied to the carbonyl of acetamido 
group of melatonin maintaining the 5-methoxytryptamine skeleton intact. 
Fewer exist in which the whole moiety has been bioisosterically replaced 
(figure 2).  In 1998 Leclerc et al. synthesized a melatonin bioisostere in which 
the acetamido moiety was replaced by ethylurea (1.3). This compound proved 
to be a full melatonergic agonist in ovine pars tuberalis cells, showing a 
biphasic binding curve (pKi1, 11.50; pKi2, 7.92)27. Compound ML-23 is reported 
to be a melatonin antagonist able to displace 2-[125I]-iodomelatonin in prostate 
(IC50, 0.14 nM)32 that has been proposed for the treatment of Parkinson 
disease33. Another compound that is currently being studied for several 
disorders is NeuP11. In both NeuP11 and compound 1.4 the amine group is 
acylated with an unusual aromatic acid, maintaining good MT1 and MT2 
binding affinities34–36. More recently Rami et al. in 2013, described the use of 5-
membered ring heterocycles as bioisosteres of the acetamido group (1.5) and 
of the carbonyl group (1.6, 1.7) of agomelatine. The maintenance of the 
acetamido portion in melatonergic ligands is also justified by its relative 
metabolic stability; the main metabolic hotspots of melatonin are position 6 
and demethylation at position 5, being deacetylation a minor metabolic 
event38,39. 
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Cpd. MT1 Ki (nM) MT2 Ki (nM) 
NeuP1134 22 34 
1.434 13 7 
1.537 80 25 
1.637 34 12 
1.737 48 20 
 
Figure 2. Melatonin analogues in which the N-acetyl group has been totally or 
partially replaced and their reported binding affinities. 
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Approach 
Bioisosteric replacement of the acetamide could represent an 
interesting tool in the biostructural understanding of the not so well-known 
properties (size, shape, electronic distribution, lipophilicity) of the melatonin 
binding pocket where the acetamido portion is accommodated within the 
receptors. Herein, we have bioisosterically replaced the acetamido fragment of 
melatonin with a series of reversed amides and heteroaromatic azoles (figure 
3). We have included in this study the hallucinogenic natural occurring 
alkaloid N,N-dimethyl-5-methoxytryptamine (1.36) to evaluate how this 
serotonin analogue behaves within the orthosteric locus of melatonin 
receptors40. The bioisosterism of amides has been widely studied in the 
development of peptidomimetics, and its substitution for heterocycles is 
common41,42. In order to establish a structure-activity relationship study of 
different azolic bioisosteres we have utilized common and well established 
peptidic bond bioisosteres: oxazole, 1,2,4-oxadiazole and  1,3,4-oxadiazole43, as 
well as some other relatively acidic azoles bearing a hydrogen that could 
intervene in a captodative hydrogen bond: 1,3,4-oxadiazol-(thio)ones, 1,3,4-
triazol-(thio)ones and a 1,3,4-aminothiazole. The thermodynamic solubility at 
pH 7.4 of those compounds showing significant binding on melatonin 
receptors and representative of each family of compounds was determined 
and it was taken as an indirect evaluation of their hydrophilicity. For those 
azolic compounds bearing an acidic proton the solubility was also determined 
at different pH values in order to indirectly confirm their acidic character44. 
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Figure 3. Illustration of the different replacements of the acetamido moiety of 
melatonin carried out in this work. 
 
Chemistry 
Synthesis of retroamides and oxazoles 
Indoleamides 1.8 - 1.11, and were synthesized starting from the 
corresponding acids activated with carbonyldiimidazole (CDI) and 
propargylamine or allylamine (scheme 1). Subsequently propargyl amides 1.8 
and 1.9 underwent gold(III) catalyzed cycloisomerization affording the 
corresponding oxazoles 1.12 and 1.1345,46.  
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Scheme 1. Reagents and conditions.  (a) CDI, CH2Cl2, propargylamine or allylamine, rt; 
(b) AuCl3, DCM, N2, rt. 
 
According to the mechanism proposed by Yao et al., gold (III) 
coordinates the terminal alkyne that suffers the attack of the amide oxygen on 
its enol form to give the oxazole and thus, the catalyst is regenerated (scheme 
2)47. 
R N
H
O
AuCl3 O
NR
AuCl2
O
NR
Me
HCl AuCl3
R=
N
H
MeO
1.12
 
Scheme 2. Adapted mechanism from Yao et al.47 for the synthesis of 1.12. 
 
Ester 1.14 was obtained by acid catalyzed Fischer esterification from 2-
(5-methoxyindol-3-yl)acetic acid. Ester 1.15 was obtained via Michael addition 
of the electron-rich heteroaromatic 5-methoxyindole over ethylacrylate 
catalyzed by anhydrous zirconium (IV) chloride in good yield (scheme 3)48. 
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Scheme 3. Reagents and conditions. (c) H2SO4 (cat.), EtOH, reflux; (d) ethylacrylate, 
ZrCl4 (anh.), CH2Cl2, N2, rt. 
 
Synthesis of 1,2,4- and 1,3,4-oxadiazoles 
1,2,4-oxadiazoles 1.16 and 1.17 were prepared directly from the 
corresponding esters 1.14 and 1.15 by cyclocondensation with acetamidoxime 
in fair yields(scheme 4)49. To obtain 1,3,4-oxadiazole isomers, esters 1.14 and 
1.15 were subjected to microwave-promoted hydrazinolysis yielding 
hydrazides  1.18 and 1.19 in quantitative yields. The hydrazides were 
subjected to condensation with the corresponding orthoester in acidic medium 
to afford 1,3,4-oxadiazoles 1.20 - 1.22 (scheme 4).  
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Scheme 4. Reagents and conditions. (e) acetamidoxime, NaH, THF, mol. sieves, 80ºC; (f) 
hidrazine hydrate, 150°C (mw), 45 min; (g) orthoester, AcOH (cat.), 125°C (mw), 1h. 
 
The synthesis of 1,3,4-oxadiazoles from hydrazides and orthoesters 
was performed with acid catalysis, which increases the electrophilic potential 
of the orthoester favoring the attack of the nucleophilic hydrazide. The 
subsequent elimination of an alcohol molecule yields the corresponding 1,3,4-
oxadiazole. An adapted mechanism leading to 1.20 from 1.18 is shown in 
scheme 5. 
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Scheme 5. Proposed mechanism for the acid-catalysed cyclocondensation of 
hydrazides with ethylorthoacetate to form 1,3,4-oxadiazoles adapted to the 
preparation of 1.20.  
 
Synthesis of 4-alkyl-1,2,4-triazol-5-(thio)ones and 2-amino-1,3,4-thiadiazol  
Reaction of hydrazides 1.18 and 1.19 with methylisocyanate or 
ethylisothiocyanate afforded the corresponding acylsemicarbazides 1.23 and 
1.26, or acylthiosemicarbazides 1.27 and 1.28, that underwent microwave-
induced cyclocondensation in basic medium to give 4-methyl-1,2,4-triazol-5-
ones 1.25 and 1.26, and 4-ethyl-1,2,4-triazol-5-thiones 1.29 and 1.30 in good 
and very good yields, respectively (scheme 6). There are several reports in the 
literature employing different methods for the synthesis of 2-amino-1,3,4-
oxadiazoles and 2-amino-1,3,4-thiadiazoles from acylsemicarbazides and 
acylsemithiocarbazides. After different failed attempts with sulfuric acid50 and 
Pv-reagent43, only in the case of acylsemithiocarbazide 1.27 successful 
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cyclization to 2-amino-1,3,4-thiadiazole 1.31 was achieved with phosphorus 
oxychloride at room temperature in fair yield. 
 
Scheme 6. Reagents and conditions. (h) MeNCO, EtOH, rt; (i) NaOH (aq.), EtOH, 100ºC 
(mw), 15 min; (j) EtSCN, EtOH, rt; (k) POCl3, rt. 
 
Since two different azoles can be obtained from the same intermediate 
in different conditions, two mechanisms are proposed for the synthesis of 1.30 
and 1.31 from 1.27. In basic medium, a proton is cleaved from the 
acylsemithiocarbazide, and the formed anion is stabilized by resonance. Sulfur 
anion promotes the intramolecular attack of the imine nitrogen over the 
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carbonyl forming a triazolidin-thione that evolves to 1.30 by elimination of a 
water molecule (scheme 7A).  In the second case, phosphoryl oxychloride 
coordinates to the acetylsemithiocarbazide oxygen on its enol form. Direct 
attack of sulfur on its thioenol form gives 1.31 (scheme 7B). 
 
R=
N
H
MeO
1.27 POCl3 N
O H
N
H
N
S
Et
R
Cl2OP
N
O
N
H
N
Et
R
Cl2OP
SH
PO2Cl R S
NN
N
H
Et
1.31
B
-HCl -HCl
 
Scheme 7. Suggested mechanism for the cyclocondensation of 1.27 (A) in basic 
medium and (B) in acid medium (phosphorus oxychloride). 
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Synthesis of 1,3,4-oxadiazol-2-(thio)ones 
When microwave-heated in the presence carbonyldiimidazole and 
triethylamine hydrazides 1.18 and 1.19  afforded the corresponding 1,3,4-
oxadiazole-2-ones 1.32 and 1.33. In basic medium, with carbon disulfide, 1,3,4-
oxadiazole-2-thiones 1.34 and 1.35 were obtained. (scheme 8) 
 
Scheme 8. Reagents and conditions. (l) CDI, TEA, THF, 100ºC (mw), 10 min; (m) CS2, 
EtOH, KOH (aq.). 150ºC (mw), 10 min. 
 
NMR studies on the tautomerism of hydrogen-bearing azoles 
Compounds like 1.32 among others in this work can exist in two 
possible tautomeric forms as shown on figure 451. 
N
H
MeO
ON
N
O
N
H
MeO
ON
N
O
H
H
1.32
1
2
3
4
5
1'
2'
4'
6
6'
7'
in DMSO-d6
8'
7a'
keto tautomer enol tautomer  
Figure 4. Possible tautomers of 1.32. 
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The unequivocal attribution of proton signals of 1.32 was done with 
the 1H-NMR spectrum aided by the COSY correlations. The observed 1H-13C 
HSQC cross-peaks allowed the identification of all hydrogenated carbons. 1H-
13C HMBC spectrum permitted the characterization of the quaternary carbons 
and confirmed the assignation. In the 150-160 ppm field of the 13C spectrum, 
three quaternary carbons are found (figure 5). One matched to C-5’ of the 
indole and the other two to the azole ring. The HMBC correlation between H-
8’ and C-5’ (3.73 ppm, 153.25 ppm) allowed the identification of the indole 
carbon C-5’ (153.18 ppm). The HMBC correlation observed between H-6 and 
C-5 (3.96 ppm, 156.55 ppm) allows the assignation of C-5 (156.46 ppm), and 
consequently of C-2 (155.07 ppm). In the 1H-NMR, only two protons are found 
in the higher field: the indole H-1’ (10.89 ppm) and the azole hydrogen (12.08 
ppm). The correlation found on 1H-13C HMBC between the latter, not only 
with C-2 (12.11 ppm, 155.12 ppm), but also with C-5 (12.11 ppm, 156.55 ppm) 
allowed us to conclude that this hydrogen is in fact held over nitrogen the N3 
(H-3, 12.08 ppm) thus, permitting the unequivocal assignation of the 
compound (see experimental section), and confirming that the only tautomer 
observed in DMSO solution was the keto-form: the oxadiazolone (figure 4).  
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Figure 5. 1.32 selected observed 1H-13C HMBC correlations. 13C-NMR spectra of 1.32 in 
the vertical axis (f1, ppm) and 1H-NMR spectra in the horizontal axis (f2, ppm).  
 
This assignment was further confirmed in the 1H-15N HMBC 
correlation. Two secondary nitrogens are observed in the bidimensional 
spectrum, N-1’ (-244.60 ppm) and N-3 (-224.46 ppm), as they showed satellital 
signals around their corresponding hydrogens H-1’ (10.91 ppm, -244.60 ppm) 
and H-3 (12.10 ppm, -224.46 ppm). Moreover a correlation could be observed 
between H-2’ and N-1’ (7.27 ppm, -244.60 ppm). The correlation between H-3 
and N-4 (12.09 ppm - 437.65 ppm) allowed the identification of N-4, the 
tertiary nitrogen in the oxadiazolone ring, and confirmed the proposed 
structure (figure 6).  
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Figure 6. Observed 1H-15N HMBC correlations of 1.32. 15N-NMR spectra of 1.32 in the 
vertical axis (f1, ppm) and 1H-NMR spectra in the horizontal axis (f2, ppm). 
 
Since 1H-13C HMBC experiment was sufficient for the identification of 
the major tautomer in DMSO solution, this experiment was performed with all 
synthesized compounds in the oxadiazolone, oxadiazolthione and triazolone 
series. In all cases the keto-tautomer was the only species observed in DMSO-
d6.  
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In the particular case of 1.31 the COSY experiment was sufficient for 
the characterization of the 2-amino-1,3,4-thiadiazole ring. The protons held on 
C-2 (H-2, 3.17 ppm) couple with the one held on the nitrogen N-3 (H3, 7.39 
ppm) (figure 7).  
 
 
Figure 7. Observed COSY correlation between H2 and H3 of 1.31. 1H-NMR spectrum 
of 1.31 in the vertical axis (f1, ppm) and in the horizontal axis (f2, ppm). 
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Only these two examples are given to exemplify the characterization of 
these series of compounds. The 5-methoxyindole pattern was easily identified 
for all derivatives both in  1H-NMR and 13C-NMR spectra. The identification of 
the methylene or ethylene linker was straightforward in the lower field of 
both spectra. The 1H-13C HMBC correlation between the hydrogens of the 
linker and the quaternary carbons of the different azoles permitted their 
unequivocal assignation. 
 
 
Pharmacology 
Radioligand binding studies on melatonin receptors MT1 and MT2 
The binding affinities of the newly synthesized compounds are 
reported in table 1. Retroamides with unsaturated side chains showed the 
highest affinity of all families of compounds, with Kis in the nano and sub-
nanomolar range. The alkenyl or alkynyl substitution does not seem to 
significantly affect the potency of the compounds; conversely, the length of 
the spacer does. Ethylene spacer is preferred in both cases (1.9 and 1.11) and 
compound 1.11 displays only 3-fold lower binding affinity at MT2 receptors 
than melatonin  
Oxadiazole-bearing compounds affinity is clearly more favored by a 
methylene (1.16 and 1.20) than an ethylene spacer (1.17, 1.21). Removal of the 
methyl substituent in the case of 1,3,4-oxadiazoles slightly favors affinity 
(1.22). The isomery of the oxadiazole does not seem relevant in the case of 
methylene-oxadiazoles (1.16, 1.20). Oxazoles 1.12 and 1.13 do not seem to 
match the oxadiazole profile and show significantly lower binding affinities. 
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1,3,4-triazolones and –thiones are the most penalized derivatives 
together with oxazoles and 1,3,4-oxadiazolthiones. Only those bearing a 
methylene spacer (1.25 and 1.29) have an affinity constant <1 μM at the MT2 
subtype.  
1,3,4-Oxadiazolones and –thiones display the most dramatic drop in 
binding affinity. The 1,3,4-oxadiazolthione ring is clearly detrimental; only 
compound 1.34 shows some affinity for MT2. Conversely, the ethylene-1,3,4-
oxadiazolone 1.33 is the compound with the highest affinity for both MT1 and 
MT2 of all synthesized azolic compounds. 
The compound with the most marked selectivity profile together with 
rather good binding potency for the MT2 subtype is 2-amino-1,3,4-thiadiazole 
(1.31). Unfortunately the synthesis of other amino-azoles was not 
accomplished and a complete SAR study could not be done. Unexpectedly 
equipotent at MT2 is the dimethylamino derivative 1.36, but with a less 
marked selectivity profile (10-fold). 
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Table 1. Radioligand displacement binding studies at MT1 and MT2 receptors. (Ki 
,nM). 
 
Cpd. n R  MT1 MT2 
Ratio 
(MT1/MT2)a 
Mel. 2 
 
 0.091±0.005 0.15±0.07 0.6 
1.8 1 
 
 14±4 3.8±0.5 3.6 
1.9 2  5.0±0.9 1.0±0.6 5 
1.10 1 
 
 17±0.7 4.9±4 3.5 
1.11 2  2.5±0.2 0.45±0.08 5.5 
1.12 1 
 
 280±20 >10000 - 
1.13 2  >10000 498±11 - 
1.16 1 
 
 170±15 44±3 3.9 
1.17 2  >10000 >10000 - 
1.20 1 
 
 210±10 16±3 10 
1.21 2  709±10 190±8 3.6 
1.22 2 
 
 570±10 68±15 8.6 
 
a Ratio calculated only for compounds with Ki < 100 nM for either of the subtypes. 
 
 
 
 25 
 
Table 1.  (cont.) 
1.25 1 
 
 >10000 560±60 - 
1.26 2  >10000 >10000 - 
1.29 1 
 
 >10000 220±50 - 
1.30 2  >10000 >10000 - 
1.31 1 
 
 >10000 17±3 >500 
1.32 1 
 
 >10000 160±50 - 
1.33 2  35±1 4±0.5 10 
1.34 1 
 
 >10000 535±30 - 
1.35 2  >10000 530±50 - 
1.36 2 
 
 210±10 16±0.5 10 
a Ratio calculated only for compounds with Ki < 100 nM for either of the 
subtypes. 
 
Functional studies on melatonin receptors MT1 and MT2 
Only compounds showing significant affinity for either receptor were 
functionally characterized in the [35S]GTPS binding assay. Results are 
summarized in table 2. 
Retroamides resulted the most potent compounds. The length of the 
spacer determined the profile. Compounds 1.8 and 1.11 with the methylene 
spacer were partial agonists, whereas those bearing an ethylene, 1.9 and 1.11, 
resulted full agonists, but significantly less potent than melatonin. 
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The tested azole-containing compounds showed a very similar 
behavior. Weak partial agonist at the MT2, and little or no effect at the MT1. 
Only compounds 1.20 and 1.33 showed an EC50 in the 10-8 range. 
1.36 resulted nearly equipotent at both receptor subtypes but with 
higher efficacy at the MT1 receptor than at the MT2. 
 
Table 2. Functional studies at MT1 and MT2 of selected compounds 
 
   MT1 MT2 
Cpd. n R EC50 (nM) Emax EC50 (nM) Emax 
Mel. 2 
 
0.098 
±0.003 100% 
0.069 
±0.003 100% 
1.8 1 
 
289±13 67±8% 81±3 82±5% 
1.9 2 38±3 106±9% 3±0.3 99±9% 
1.10 1 
 
525±307 64±4% 132±70 70±8% 
1.11 2 204±54 92±2% 11±9 88±4% 
1.12 1 
 
- - 989±23 23±4% 
1.13 2 - - 503±5 32±1% 
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Table 2.  (cont.) 
1.16 1 
 
711±23 16±2% 295±13 48±2% 
1.17 2 - - - - 
1.20 1 
 
>10uM - 71±28 24±3% 
1.21 2 961±16 19±6% 881±23 32±4% 
1.22 2 
 
>10uM - 457±141 25±2% 
1.25 1 
 
- - >10uM - 
1.26 2 - - - - 
1.29 1 
 
- - >10uM - 
1.30 2 - - - - 
1.31 1 
 
- - 110±25 35±7% 
1.32 1 
 
>10uM - >10uM - 
1.33 2 326±30 26±4% 29±3 29±3% 
1.34 1 
 
>10uM - >10uM - 
1.35 2 - - 1096±316 32±9% 
1.36 2 
 
257±98 62±3% 112±110 28±3% 
 
 
Thermodynamic solubility studies 
The thermodynamic solubility of representatives of each family of 
azoles was determined in buffer at pH 7.4 (table 3). For comparison purposes 
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the solubility of agomelatine and melatonin at pH 7.4 were also determined. 
Melatonin was the most soluble compound at physiologic pH. No significant 
differences were found between 1,2,3-oxadiazole 1.16 and 1,3,4-oxadiazole 
1.20 at pH 7.4 showing a solubility similar to that of agomelatine. 
Additionally, for those compounds bearing acid azoles and 1.31, their 
solubility was also determined at pH 5.5 and pH 9.3 as an indirect estimation 
of their acid-basic properties (figure 8). The solubility of 1.33, 1.34, 1.24 and 
1.30 showed a clear dependence on the pH, peaking at basic pH. It is 
especially notable in the case of 1.33 and 1.34, what evidences the acidic nature 
of the compounds. The sulfur substitution in 1.35, compared to 1.33, improves 
the pH-dependent increase in solubility. Derivative 1.31 also showed a mild 
pH dependence of its solubility, higher at acidic pH, supporting its weak basic 
nature52. 
 
Table 3. Thermodynamic solubility of selected compounds. 
 Thermodynamic solubility (µM) 
Cpd. pH 5.5 pH 7.4 pH 9.3 
Melatonin nd 6640±25 nd 
Agomelatine nd 804±24 nd 
1.16 nd 1165±23 nd 
1.20 nd 970±8 nd 
1.26 860±13 1104±17 1408±30 
1.30 131±1 137±1 208±2 
1.31 1718±85 1417±77 1437±78 
1.33 1406±1 2100±20 7920±30 
1.34 907±5 3460±200 18660±40 
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Figure 8. Solubility of azole melatonergic ligands at different pH values.  
 
Discussion 
Inverted amides have already been reported as a class of melatonin 
receptor ligands, for example on the naphthalene scaffold of agomelatine, but 
not yet on the classical 5-methoxyindole scaffold27,53. Binding data obtained 
are consistent with literature ones; the two most potent compounds within the 
series are inverted amides with an ethylene spacer, 1.9 and 1.11. Both 
compounds retain good binding affinity, particularly for the MT2 subtype. 
This could be due to their ability to arrange their pharmacophoric groups in a 
way resembling that of melatonin in its bioactive conformation (figure 9)11,54. 
This hypothesis is also supported by their full agonistic properties. 
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Figure 9. Superposition of melatonin (yellow carbons) in its putative bioactive 
conformation11 and 1.11 (pink carbons). 
 
 Binding potency of azole derivatives more affected by the length of 
the spacer being the differences 10-fold or higher in the case of active 
compounds. The preferred spacer depends on the nature of the azole attached 
to it. In the case of the oxazoles the low affinity displayed does not allow to 
draw any conclusions even if the spacer seems to determine the preferred 
receptor subtype. In the case of 1,2,4- and 1,3,4-oxadiazole matching pairs the 
methylene spacer is clearly preferred (1.16-1.17, 1.20-1.21). Superposition of 
1.16 and 1.20 with the active bioconformation of melatonin reveals that the 
nitrogen atom of the oxadiazoles can be superposed on the amide oxygen of 
melatonin (figure 10). Following this hypothesis, the lack of affinity of oxazole 
1.12 could be attributed to the absence of the second nitrogen atom present in 
the oxadiazole ring. 
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Figure 10. 1.16 (green carbons) and 1.20 (gray carbons) superposed on melatonin 
(yellow carbons). 
 
Compound 1.22, the nor-isomer of 1.21 shows the same selectivity and 
potency as 1.20, whereas 1.21 is penalized in its binding to MT2. This penalty 
is probably attributable to steric clashes in the region where the amide of 
melatonin is accommodated. With the nitrogen closer to the ethylene spacer 
(nitrogen in position 4) mimicking the carbonyl group of melatonin, the 
methyl group attached to the heterocycle would point out beyond the methyl 
end of melatonin (figure 11).  
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Figure 11. 1.21 (gray carbons) superposed on melatonin (yellow carbons). 
 
With regard on the oxadiazole ring isomerism, the comparison 
between the isomer pairs 1.20-1.16 and 1.21-1.17, assuming that each pair 
would bind in a similar pose, demonstrates that the 1,3,4-oxadiazole ring is 
slightly preferred by the melatonergic system in terms of potency. The 
isomerism of the oxadiazole does not seem to make a difference in the 
selectivity; the same subtle MT2 preference was observed in the azolic 
compounds described by Rami et al37. The carbonyl group of melatonin is 
putatively involved in a hydrogen bond as acceptor; this is especially relevant 
in the case of the MT2 subtype. Moreover the NH group is not essential in this 
receptor subtype55,56. Therefore the contribution of the carbonyl to the binding 
to MT2 should be of great relevance. Assuming that an imine-like nitrogen 
within the oxadiazole ring substitutes for the carbonyl group of melatonin, the 
hydrogen bond donor properties of the heterocycle shall be of relevance for 
MT2 recognition. Previous studies on both oxadiazole isomers revealed that 
1,3,4-oxadiazole nitrogens calculated hydrogen bond acceptor properties are 
greater than those of 1,2,4-oxadiazoles43. Even if the contribution of this 
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calculated difference is limited it could explain the MT2 preference towards 
1,3,4-oxadiazoles.  
In the case of acidic azoles, the affinity constants of the compounds 
with a methylene linker 1.32, 1.34, 1.25, 1.29 are all within the 2·10-7 - 6·10-7 M 
range for the MT2 receptor, regardless of the azole or the bulk of the 
substituents in it. Conversely, their ethylene counterparts (1.35, 1.26, 1.30) 
show virtually no affinity at all for either receptor subtype, with the 
remarkable exception of 1.33 that turned out to be the most potent compound 
in the whole series of azoles. The 1,3,4-oxadiazolone ring of 1.33 can exist in 
two different tautomer forms (exemplified in figure 4 for 1.32). Even if its 
NMR-characterization in DMSO shows a single species, the keto form, the 
presence of an equilibrium in physiological medium cannot be excluded. 
Moreover, the acidic nature of the heterocycle further confirmed by its 
differential solubility at different pHs could also imply the existence of 
equilibrium with the conjugated base in aqueous media. Melatonin solubility 
is reported to be around 430 μM in water57. In our experiment the solubility of 
melatonin was found to reach the mM range (6.64 mM) in buffer solution at 
pH 7.4. The solubility of 1.33 at pH 7.4 is lower, but within the same 
concentration range as melatonin. The bioisosteric replacement of the N-acetyl 
group of melatonin for 1,3,4-oxadiazolone represents a lower drop (~3-fold) in 
solubility than the indole-naftalene scaffold hopping (8-fold) what suggest a 
comparable degree of hydrophilicity of the 1,3,4-oxadiazolone ring and the 
acetamide at physiological pH. It is not possible to determine the exact 
contribution of the combination of hydrophilicity, acidity and plausible 
tautomerism to the binding of the compound since it adds a great degree of 
complexity to the interpretation of putative interactions within an already 
elusive binding pocket. Nevertheless, superimposition of 1.33 to the putative 
bioactive conformation of melatonin suggests that the nitrogen of the 
heterocycle closer to the ethylene spacer (the nitrogen in position 4), can 
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mimic the carbonyl of the amide group of melatonin (figure 12). Compounds 
1.35, 1.26 and 1.30 could be superimposed to the structure of melatonin in a 
similar manner; nevertheless none of them display any affinity for either MT1 
or MT2. In the case of 1.34, the sulfur atom that replaces for the carbonyl-like 
oxygen of 1.33 not only represents an additional bulk in the molecule, but also 
the acidity and the putative tautomeric equilibrium in aqueous media could 
be affected, and in turn be responsible for its lack of affinity. The same applies 
for compounds 1.26 and 1.30, in which not only the nature of the azole is 
different, but also the substituent attached to it also represents a greater bulk 
more likely to be impeded by steric clashes within the receptor binding site.  
 
 
 
Figure 12. 1.33 (orange carbons) in its keto form superposed to melatonin (yellow 
carbons). 
 
The promising profile of the slightly basic compound 1.31 encouraged 
us to try to broaden up the family of amino-thiadiazoles and amino-
oxadiazoles, but unfortunately the synthetic approaches have failed with the 
exception of 1.31. This compound showed the highest selectivity towards the 
MT2 receptor of all compounds included in this work. Its binding affinity 
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constant for the MT2 is similar to that of methylene-oxadiazoles 1.20 and 1.16, 
with virtually no affinity for the MT1. This selectivity could be attributed to 
the ability of the MT2 receptor only to accommodate the ethylamino chain of 
1.31 within the binding pocket.  
Compound 1.36 shows a milder selectivity for the MT2 than 1.31. The 
pKa of its non-methoxylated analogue is 8.68, what translates into a 
protonated state at physiological pH58. Therefore 1.36 should be mostly on its 
protonated state upon binding to melatonin receptors.  MT1 and MT2 receptor 
models suggest the presence of a tyrosine residue (Tyr 298) on the 
transmembrane domain 7 that might be involved in a cation-π interaction with 
the protonated ending of the molecule17. The differential selectivity could be 
attributed to the ease of accommodating the bulky dimethylammonium 
group. The 2-[125I]iodomelatonin displacement of 1.36 together with other 
basic tryptamines were already tested in hamster brain membranes59. The 
ability of 1.36 to displace the radioligand from brain binding sites was found 
to be 134-fold less than melatonin, and comparable to that of bufotenin (N,N-
dimethyl-5-hydroxytryptamine) or 5-methoxytryptamine. In our case a similar 
decrease in affinity was found at the MT2 subtype (100-fold). Besides its well-
known agonistic properties at 5-HT receptors60,61, this methoxylated 
tryptamine is also able to partially activate both melatonin receptors, being 2-
fold more efficient at MT1. Provided the hypothermic effect elicited by 
melatonin62, this finding, arises question on whether the hypothermia 
observed in rats pretreated with a 5-HT2A antagonists, could be mediated not 
only via 5-HT1A, but also via melatonergic receptors40. 
In contrast to the differences found in the binding affinity of all tested 
compounds bearing a five-membered ring, their functional profile is markedly 
similar and appears unaffected by the nature of the azole employed to replace 
for the acetamido chain of melatonin.  Whilst the potency varies depending on 
the compound, they all retain the mild MT2 subtype preference, and are 
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partial agonists with an Emax that barely goes above the 30% relative to 
melatonin at either receptor subtype. This class of compounds, upon binding 
to MT2, presumably fit their heterocyclic substituent in the pocket where the 
amide of melatonin is placed as depicted above (exemplified for 1.20 and 1.33 
in figures 10 and 12). Nevertheless the relatively low binding affinity of these 
compounds suggests that either the accommodation of the azole ring in the 
region occupied by the acetyl group of melatonin is hampered by some steric 
clash, or that this accommodation is secondary to some alteration in the 
proper arrangement of the 5-methoxyindol-3-ylalkyl portion, possible 
impeding the conformational changes that lead to receptor activation, 
resulting in the observed partial agonism. 
 
Conclusions 
We have synthesized and characterized different retroamides, azoles, 
and the hallucinogenic alkaloid 5-methoxy-N,N-dimethyltryptamine at the 
melatonin receptors MT1 and MT2. This study allowed us to broaden up the 
spectrum of moieties with varying electronic configurations, molecular 
volume, and H-bond capability that can totally or partially replace for the N-
acetyl group of melatonin, especially at MT2 receptors. The most conservative 
approach, the retroamide replacement, has proven to be the best approach 
being all the synthesized analogues potent at either melatonin receptor 
subtype. In the case of oxadiazoles, both 1,3,4- and 1,2,4-isomers are able to 
substitute for the acetamide moiety, retaining the ability to bind the 
melatonergic receptors. Bigger differences within the series can be observed in 
the case of azoles able to intervene as hydrogen bond donors, being all its 
representatives devoid of significant affinity with the exception of 1.33 and 
1.31. Unfortunately the synthetic efforts employed to broaden up the amino-
(oxa/thia)diazole family failed, but its only member selectivity profile appears  
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promising. Derivative 1.33 represents a good starting point for further SAR 
studies that could help in the understanding of molecular recognition exerted 
by the melatonin receptors MT1 and MT2. 
In this work we have been very conservative in keeping the 5-
methoxyindole moiety so as to maintain the N-acetyl chain as the only source 
of structural diversity among the synthesized ligands, and the sole point of 
comparison to the natural ligand, melatonin. Additional melatonin-binding 
sites and receptors have been identified63. As abovementioned the polar 
nitrogen in position N1 can be suppressed without negatively-affecting the 
affinity of the ligands for the melatonergic receptors MT1 and MT2. 
Nevertheless, this hydrogen could potentially be essential in the recognition of 
melatonin by other systems not yet fully characterized but responsible for the 
pleiotropic actions of the pineal neurohormone. In this respect, the 
bioisosteres synthesized in this work could expand the scope of bioisosterism 
application to other not-so-well characterized systems.  
Our results highlight once more the importance of the acetamido 
moiety of melatonergic ligands in the activation of melatonin receptors, and 
opens the door for development of novel ligands with different 
pharmacological profiles by modulation of the interaction with the locus 
where the acetamido moiety of melatonin is accommodated in melatonin 
receptors. We have demonstrated how the replacement of the acetamido 
moiety for certain azoles can modulate the activation of the receptor yielding 
compounds with different pharmacological profiles. Integration of the 
acetamide bioisosteric groups developed in this work in other validated 
aromatic or heteroaromatic scaffolds could open up a plethora of possibilities 
in the development of new melatonergic ligands of MT1 and specially MT2 
receptors. 
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Experimental section 
Chemistry. General Methods. Reagents and solvents were purchased from 
common commercial suppliers and were used without further purification. 
Analytical thin-layer chromatography (TLC) was carried out using Merck 
silica gel 60 F254 plates, and the compounds were visualized under UV-light 
( = 254 or 365 nm) and/or stained with phosphomolybdic acid 10% wt. in 
ethanol. Automatized chromatographic separation was carried out in a 
IsoleraOne (Biotage) using different silica Si50 cartridges from Agilent 
Technologies. High-performance liquid chromatography was performed on a 
Waters analytical HPLC-MS (Alliance Watters 2690) equipped with a SunFire 
C18 4.6 x 50 mm column, a UV photodiode array detector ( = 214–274 nm) 
and cuadrupole mass spectrometer (Micromass ZQ). HPLC analyses were 
used to confirm the purity of all compounds (>95%) and were performed on 
Waters 6000 equipment, at a flow rate of 1.0 mL/min, with a UV photodiode 
array detector ( = 214–274 nm), and using a Delta Pak C18 5 µm, 300 Å 
column. The elution was performed in a gradient mixture of MeCN/water. 
Melting points (uncorrected) were determined in a MP70 apparatus (Mettler 
Toledo). 1H NMR and 13C NMR spectra were recorded in CDCl3 or DMSO-d6 
solutions using the following NMR spectrometers: Varian INOVA-300, Varian 
INOVA-400, Varian Mercury-400 or Varian Unity-500. Chemical shifts are 
reported in δ scale (ppm) relative to internal Me4Si. J values are given in hertz, 
and spin multiplicities are expressed as s (singlet), d (doublet), t (triplet), q 
(quartet), or m (multiplet). Mass spectra (MS) were obtained by electron spray 
ionization (ESI) in positive mode using a Hewlett-Packard MSD 1100 
spectrometer. Elemental analyses were carried out in a Perkin-Elmer 240C 
equipment in the Centro de Química Orgánica ‘Manuel Lora-Tamayo’ (CSIC) 
and the results are within ± 0.4% of the theoretical values.  
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Synthesis of amides. General procedure. 
The corresponding acid (1 mmol) is dissolved in dry acetonitrile (MeCN, 20 
mL).  Carbonyldiimidazole (CDI, 1.2 mmol) and a catalytic amount of 
dimethylaminopyridine (DMAP, 0.01 mmol) are then added. After stirring for 
2h at 50ºC, the corresponding unsaturated amine  is added to the solution. 
After stirring for 2 additional hours at room temperature (r.t.) the solvent is 
evaporated. The resulting crude is resuspended in HCl 1M (20 mL), and the 
suspension extracted with ethyl acetate (EtOAc, 3 x 20 mL). The combined 
organic layers were washed with NaOH 2M (3 x 20 mL), dried over 
anhydrous MgSO4, and concentrated in vacuo to yield the corresponding 
amide. 
 
N-propargyl-2-(5-methoxy-1H-indol-3-yl)-acetamide (1.8).  
According to the general procedure for the 
preparation of amides, from 2-(5-methoxy-1H-
indol-3-yl)acetic acid (200 mg, 1 mmol) and 
propargylamine (0.64 mL, 1 mmol), 1.8 (146 mg, 
61%) was obtained as a white solid of mp: 117 – 
118ºC. 1H NMR (300 MHz, CDCl3) δ 8.35 (s, 1H), 7.25 (d, J = 8.8 1H), 7.17 – 7.05 
(m, 2H), 6.85 (dd, J = 8.7, 2.5 Hz, 1H), 6.66 (s, 1H), 4.21 (s, 2H), 3.85 (s, 3H), 2.26 
(s, 3H). 13C NMR (75 MHz, CDCl3) δ 161.52, 155.48, 144.90, 133.81, 128.38, 
129.21, 124.04, 112.82, 112.72, 109.16, 106.68, 56.87, 28.43, 13.14. HRMS (ESI+): 
m/z calcd for C14H14N2O2 (M)+ 242.1055, found 242.1063. HPLC purity 100% 
(230 to 400 nm). 
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N-propargyl-3-(5-methoxy-1H-indol-3-yl)-propanamide (1.9).  
According to the general procedure for the 
preparation of amides, from 3-(5-methoxy-1H-
indol-3-yl)propanoic acid (192 mg, 1 mmol) and 
propargylamine (0.71 mL, 1.1 mmol), 1.9 (160 mg, 
65%) was obtained as a white solid of mp: 118 – 
119ºC. 1H NMR (300 MHz, DMSO) δ 10.57 (s, 1H), 8.29 (s, 1H), 7.18 (d, J = 8.7 
Hz, 1H), 7.02 (s, 1H), 6.97 (s, 1H), 6.68 (d, J = 8.6 Hz, 1H), 3.90 – 3.80 (m, 2H), 
3.74 (s, 3H), 3.09 – 3.07 (t, J = 2.7 Hz , 1H), 2.85 (t, J = 7.7 Hz, 2H), 2.42 (t, J = 6.8 
Hz, 2H). 13C NMR (75 MHz, Acetone-d6) δ 173.16, 155.26, 133.31, 129.32, 
124.06, 115.76, 113.29, 112.93, 101.79, 82.19, 72.44, 56.54, 37.93, 29.38, 22.53. 
HRMS (ESI+): m/z calcd for C15H16N2O2 (M)+ 256.1212, found 256.1202. HPLC 
purity 97% (230 to 400 nm). 
 
N-allyl-2-(5-methoxy-1H-indol-3-yl)acetamide (1.10).  
According to the general procedure for the 
preparation of amides, from 2-(5-methoxy-1H-
indol-3-yl)acetic acid (168 mg, 0.84 mmol) and 
allylamine (92 μL, 1.26 mmol), 1.10 (178 mg, 86%) 
was obtained as a yellow oil that crystalised upon standing.  Mp: 92 – 93ºC.  
1H NMR (300 MHz, DMSO) δ 10.71 – 10.66 (s, 1H), 8.05 – 7.97 (m, 1H), 7.24 – 
7.19 (d, J = 8.7 Hz, 1H), 7.14 – 7.12 (d, J = 2.2 Hz, 1H), 7.07 – 7.04 (d, J = 2.3 Hz, 
1H), 6.74 – 6.67 (dd, J = 8.7, 2.4 Hz, 1H), 5.85 – 5.70 (ddt, J = 17.1, 10.3, 5.2 Hz, 
1H), 5.12 – 5.05 (dd, J = 17.2, 1.8 Hz, 1H), 5.03 – 4.97 (dd, J = 10.3, 1.7 Hz, 1H), 
3.74 – 3.72 (s, 3H), 3.71 – 3.66 (m, 2H), 3.48 – 3.48 (s, 2H). 13C NMR (75 MHz, 
DMSO) δ 170.51, 152.96, 135.49, 131.21, 127.49, 124.42, 114.85, 111.90, 111.04, 
108.61, 100.53, 55.30, 40.90, 32.70.HRMS (ESI+): m/z calcd for C14H16N2O2 (M)+ 
244.1212, found 244.1202. HPLC purity 100% (230 to 400 nm). 
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N-allyl-3-(5-methoxy-1H-indol-3-yl)propanamide (1.11).  
 According to the general procedure for the 
preparation of amides, from 3-(5-methoxy-1H-
indol-3-yl)propanoic acid (80 mg, 0.36 mmol) 
and allylamine (40 μL, 0.54 mmol), 1.11 (81 
mg, 87%) was obtained as a brownish solid of mp: 173 – 174ºC. 1H NMR (300 
MHz, DMSO) δ 10.62 – 10.54 (s, 1H), 8.03 – 7.93 (t, J = 5.5 Hz, 1H), 7.22 – 7.16 
(d, J = 8.7 Hz, 1H), 7.05 – 7.01 (d, J = 2.3 Hz, 1H), 6.99 – 6.97 (d, J = 2.4 Hz, 1H), 
6.72 – 6.66 (dd, J = 8.7, 2.4 Hz, 1H), 5.83 – 5.69 (ddt, J = 17.2, 10.3, 5.2 Hz, 1H), 
5.11 – 4.98 (m, 2H), 3.76 – 3.74 (s, 3H), 3.71 – 3.65 (tt, J = 5.6, 1.7 Hz, 2H), 2.92 – 
2.83 (t, J = 7.7 Hz, 2H), 2.48 – 2.41 (t, J = 7.7 Hz, 2H). 13C NMR (75 MHz, 
DMSO) δ 172.08, 153.25, 135.87, 131.72, 127.66, 123.14, 115.30, 113.98, 112.25, 
111.34, 100.62, 55.72, 41.18, 36.48, 21.44. HRMS (ESI+): m/z calcd for C15H18N2O2 
(M)+ 258.1368, found 258.1370. HPLC purity 100% (230 to 400 nm). 
 
Synthesis of oxazoles. 
5-((5-methoxy-1H-indol-3-yl)methyl)-2-methyloxazole (1.12).  
To a solution of 1.8 (100 mg, 0.41 mmol) in 10 mL 
of dry dichloromethane was added 
gold(III) chloride (12 mg, 0.041 mmol). The 
resulting mixture was stirred at r.t. under  inert 
atmosphere for  18 h. After this time, triethylamine (TEA, 0.5 mL) was added 
and the reaction mixture was filtered over a short plug of silica gel eluting 
with EtOAc. The solvent was evaporated and the resulting oil 
chromatographed on silica (gradient Hexane: EtOAc) to afford 1.12 (18 mg, 
18%) as a coloured solid of mp: 106 – 108ºC. 1H NMR (300 MHz, CDCl3) δ 8.35 
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(s, 1H), 7.25 (d, J = 8.8 1H), 7.17 – 7.05 (m, 2H), 6.85 (dd, J = 8.7, 2.5 Hz, 1H), 
6.66 (s, 1H), 4.21 (s, 2H), 3.85 (s, 3H), 2.26 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 
161.52, 155.48, 144.90, 133.81, 128.38, 129.21, 124.04, 112.82, 112.72, 109.16, 
106.68, 56.87, 28.43, 13.14. HRMS (ESI+): m/z calcd for C14H14N2O2 (M)+ 
242.1055, found 242.1055. HPLC purity 100% (230 to 400 nm). 
 
5-(2-(5-methoxy-1H-indol-3-yl)ethyl)-2-methyloxazole (1.13).  
Starting from 1.9 (30 mg, 0.11 mmol), the compound 
was synthesized according to the procedure 
described for 1.8, and thus 1.13 (11 mg, 38%) 
obtained as a light brown solid of mp: 100 – 105ºC. 
1H NMR (300 MHz, CDCl3) δ 7.94 (s, 1H), 7.25 (d, J 
= 8.8 Hz, 1H), 7.03 (d, J = 2.3 Hz, 1H), 7.00 (s, 1H), 6.86 (dd, J = 8.8, 2.4 Hz, 1H), 
6.64 (s, 1H), 3.87 (s, 3H), 3.24 – 3.17 (m, 2H), 3.11 (ddd, J = 9.4, 6.1, 2.0 Hz, 2H) 
2.29 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 166.32, 155.90, 145.49, 131.08, 127.71, 
128.10, 123.63, 112.61, 111.72, 110.01, 105.79, 55.46, 28.28, 24.97, 12.43. HRMS 
(ESI+): m/z calcd for C15H16N2O2 (M)+ 256.1212, found 256.1209. HPLC purity 
95% (230 to 400 nm). 
 
Synthesis of esters. 
Ethyl 2-(5-methoxy-1H-indol-3-yl)acetate (1.14).  
To a solution of acid 2-(5-methoxy-1H-indol-3-yl)acetic 
acid (3.5 g, 17.07 mmol) in 50 mL of EtOH was added 25 
drops of concentrated sulfuric acid. The mixture was 
heated under reflux for 2 h, cooled to room 
temperature, neutralized with a solution of NaOH 2M, and evaporated in 
vacuo. The  residue was resuspended in water (40 mL) and extracted with 
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EtOAc (3 x 40 mL). Removal of the solvent under reduced pressure gave 1.14 
(3.42 mg, 86%) as a light yellow solid. 1H NMR (300 MHz, DMSO) δ 10.77 (s, 
1H), 7.23 (d, J = 8.7 Hz, 1H), 7.19 (d, J = 2.3 Hz, 1H), 6.98 (d, J = 2.4 Hz, 1H), 
6.72 (dd, J = 8.7, 2.4 Hz, 1H), 4.07 (q, J = 7.1 Hz, 2H), 3.74 (s, 3H), 3.68 (s, 2H), 
1.18 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, DMSO) δ 171.52, 153.06, 131.19, 
127.38, 124.61, 112.04, 111.19, 106.75, 100.27, 59.98, 55.26, 30.89, 14.14. HPLC-
MS (230 to 400 nm) 100% (m/z) [MH+] 234.44 
 
Ethyl 3-(5-methoxy-1H-indol-3-yl)propanoate (1.15). 
 5-methoxy-1H-indole (5.0 g, 34 mmol) was 
placed in a dry flask and dissolved in 
dichloromethane (DCM, 40 mL) and ethyl 
acrylate (21.7 mL, 0.2 mol) added. Finally 
anhydrous ZrCl4 (1.0 g, 4.29 mmol) is added to 
the solution. The mixture is kept stirring at r.t. for 18h, after which the catalyst 
is filtered off and the solvent and excess of ethyl acrylate are removed under 
vacuum and collected in a cold trap. The resulting crude was 
chromatographed on silica (gradient DCM: MeOH) to afford 1.15 (6.1 g, 71%) 
as a white pearly solid. 1H NMR (300 MHz, CDCl3) δ 7.88 (s, 1H), 7.24 (d, J = 
8.8 Hz, 1H), 7.04 (d, J = 2.3 Hz, 1H), 6.99 (s, 1H), 6.86 (dd, J = 8.8, 2.4 Hz, 1H), 
4.15 (q, J = 7.1 Hz, 2H), 3.87 (s, 3H), 3.07 (t, J = 7.7 Hz, 2H), 2.71 (t, J = 7.6 Hz, 
2H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 173.40, 153.93, 131.38, 
127.55, 122.12, 114.77, 112.22, 111.77, 100.56, 60.32, 55.92, 34.81, 20.60, 14.19. 
HPLC-MS (230 to 400 nm) 100% (m/z) [MH+] 248.06. 
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Synthesis of 1,2,4-Oxadiazoles 
5-((5-methoxy-1H-indol-3-yl)methyl)-3-methyl-1,2,4-oxadiazole (1.16).  
Acetamidoxime (95 mg, 1.3 mmol), 1.5 g of 
molecular sieves (3Å), and sodium hydride (61 mg, 
2.5 mmol) are suspended in anhydrous THF (4 mL) 
and stirred at 50º. After stirring for 2h, 1.14 (150 mg, 
0.64 mmol) is slowly added to the mixture dissolved in 2 mL of THF that is 
kept with gentle stirring for 18h. The mixture is then filtered and  the solids 
washed with EtOAc (10 mL). The filtrate is evaporated under vacuum and the 
crude obtained chromatographed on silica (gradient DCM: MeOH) to afford 
1.16 (87 mg, 56%) as a brownish solid of mp: 100 – 102ºC. 1H NMR (300 MHz, 
CDCl3) δ 8.01 (s, 1H), 7.30 – 7.23 (m, 1H), 7.20 (d, J = 2.6 Hz, 1H), 7.05 (d, J = 2.4 
Hz, 1H), 6.88 (dd, J = 8.8, 2.4 Hz, 1H), 4.31 (s, 2H), 3.86 (s, 3H), 2.37 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 178.23, 167.24, 154.38, 131.23, 127.15, 123.74, 112.89, 
112.06, 107.76, 100.33, 55.88, 23.26, 11.60. HRMS (ESI+): m/z calcd for 
C13H13N3O2 (M)+ 243.1017, found 243.1008. HPLC purity 100% (230 to 400 nm). 
 
5-(2-(5-methoxy-1H-indol-3-yl)ethyl)-3-methyl-1,2,4-oxadiazole (1.17).  
Starting from 1.15 (173 mg, 0.7 mmol), the 
compound was synthesized according to the 
procedure described for 1.16, and thus 1.17 (80 
mg, 45%) obtained as an off-white solid of mp: 75 
– 76ºC. 1H NMR (400 MHz, DMSO) δ 10.66 (s, 
1H), 7.21 (d, J = 8.7 Hz, 1H), 7.09 (d, J = 2.4 Hz, 1H), 6.99 (d, J = 2.4 Hz, 1H), 
6.71 (dd, J = 8.7, 2.4 Hz, 1H), 3.76 (s, 3H), 3.23 (t, J = 7.2 Hz, 2H), 3.12 (t, J = 7.4 
Hz, 2H), 2.30 (s, 3H). 13C NMR (101 MHz, DMSO) δ 180.04, 167.35, 153.71, 
131.95, 127.73, 123.90, 112.82, 112.73, 111.95, 100.54, 55.99, 27.40, 22.58, 11.80. 
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HRMS (ESI+): m/z calcd for C14H15N3O2 (M)+ 257.1164, found 257.1172. HPLC 
purity 100% (230 to 400 nm). 
 
Synthesis of hydrazides. 
2-(5-methoxy-1H-indol-3-yl)acetohydrazide (1.18). 
 A mixture of 1.14 (1.53 g, 6.5 mmol), and excess of 
hydrazine hydrate (5 mL) in EtOH (6 mL) was 
heated to 155°C for 45 min under microwave 
irradiation. After removing the solvent, the milky 
crude is resuspended in water (70 mL) and extracted with EtOAc (6 x 50 mL). 
The extracts were dried over anhydrous magnesium sulfate and solvent 
removed to give 1.18 (1.40 g, 98%) as a white solid. 1H NMR (300 MHz, 
DMSO) δ 10.71 – 10.62 (s, 1H), 9.12 – 9.05 (s, 1H), 7.23 – 7.17 (d, J = 8.7 Hz, 1H), 
7.14 – 7.08 (d, J = 2.3 Hz, 1H), 7.08 – 7.04 (d, J = 2.3 Hz, 1H), 6.73 – 6.64 (dd, J = 
8.7, 2.4 Hz, 1H), 4.19 – 4.15 (s, 2H), 3.75 – 3.73 (s, 3H), 3.40 – 3.38 (s, 2H). 13C 
NMR (75 MHz, DMSO) δ 170.13, 152.94, 131.16, 127.48, 124.31, 111.83, 110.92, 
108.41, 100.71, 55.35, 30.74. HPLC-MS (230 to 400 nm) 100% (m/z) [MH+] 
220.11.  
 
3-(5-methoxy-1H-indol-3-yl)propanehydrazide (1.19). 
 Starting from 1.15 (3.0 g, 12.1 mmol), the compound 
was synthesized according to the procedure 
described for 1.18, and thus 1.19 (2.8 g, 100%) was 
obtained as an off-white solid. 1H NMR (300 MHz, 
DMSO) δ 10.59 (s, 1H), 9.00 (s, 1H), 7.20 (d, J = 8.7 Hz, 1H), 7.01 (dd, J = 17.7, 
2.3 Hz, 1H), 6.70 (dd, J = 8.7, 2.4 Hz, 1H), 4.18 (s, 2H), 3.76 (s, 3H), 2.87 (t, J = 
 46 
 
8.1 Hz, 2H), 2.37 (t, J = 7.8 Hz, 2H). HPLC-MS (230 to 400 nm) 96% (m/z) [MH+] 
234.08. 
 
Synthesis of 1,3,4-Oxadiazoles. General procedure. 
The corresponding hydrazide (0.5 mmol) is suspended in an excess of the 
corresponding orthoester (1 mL) and a catalytic amount of acetic acid (1 
drop)is added. The mixture is heated in a microwave system for 1h at 125ºC. 
Then the excess of the orthoester is rotoevaporated and the crude 
chromatographed on silica (gradient DCM:MeOH) and thus the 
corresponding 1,3,4-oxadiazole was obtained. 
 
2-((5-methoxy-1H-indol-3-yl)methyl)-5-methyl-1,3,4-oxadiazole (1.20).  
According to the general procedure for the preparation of 
1,3,4-oxadiazoles, from 1.18 (100 mg, 0.45 mmol), triethyl 
orthoacetate (1 mL) and a catalytic amount of acetic acid, 
1.20 (71 mg, 64%) is obtained a brownish solid of mp: 139 – 
140ºC. 1H NMR (300 MHz, CDCl3) δ 8.33 (s, 1H), 7.25 (d, J = 
8.8 Hz, 1H), 7.14 (s, 1H), 7.06 (d, J = 2.2 Hz, 1H), 6.86 (dd, J = 8.8, 2.4 Hz, 1H), 
4.27 (s, 2H), 3.84 (s, 3H), 2.44 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 165.95, 
163.93, 154.25, 131.26, 127.15, 123.78, 112.75, 112.09, 107.86, 100.24, 55.85, 22.09, 
10.94. HRMS (ESI+): m/z calcd for C13H13N3O2 (M)+ 243.1008, found 243.1017. 
HPLC purity 100% (230 to 400 nm). 
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2-(2-(5-methoxy-1H-indol-3-yl)ethyl)-5-methyl-1,3,4-oxadiazole (1.21).  
According to the general procedure for the 
preparation of 1,3,4-oxadiazoles, from 1.19 (405 mg, 
1.74 mmol), triethyl orthoacetate (3.5 mL) and a 
catalytic amount of acetic acid 1.21 (257 mg, 57%) is 
obtained a brownish solid of mp: 156 – 157ºC. 1H 
NMR (300 MHz, CDCl3) δ 7.91 (s, 1H), 7.26 (d, J = 8.8 Hz, 1H), 7.03 (s, 1H), 6.99 
(d, J = 2.4 Hz, 1H), 6.87 (dd, J = 8.8, 2.4 Hz, 1H), 3.87 (s, 3H), 3.24 – 3.20  (m, J = 
4.7 Hz, 4H), 2.48 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 166.79, 163.64, 154.05, 
131.37, 127.39, 122.40, 113.78, 112.34, 111.95, 100.28, 55.93, 26.17, 22.34, 10.90. 
HRMS (ESI+): m/z calcd for C14H15N3O2 (M)+ 257.1164, found 257.1158. HPLC 
purity 100% (230 to 400 nm). 
 
2-(2-(5-methoxy-1H-indol-3-yl)ethyl)-1,3,4-oxadiazole (1.22).  
According to the general procedure for the preparation 
of 1,3,4-oxadiazoles, from 1.19 (120 mg, 0.5 mmol), 
trimethyl orthoformiate (1 mL) and a catalytic amount 
of acetic acid 1.22 (41 mg, 34%) is obtained an off-white 
solid of mp: 148 – 149ºC. 1H NMR (300 MHz, DMSO) δ 
9.73 (s, 1H), 8.40 (s, 1H), 7.18 (d, J = 8.8 Hz, 1H), 6.92 (d, J 
= 2.5 Hz, 1H), 6.87 (d, J = 2.5 Hz, 1H), 6.71 (dd, J = 8.7, 2.5 Hz, 1H), 3.76 (s, 3H), 
3.23 – 3.14 (m, 4H). 13C NMR (75 MHz, DMSO) δ 165.54, 152.51, 152.08, 130.55, 
126.06, 121.78, 111.40, 111.15, 110.63, 98.79, 54.71, 24.99, 21.28. HRMS (ESI+): 
m/z calcd for C13H13N3O2 (M)+ 243.1008, found 243.1014. HPLC purity 98% (230 
to 400 nm). 
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Acyl(thio)semicarbazides. General method. 
The corresponding hydrazide (1 mmol) is dissolved in EtOH (10 mL) and 
then, the corresponding isocyanate or isothiocyanate (1 mmol)  is added. The 
mixture is kept stirring until the reaction is finished, typically after 1h in the 
case of methylisocyanate. Longer times were needed in the case of 
ethylisothiocyanate. After the reaction time, solvent is removed and the 
resulting solid used as such in the next step. 
1-(2-(5-methoxy-1H-indol-3-yl)acetyl)-4-methylsemicarbazide (1.23).  
According to the general method for the 
preparation of acylsemicarbazides, from 1.18 (73 
mg, 0.33 mmol) and methylisocyanate (21 μL, 0.33 
mmol), after one hour stirring, 1.23 (91 mg, 99%) 
was obtained as a white solid. HPLC-MS (230 to 
400 nm) 97% (m/z) [MH+] 277.37 
 
1-(3-(5-methoxy-1H-indol-3-yl)propanoyl)-4-methylsemicarbazide (1.24).  
According to the general method for the 
preparation of acylsemicarbazides, from 1.19 
(230 mg, 0.98 mmol) and methylisocyanate (68 
μL, 1 mmol), after one hour stirring, 1.24 (290 
mg, 100%) was obtained as a white solid. HPLC-
MS (230 to 400 nm) 98% (m/z) [MH+] 291.40. 
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1-(2-(5-methoxy-1H-indol-3-yl)acetyl)-4-ethylsemithiocarbazide (1.27).  
According to the general method for the 
preparation of acylthiosemicarbazides, from 1.18 
(116 mg, 0.5 mmol) and ethylisothiocyanate (44 
μL, 0.5 mmol), after 18h stirring, 1.27 (150 mg, 
94%) was obtained as a white solid. HPLC-MS 
(230 to 400 nm) 99% (m/z) [MH+] 307.37. 
 
1-(3-(5-methoxy-1H-indol-3-yl)propanoyl)-4-ethylsemithiocarbazide (1.28).   
According to the general method for the 
preparation of acylthiosemicarbazides, from 1.19 
(506 mg, 2.17 mmol) and ethylisothiocyanate (190 
μL, 2.17 mmol), after 18h stirring, 1.28 (707 mg, 
100%) was obtained as a white solid. HPLC-MS 
(230 to 400 nm) 90% (m/z) [MH+] 321.26. 
 
 
Synthesis of 1,2,4-triazol-5-(thi)ones. General method. 
The corresponding acylsemicarbazide or acylsemithiocarbazide (1 mmol) is 
dissolved in EtOH (10 mL) and NaOH 2M (7 mL) is added. The mixture is 
heated under microwave irradiation at 100ºC for 15 min. The solvent is 
evaporated and the crude redisolved in water. The mixture is progressively 
acidified to pH 2 with conc. HCl, thus the corresponding triazole precipitates 
off the solution and is collected by filtration. When necessary, the precipitate 
was chromatographed in silica (gradient DCM:MeOH) for further purification. 
 
 50 
 
3-((5-methoxy-1H-indol-3-yl)methyl)-4-methyl-1H-1,2,4-triazol-5(4H)-one 
(1.25).  
According to the general method for the synthesis 
of 1,2,4-triazol-5-ones, from 1.23 (82 mg, 0.3 
mmol), 1.25 (58 mg, 75%) was obtained as a light 
orange  pearly solid mp: 218 – 219ºC. 1H NMR 
(300 MHz, DMSO) δ 11.41 (s, 1H), 10.82 (s, 1H), 7.25 (d, J = 8.8 Hz, 1H), 7.20 (d, 
J = 2.3 Hz, 1H), 7.01 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 8.8, 2.4 Hz, 1H), 3.95 (s, 
2H), 3.72 (s, 3H), 2.98 (s, 3H). 13C NMR (75 MHz, DMSO) δ 155.65, 153.43, 
147.20, 131.77, 127.50, 124.77, 112.51, 111.54, 107.40, 100.68, 55.65, 26.88, 22.86. 
HRMS (ESI+): m/z calcd for C13H14N4O2 (M)+ 258.1117, found 258.1113. HPLC 
purity 100% (230 to 400 nm). 
 
3-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-methyl-1H-1,2,4-triazol-5(4H)-one 
(1.26).  
According to the general method for the synthesis 
of 1,2,4-triazol-5-ones, from 1.26 (290 mg, 1 mmol) 
and after chromatographic purification on silica, 
1.26 (110 mg, 41%) was obtained as a white 
powder of mp 201 – 202 ºC. 1H NMR (500 MHz, 
DMSO) δ 11.38 (s, 1H), 10.67 (d, J = 3.0 Hz, 1H), 
7.22 (d, J = 8.7 Hz, 1H), 7.12 (d, J = 2.4 Hz, 1H), 6.94 (d, J = 2.4 Hz, 1H), 6.70 
(dd, J = 8.7, 2.4 Hz, 1H), 3.75 (s, 3H), 3.01 (s, 3H), 2.98 (t, 2H), 2.82 (t, 2H). 13C 
NMR (126 MHz, DMSO-d6) δ 155.65, 153.39, 148.13, 131.70, 127.66, 123.70, 
113.24, 112.45, 111.60, 100.26, 55.68, 26.75, 26.73, 21.74. HRMS (ESI⁺): Calcd. for 
C₁₄H₁₆N₄O₂ (M)+ 272.1283, found m/z 272.1273. HPLC purity 100% (230 to 400 
nm). 
 
N
H
O N
H
N
N O
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4-ethyl-3-((5-methoxy-1H-indol-3-yl)methyl)-1H-1,2,4-triazole-5(4H)-thione 
(1.29).  
According to the general method for the 
synthesis of 1,2,4-triazol-5-thiones, from 1.27 (40 
mg, 0.13 mmol), 1.29 (30 mg, 80%) was obtained 
as a shiny brownish solid of mp: 200 - 203 ºC. 1H 
NMR (300 MHz, DMSO) δ 13.51 (s, 1H), 10.88 (s, 
1H), 7.27 (d, J = 3.2 Hz, 1H), 7.25 (d, J = 3.2 Hz, 1H), 6.99 (d, J = 2.3 Hz, 1H), 
6.74 (dd, J = 8.8, 2.4 Hz, 1H), 4.16 (s, 2H), 3.90 (q, J = 7.0 Hz, 2H), 3.72 (s, 3H), 
0.94 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, DMSO) δ 166.63, 153.49, 151.61, 
131.74, 127.43, 125.08, 112.60, 111.58, 107.29, 100.64, 55.65, 38.62, 22.22, 13.23. 
HRMS (ESI+): m/z calcd for C14H16N4OS (M)+ 288.1045, found 288.1036. HPLC 
purity 100% (230 to 400 nm) 
 
4-ethyl-3-(2-(5-methoxy-1H-indol-3-yl)ethyl)-1H-1,2,4-triazole-5(4H)-thione 
(1.30).  
According to the general method for the 
synthesis of 1,2,4-triazol-5-thiones, from 1.28 (200 
mg, 0.62 mmol), and after chromatographic 
purification on silica 1.30 (140 mg, 84%) was 
obtained as a white powder of mp: 214 – 217ºC. 
1H NMR (500 MHz, DMSO) δ 13.52 (s, 1H,), 10.68 (d, J = 2.7 Hz, 1H), 7.22 (d, J 
= 8.7 Hz, 1H), 7.14 (d, J = 2.4 Hz, 1H), 6.96 (d, J = 2.4 Hz, 1H), 6.70 (dd, J = 8.7, 
2.4 Hz, 1H), 3.91 (q, J = 7.2 Hz, 2H), 3.75 (s, 3H), 3.06 – 3.02 (m, 2H), 3.02 – 2.97 
(m, 2H), 1.14 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 166.26, 153.42, 
152.45, 131.69, 127.60, 123.77, 113.04, 112.48, 111.66, 100.24,  55.69, 38.40, 26.15, 
22.05, 13.77. HRMS (ESI⁺): Calcd for C₁₅H₁₈N₄OS (M)+ 302.1201, found m/z 
302.1207. HPLCMS (230 to 400 nm) 98% (m/z) (M+) 303.28 
 52 
 
 
Synthesis of amino-1,3,4-thiadiazol 1.31.  
N-ethyl-5-((5-methoxy-1H-indol-3-yl)methyl)-1,3,4-thiadiazol-2-amine (1.31).  
POCl3 (1 mL) was added over 1.27 (92 mg, 0.3 
mmol) and the mixture kept stirring at r.t. for 
18h. After this time water (10 mL) was 
carefully added to the mixture and then 
basified at 0ºC to pH 9-10 with NaOH 2M. The 
mixture was extracted with EtOAc (3 x 20 mL), and the extracts dried over 
MgSO4. After evaporation of the solvent 1.31 (58 mg, 67%) was recovered as 
an off-white solid of mp: 136 – 139ºC. 1H NMR (500 MHz, DMSO) δ 10.79 (s, 
1H), 7.40 (t, J = 5.3 Hz, 1H), 7.23 (d, J = 8.7 Hz, 1H), 7.21 (d, J = 2.5 Hz, 1H), 6.94 
(d, J = 2.4 Hz, 1H), 6.72 (dd, J = 8.7, 2.4 Hz, 1H), 4.19 (s, 2H), 3.70 (s, 3H), 3.18 
(qd, J = 7.2, 5.3 Hz, 2H), 1.09 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 
168.98, 159.10, 153.54, 131.84, 127.39, 124.74, 112.63, 111.64, 110.96, 100.72, 
55.76, 39.63, 26.47, 14.74.  HRMS (ESI⁺): Calcd. for C₁₄H₁₆N₄OS (M)⁺ 288.1045, 
found m/z 288.1050. HPLC-MS (230 to 400 nm) 95% (m/z) [MH+] 289.40. 
 
Synthesis of 1,3,4-oxadiazol-2-(thio)ones 
5-((5-methoxy-1H-indol-3-yl)methyl)-1,3,4-oxadiazol-2(3H)-one (1.32).  
A mixture of 1.18 (86 mg, 0.4 mmol), CDI 
(76 mg, 0.47 mmol), TEA (0.11 mL, 0.8 
mmol) dissolved in THF is heated to 
100°C for 15 min. Solvent was 
evaporated and the residue is 
resuspended in a small amount of water (2 mL), basified to pH 12-13 with 
NaOH (conc.) and filtered.  The filtrate was collected and acidified with HCl 
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(conc.) and thus, the compound precipitates. The precipitate was filtered off to 
afford 1.32 (72 mg, 73%) as a white pearly solid of mp: 140 – 141ºC. 1H NMR 
(300 MHz, DMSO) δ 12.08 (s, 1H, N3), 10.89 (s, 1H, N1’), 7.26 (d, J = 6.1 Hz, 
1H, H7’), 7.24 (s, 1H, H2’), 7.00 (d, J = 2.3 Hz, 1H, H4’), 6.74 (dd, J = 8.8, 2.4 Hz, 
1H, H6’), 3.97 (s, 2H, H6’), 3.73 (s, 3H, H8’). 13C NMR (75 MHz, DMSO) δ 
156.46 (C5), 155.07 (C2), 153.18 (C5’), 131.24 (C7a’ ), 127.03 (C3a’), 124.78 (C2’), 
112.22 (C7’), 111.27 (C6’), 105.87 (C3’), 100.11 (C4’), 55.30 (C8’), 22.54 (C6). 
HRMS (ESI+): m/z calcd for C12H11N3O3 (M)+ 245.0800, found 246.0802. HPLC 
purity 100% (230 to 400 nm). 
 
5-(2-(5-methoxy-1H-indol-3-yl)ethyl)-1,3,4-oxadiazol-2(3H)-one (1.33).  
Starting from 1.19 (146 mg, 0.62 mmol), the 
compound was synthesized according to the 
procedure described for 1.32, and thus 1.33 (138 mg, 
86%) was obtained as an off-white solid of mp: 140 – 
144ºC. 1H NMR (400 MHz, DMSO) δ 12.00 (s, 1H), 
10.66 (s, 1H), 7.20 (d, J = 8.7 Hz, 1H), 7.09 (d, J = 2.3 
Hz, 1H), 6.95 (d, J = 2.4 Hz, 1H), 6.69 (dd, J = 8.7, 2.4 Hz, 1H), 3.74 (s, 3H), 2.97 
(t, J = 7.4 Hz, 2H), 2.85 (t, J = 7.7 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 157.65, 
155.77, 153.70, 131.92, 127.77, 124.00, 112.76, 112.72, 111.93, 100.36, 55.92, 27.55, 
21.54. HRMS (ESI+): m/z calcd for C13H13N3O3 (M)+ 259.0957, found 259.0966. 
HPLC purity 100% (230 to 400 nm). 
 
5-((5-methoxy-1H-indol-3-yl)methyl)-1,3,4-oxadiazole-2(3H)-thione (1.34).  
A mixture of 1.18 (83 mg, 0.37 mmol), KOH (70 
mg, 1.24 mmol) and an excess of carbon disulfide 
(1.35 mL, 38 mmol) in EtOH was heated to 155°C 
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for 10 min under microwave irradiation.  Solvent and carbon disulfide excess 
was evaporated under reduced pressure and the residue resuspended in 
water. The solution was acidified with conc. HCl and 1.34 (91 mg, 95%) 
precipitated as a yellow solid that was filtered off. Mp: 171 – 173ºC.  1H NMR 
(300 MHz, DMSO) δ 14.37 – 14.29 (s, 1H), 10.95 – 10.88 (s, 1H), 7.29 – 7.24 (d, J 
= 11.8 Hz, 1H), 7,28—7.27 (s, 1H), 7.02 – 6.99 (d, J = 2.3 Hz, 1H), 6.77 – 6.72 (dd, 
J = 8.8, 2.4 Hz, 1H), 4.18 – 4.15 (s, 2H), 3.74 – 3.72 (s, 3H). 13C NMR (75 MHz, 
DMSO) δ 177.73, 163.44, 153.25, 131.23, 126.94, 125.01, 112.28, 111.38, 105.39, 
100.08, 55.31, 21.74. HRMS (ESI+): m/z calcd for C12H11N3O2S (M)+ 261.0572, 
found 261.0577. HPLC purity 100% (230 to 400 nm). 
 
5-(2-(5-methoxy-1H-indol-3-yl)ethyl)-1,3,4-oxadiazole-2(3H)-thione (1.35).  
Starting from 1.19 (116 mg, 0.5 mmol), the compound 
was synthesized according to the procedure 
described for 1.34, and thus 1.35 (56 mg, 41%) was 
obtained as an off-white solid of mp: 99 – 101ºC. 1H 
NMR (400 MHz, DMSO) δ 14.29 (s, 1H), 10.70 (d, J = 
2.6 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 7.11 (d, J = 2.4 
Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 6.70 (dd, J = 8.7, 2.4 Hz, 1H), 3.76 (s, 3H), 3.10 
– 2.97 (m, 4H). 13C NMR (101 MHz, DMSO) δ 177.69, 164.05, 153.08, 131.25, 
127.06, 123.38, 112.12, 111.84, 111.37, 99.70, 55.31, 26.14, 21.05. HRMS (ESI+): 
m/z calcd for C13H13N3O2S (M)+ 275.0728, found 275.0726. HPLC purity 95% 
(230 to 400 nm). 
 
Assays for MT1 and MT2 receptor subtypes. 2-[125I]Iodomelatonin (2200 
Ci/mmol) was purchased from NEN (Boston, MA). Other drugs and 
chemicals were purchased from Sigma–Aldrich (Saint Quentin, France).  
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2-[125I]Iodomelatonin binding assay conditions were essentially as previously 
described64.  Briefly, binding was initiated by addition of membrane 
preparations from transfected CHO cells stably expressing the human 
melatonin MT1 or MT2 diluted in binding buffer (50 mM Tris–HCl buffer, pH 
7.4, containing 5 mM MgCl2) to 2-[125I]iodomelatonin (20 pM for MT1 and MT2 
receptors expressed in CHO cells) and the tested drug. Non-specific binding 
was defined in the presence of 1 µM melatonin. After 120 min incubation at 37 
°C, reaction was stopped by rapid filtration through GF/B filters presoaked in 
0.5% (v/v) polyethylenimine. Filters were washed three times with 1 mL of 
ice-cold 50 mM Tris–HCl buffer, pH 7.4.  
Data from the dose–response curves (seven concentrations in duplicate) were 
analysed using the program PRISM (Graph Pad Software Inc., San Diego, CA) 
to yield IC50 (inhibitory concentration 50). Results are expressed as Ki with Ki 
= IC50/1 + ([L]/KD), where [L] is the concentration of radioligand used in the 
assay and KD, the dissociation constant of the radioligand characterizing the 
membrane preparation. 
[35S]GTPS binding assay was performed according to published 
methodology64. Briefly, membranes from transfected CHO cells expressing 
MT1 and MT2 receptor subtypes and compounds were diluted in binding 
buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 3 µM GDP, 3 mM MgCl2, and 20 
µg/mL saponin). Incubation was started by the addition of 0.2 nM [35S]GTPS 
to membranes (20 µg/mL) and drugs, and further followed for 1 h at room 
temperature. Reaction was stopped by rapid filtration through GF/B filters 
followed by three successive washes with ice-cold buffer. 
Usual levels of [35S]GTPS binding (expressed in dpm) were for CHO-MT2 
membranes: 2000 for basal activity, 8000 in the presence of melatonin 1 µM 
and 180 in the presence of GTPS 10 µM which defined the non-specific 
binding. Data from the dose–response curves (seven concentrations in 
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duplicate) were analyzed by using the program PRISM (Graph Pad Software 
Inc., San Diego, CA) to yield EC50, with EC50 the effective concentration 50%) 
and Emax (maximal effect) for agonists. 
 
Thermodinamic solubility determination. 
UV maximums are extracted from recorded UV-spectrum of the compounds 
in the 270-400 nm range. A 10 mM stock solution of the corresponding 
compound in DMSO is prepared. A calibration line is built by measuring the 
absorbance at the corresponding maximum wavelength of sequential dilutions 
of the stock solution in buffer-MeCN (80:20) mixture in a 96-well plate 
containing 200 µL per point. The buffers employed are: pH 1.2 KCl 45 mM 
buffer, pH 7.4 phosphate 45 mM buffer and pH 9.4 NH4Cl buffer. In order to 
validate the calibration line, and exclude interferences due to the presence of 
5% DMSO, a quality control standard of known concentrations is employed. 
The calibration line is accepted if R2>0.990, the residual value of each point 
<15% and the relative error of the quality control standard <15%. The 
solubility determination is made as follows: 200 µL of buffer solution are 
added over approximately 1 mg accurately weighted of the corresponding 
compound in order to achieve a saturated solution. The mixture is kept at 
room temperature in an orbital stirrer at 320 rpm for 24h and then centrifuged 
at 135 rpm for 15 min. 160 µL of the supernatant are transferred to a 96-well 
plate and diluted with 40 µL of a buffer-MeCN (80:20) mixture. The solubility 
is determinated by extrapolation to the calibration line within the linearity 
range and expressed in mol/L. The expermients were run in triplicates.  
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Superimposition computational studies. 
 Compounds were built with Maestro 9.265 and subjected to an energy 
minimization procedure using the OPLS200566 force field to a convergence 
threshold of 0.05 kJ mol-1 Å-1. Compounds were superposed to the putative 
bioactive conformation of melatonin11 having torsion angles: τ1 (C3a–C3–Cβ–
Cα)  -90°; τ2( C3–Cβ–Cα–N)  180°; τ3( Cβ–Cα–N–CO)  180°. Superposed 
atoms are: methoxy oxygens, C3a, C5 and C7 of the benzene ring of indoles 
and the amide oxygen of melatonin superposed to the N atom within the five-
membered cycles. 
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Chapter 2 
 
Neurogenesis   studies   on   melatonin 
analogues 
 
Introduction 
The central nervous system of adult mammals has long been 
considered a complex static structure unable to undergo any regenerative 
process to refurbish dead nodes. This dogma was challenged by Altman in the 
1960s and neuron self-renewal has been demonstrated ever since in many 
species including primates and humans1–3. The neurogenic process implies the 
proliferation of new cells, migration, cell differentiation, and integration 
within the neural circuitry. In lower vertebrates the neurogenic process is 
widely extended in the central nervous system, whereas in animals with 
higher brain complexity is restricted to a few regions4. In adult human brain 
neurogenesis is vestigial; only two brain region retain a significant continuous 
neurogenic turnover: the subventricular zone (SVZ) lining the lateral 
ventricles; and the subgranular zone (SGZ) which is a part of the dentate 
gyrus of hippocampus.  
Hippocampus belongs to the limbic system and plays important roles 
in the consolidation of information from short-term memory to long-term 
memory and spatial navigation. Although the relevance of neurogenesis in 
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adult brain hippocampus remains to be determined, it seems to play a role in 
certain learning processes and memory consolidation5. Neurogenesis in the 
dentate gyrus is dynamic and responds to physiological, pathological and 
pharmacological stimuli6. Ageing, for instance, is associated with an 
exponential decrease in hippocampal neurogenesis5. Provided the decline in 
cell proliferation occurring in elder brain, the controlled stimulation of the 
endogenous neural stem cells from adult brain neurogenic niches might be 
able to counteract the memory and cognitive deterioration subsequent to age-
related neurodegenerative diseases7,8. 
Melatonin plasma levels decline with age in a similar manner as the 
neurogenic rate does9. Whether both phenomena are related or not is still 
unclear, albeit melatonin has been reported to positively modulate 
neurogenesis10. Exogenous administration of melatonin increases precursor 
cell survival in hippocampus of mice, and promotes neuronal differentiation 
of neural precursors in vitro11. Its chronic administration increases the cell 
proliferation rate and delays the decline of the neurogenesis in the 
hippocampus of adult mice12. These data are in agreement with previous 
observations in different mice strains that concluded that exogenous 
melatonin administration does ameliorate the process of ageing, including a 
much better cognitive performance, and delays the onset of poor health states 
prior to death13. The term ‘methuselah syndrome’ was appropriately coined to 
summarize the health-preserving properties of the pineal neurohormone. 
Exploitation of these properties opens up a vast therapeutic potential in the 
development of melatonin-related cognitive-preserving agents and possibly in 
the field of regenerative medicine. Thus, we have explored the neurogenic 
potential of a selection of novel melatonin analogues, obtained in the previous 
chapter, using in vitro and in vivo experiments. The melatonergic agonists 1.9, 
1.21, 1.31, 1.33, and 1.34 were selected (figure 1), covering different 
melatonergic profiles and structural features. 
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Figure 1. Compounds subject of study. 
 
Results 
In vitro neural differentiation and maturation in the presence of different 
melatonin analogues. 
All selected melatonergic agonists (1.9, 1.21, 1.31, 1.33, and 1.34), 
together with melatonin, were screened at 10 μM in primary neural stem cells, 
which were obtained from the SGZ of the dentate gyrus of the hippocampus 
of adult Wistar rats and induced to proliferate as described in the 
experimental section. Their neurogenic potential of each compound was 
determined by direct observation of the expression of two immunostained 
markers, namely human β-tubulin III (Tuj1) and microtubule-associated 
protein 2 (MAP2). The nucleus of the cells was identified by staining with 4',6‐
diamidino-2-phenylindole (DAPI). Tuj1 is a structural protein expressed in 
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neurons of the peripheral and central nervous system (PNS, CNS) that 
contributes to microtubule stability in neuronal cell bodies and axons and 
plays a role in axonal transport14. Tuj1 is expressed in neural stem cells in the 
early stages of their differentiation to neurons. MAP2 is a neuronal 
cytoskeletal protein involved in microtubule stabilization responsible for the 
maintenance of neuronal morphology which expression is essential in early 
stages of neurogenesis15. Chronologically, Tuj1 is expressed at earlier stages of 
neural differentiation than MAP2. The expression of MAP2 in neurospheres 
indicates consolidated neuronal stage (figure 2)16. After incubation of SVZ 
neurospheres with the compounds for 7 days in culture, they were allowed to 
differentiate for 48h and finally, after immunostaining, the expression of Tuj1 
and MAP2 was visualized by confocal microscopy (figures 3 and 4 
respectively). 
 
 
Figure 2. Sequencial phases in neuronal development in vivo, along with specific 
markers employed in this work to determine neural cell life-cycle phase. Adapted 
from Kempermann et al. 200417. 
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Figure 3. SVZ-derived neurospheres expression of Tuj1 
(green) in the presence of different compounds. DAPI (blue) 
was used as a nuclear marker. Scale bar, 200 µm 
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Figure 4. Expression of MAP2 (red) in cultured SVZ neurospheres 
in the presence of different compounds. DAPI (blue) was used as a 
nuclear marker. Scale bar, 200 µm 
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Figures 3 and 4 shows the neurogenic effects of new melatonin-based 
compounds and melatonin on neural stem cell cultures, compared with the 
effect of vehicle (basal). As expected, melatonin induced both early 
neurogenesis and cell maturation. All new melatonergic agonists (1.9, 1.21, 
1.34, 1.33, and 1.31) were able to express Tuj1, in most cases better than 
melatonin, showing also the typical neuronal morphology. Greater differences 
could be observed in the expression of MAP2. From a qualitative point of 
view, the 1,3,4-oxadiazole derivatives 1.21, 1.34, 1.33 appear to be the most 
potent compounds at stimulating cell maturation, even more than melatonin 
itself. However, the propargylic intermediate 1.9 and the 1,3,4-thiadiazole 1.31 
did not promote the MAP2 expression. 
Compound 1.21 is qualitatively the most potent compound at 
stimulating the neurogenic response in vitro and 1.33 the most potent 
melatonin agonist able to promote the expression of both Tuj1 and MAP2 
(table 1). Both compounds were thus selected for studying their neurogenic 
effect in the presence of the non-selective melatonergic antagonist luzindole in 
vitro. Neurospheres from rat hippocampus were incubated with 1.21, 1.33 or 
melatonin in the presence and absence of luzindole to evaluate the implication 
of melatonin receptors MT1 and MT2 in the expression of the neurogenic 
markers (figure 5 and 6). Luzindole appeared to reduce the basal expression of 
Tuj1 compared to the compound-free control. In all three cases luzindole was 
able to block the expression of both Tuj1 and MAP2 promoted by the tested 
compounds. The blockade was complete in the case of 1.33, but in the case of 
melatonin and 1.21, luzindole was not able to fully block the expression of 
Tuj1 and MAP2, and residual expression of both markers could be observed.  
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Table 1. Summarized affinity and intrinsic activity data at melatonin receptors. Affinity measured as radioligand displacement of 2-
[125I]iodomelatonin. Intrinsic activity measured as binding of [35S]GTPγS and referenced to melatonin.  All values are accompanied by the 
SEM. Qualitative central nervous system (CNS) permeability predicted by the parallel artificial membrane permeation assay (PAMPA).  
 
 MT1  MT2  PAMPA 
CNS 
perm. 
Cpd. Ki (nM) EC50 (nM) Emax(%)  Ki (nM) EC50 (nM) Emax(%)  
Mel.a 0.091±0.005 0.098±0.003 100  0.15±0.07 0.069±0.003 100  nd 
1.9 5.0±0.9 38±3 106±9  1.0±0.6 3±0.3 99±9  + 
1.21 709±10 961±16 19±6  190±8 881±23 32±4  + 
1.31 >10000 - -  17±3 110±25 35±7  - 
1.33 35±1 326±30 26±4  4±0.5 29±3 29±3  - 
1.34 >10000 - -  535±30 >10000 agonistb  - 
a Melatonin. b A full EC50 curve could not be obtained nevertheless agonistic response was observed 
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Figure 5. Effect of luzindole on the expression of Tuj1 (green) promoted by melatonin, 1.21 and 1.33 in hippocampal-derived neurospheres. 
DAPI (blue) was used as a nuclear marker. Scale bar, 200 µm.   
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Figure 6. Effect of luzindole on the expression of  MAP2 (red) promoted by melatonin, 1.21 and 1.33 in hippocampal-derived neurospheres. 
DAPI (blue) was used as a nuclear marker. Scale bar, 200 µm.
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According to the brain-blood barrier model PAMPA prediction 
(parallel artificial membrane permeability assay), most of the heterocyclic 
melatonin are unable to cross the blood-brain barrier via passive diffusion 
(table 1). This non-cellular assay consists of an artificial membrane that 
resembles the blood-brain barrier thus permitting a facile high-throughput 
evaluation of compounds in a simplified yet validated model.  Based on the 
results obtained in the studies performed in neurospheres and its predicted 
permeability, compound 1.21 was selected for further studies. A dose-
response experiment was carried out with compound 1.21 (figure 7). 1.21 
probed to be able to stimulate the expression of Tuj1 and MAP2 at all tested 
concentrations in SVZ-derived neurospheres. Nevertheless at 100 nM the 
expression of both markers seems mildly diminished compared to 1.21 1 μM. 
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Figure 7. Dose-response effect on the expression of Tuj1 (green) and MAP2 (red) in cultured SVZ-derived neurospheres. DAPI (blue) was 
used as a nuclear marker. Scale bar, 200 µm. 
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In vivo neural differentiation and maturation after chronic treatment with 
1.21 
1.21 is qualitatively the most potent compound at stimulating the 
expression of the neurogenic markers Tuj1 and MAP2, apparently even more 
than melatonin. Being 1.21 also predicted to permeate through the blood-brain 
barrier according to the PAMPA-BBB model (table 1) it was chosen to be 
evaluated in an in vivo neurogenesis model. Control wild-type C57BL/6 male 
mice were administered BrdU (50 mg/kg) and treated mice were 
administered BrdU (50 mg/kg) and 1.21 (500µg/kg) intraperitoneally for 7 
days. Cell proliferation was measured as incorporation of BrdU into the DNA, 
and the identification of neural precursor cells was measured as expression of 
doublecortin (DCX), a microtubule-associated protein expressed by immature 
neurons which expression nearly coincides in the same neuronal development 
stage with Tuj1 (figure 2). The immunostaining of the hippocampus sections 
revealed that the administration of 1.21 slightly reduces the number of BrdU 
positive cells in the dentate gyrus of hippocampus (figure 8A). Conversely 
BrdU/DCX doubled marked nuclei augmented to nearly twice in the treated 
group compared to control mice (p<0.05, Fig. 8B). These results indicate that 7-
days administration of 1.21 increases the neural differentiation of progenitor 
cells without significantly affecting the proliferation rate.  
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Figure 8.  Hippocampal neural precursor cell proliferation and differentiation in vivo. 
(A) Number of BrdU+ in mice hippocampus in 1.21-treated group and control (B) 
Number of BrdU+/DCX+ in hippocampus in 1.21-treated group and control and 
representative microimages. 
 
The ability of the new developing neurons to reach the mature state 
was measured as NeuN expression, a neuronal nuclear antigen typically 
expressed by neurons that downregulate the expression of DCX when they 
reach the mature state (figure 2)18. An identical protocol as in the case of DCX 
expression determination was followed in terms of dosage and days of 
treatment. Rats were sacrificed 21 days after the treatment was finished in 
order to let newborn neurons reach maturity. No significant differences were 
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found in the incorporation of BrdU between the treated and the control group 
(figure 9A). In the previous assay the replication rate of progenitor cells 
slightly decreased right after treatment was finished. These results show that 
after sometime the replication rate is recovered. A 6-fold increase in the 
number of BrdU/NeuN double marked neurons was observed in the treated 
group (figure 9B), which indicates that the expression of NeuN is greatly 
enhanced in newborn mature neurons. A virtually unaffected proliferation 
rate, followed by a net increase in the number of newborn mature neurons, 
indicated that chronic administration of 1.21 potently enhances hippocampal 
neurogenesis in mice.  
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Figure 9. Hippocampal neurogenesis in vivo. (A) Number of BrdU+ in mice 
hippocampus in 1.21-treated group and control. (B) Number of BrdU+/NeuN+ in 
hippocampus in 1.21-treated group and control and representative microimages. 
 
Discussion 
In the present study we first analyzed the neurogenic effects of 
melatonin and some selected synthetic analogues in vitro, and we observed 
that the degree of potentiation of neural differentiation and maturation of 
primary neural stem cells did not correlate with their potency at melatonergic 
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receptors MT1 and MT2 (table 1). 1.9 is a full agonist, weaker at both receptor 
subtypes compared to melatonin, yet the most potent in the series of 
analogues tested and the only full agonist among them. 1.9 weakly induces 
neural differentiation whereas is clearly unable to stimulate neural maturation 
in vitro. In this regard, partial agonists 1.21, 1.33 and 1.31 seem to perform 
much better. 1.34 intrinsic activity at melatonin receptors could not be studied 
in concentrations below 10μM, 1.21 is a weak partial agonists, 1.33 is also a 
weak partial agonist but significantly more potent than 1.21. 1.31 is a selective 
MT2 partial agonist with virtually no effect on MT1. Nevertheless all three 
partial agonists were able to promote neural development in levels 
comparable to melatonin (figures 3 and 4). Despite its poor intrinsic activity 
and weak potency at melatonergic receptors 1.21 turned out to be the most 
potent compound at promoting neurogenesis in vitro, even more than the 
reference compound melatonin, in a dose dependent manner.  
In order to evaluate whether other receptors and pathways could be 
involved in the neurogenic effect of 1.21, the compound was screened at 10 
μM concentration in several receptors reportedly related to neurogenesis, 
namely: glycogen synthase kinase 3β (GSK-3B)19; cannabinoid receptors 1 and 
2 (CB1, CB2)20; serotonin receptors subtype 1A, 2A, 2B, 2C (5-HT1A, 5-HT2A, 5-
HT2B, 5-HT2C)21; serotonin transporter (SERT)22; RARα and PPARγ23.  No 
significant interaction with the abovementioned receptors was observed. MT1 
and/or MT2 are clearly implicated in the mechanism of action of 1.21, 1.33 and 
melatonin, as demonstrated by the blockade of the neurogenic effect exerted 
by luzindole in neurospheres from hippocampus (figures 5 and 6). In this 
experiment 1.33 appears to be a weak neuronal maturation inducer, 
nevertheless the expression pattern of the markers, as well as previous 
experiments (figure 3 and 4), seem to suggest that longer incubation times 
might be needed in its case to reach neural maturation in vitro.  
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Luzindole is unable to fully block the neural differentiation in vitro 
elicited by melatonin or 1.21. This effects have been already been observed in 
the case of melatonin by Ramírez-Rodríguez et al. (2009)11. The residual 
expression of Tuj1 stimulated by both melatonin and 1.21 in the presence of 
luzindole could be related to the dose of antagonist employed, perhaps unable 
to totally block the receptors or to the interaction of both compounds with 
other systems. López et al. (2010) related the neurogenic properties of 
melatonin to its intriguing role in mitochondria10. Melatonin has also been 
reported to directly interact with nuclear receptors from the retinoic acid 
superfamily among others, presumably independent to the signaling 
pathways mediated by MT1 and MT2 membrane receptors24.   
Yet unable to totally counteract the effects of melatonin and 1.21, 
interestingly, luzindole blocks the basal neural differentiation below its basal 
levels as observed in the Tuj1 expression in vitro (figure 5). This effect of 
luzindole has been already reported, and could be related to the nature of 
luzindole, reportedly a pure antagonist at MT2, and an inverse agonist at 
MT111,25. Both receptor subtypes can be found in the dentate gyrus of rat 
hippocampus26. Luzindole ability to decrease melatonergic intrinsic activity 
below its constitutive level could in turn negatively interact with other 
intracellular pathways via cross-talk, blocking or partially blocking them, and 
as a result, reduce the basal neural differentiation (figure 10A and 10B). The 
magnitude of this observed effect is rather low at basal levels, nevertheless it 
could be of relevance in the case of melatonin or 1.21, which putative 
neurogenic effects beyond MT1 and/or MT2 could be partially masked in this 
negative cross-talk.  
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Figure 10. Schematic representation of the constitutive activity of MT1 in neurospheres 
from rat hippocampus in absence (A) and presence of luzindole (luz) (B). The 
population of transient activated MT1 receptors is comparably much smaller than the 
resting conformation, but still able to positively modulate the basal neural 
differentiation in the absence of any other factors. Conversely, luzindole stabilizes the 
resting form of the MT1 receptors keeping the G-protein in its off-state, thus 
suppressing the basal formation of secondary messengers needed for the neural 
differentiation. 
Chronic treatment with 1.21 in vivo increased the number of newborn 
hippocampal neurons, without major effect on the proliferative rate. 
Assuming that both 1.21 and melatonin share a common mechanism in their 
neurogenic effect these results are partially in agreement with those 
previously reported by Ramírez-Rodríguez et al. (2009) that also observed a 
slight decrease in the amount of BrdU in C57BL/6 mice treated with 8 mg/kg 
melatonin for 7 days. A two-fold increase in BrdU/DCX labelled cells was also 
observed in their model after 14 days of treatment with melatonin. The main 
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point of divergence is the amount of newborn mature neurons. 14-Days 
treatment with melatonin did not affect the proportion of new neurons but 
did increase the number of BrdU cells in the dentate gyrus, giving as a result a 
net increase in neurogenesis. In our case, even if it is not statistically 
significative, a mild increase in the amount of BrdU cells was also observed, 
but followed by a 6-fold increase in the proportion of newborn mature 
neurons. A plausible interpretation for the observed difference lies in the 
experiment total time. In our case a 21 days latency time doubles the total time 
course of the experiment, what could in turn favor delayed expression of 
NeuN. Nevertheless the treatment duration in our protocol is half, with 16-
fold less dosage, what suggests that beyond time differences between both 
protocols 1.21 could be acting more potently than melatonin at promoting 
neurogenesis in a similar manner.  
The implication of MT1 and/or MT2 in their neurogenic actions in 
hippocampus is beyond doubt in both cases. Whether a certain subtype is 
more involved in mediating the neurogenic effect than the other is a 
challenging task beyond the scope of this work. These GPCRs are known to 
heterodimerize between them and with other membrane receptors27. The 
trend to ascribe differential effects to the stimulation of either subtype is 
continuously challenged by the complex pharmacology of the melatonergic 
receptors24. Nevertheless, it is still surprising how a weak partial agonist like 
1.21, 10-6 fold less potent than melatonin and barely able to stimulate the 
activation of melatonin receptors (≤30% relative intrinsic activity in the 
[35S]GTPγS assay), is more potent at potentiating neurogenesis in vitro, and in 
vivo. An additional functional assay was carried out with 1.21 in which its 
intrinsic activity at melatonin receptors was measured as impedance in the 
case of MT1 and as decrease of cAMP levels in the case of MT2. Briefly, MF316 
was too weak to elicit any measurable stimulation of the MT1 receptor 
whereas it behaved as a full agonists at the MT2 (EC50, 1.6 μM; Emax, 92%). A 
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plausible hypothesis to explain this behavior is functional selectivity28. This 
phenomenon is quite ubiquitous in GPCRs, and melatonin receptors are 
known to couple to several G-protein that upon activation could differentially 
activate parallel pathways24. The [35S]GTPγS assay employed for functional 
characterization is unable to discriminate between different G-proteins. 
Therefore, in the [35S]GTPγS assay a functional selective agonist that 
specifically promotes conformational state changes leading to a certain type or 
types of G-protein activation would in principle return a lower signal 
compared to a reference agonist that activates the receptor regardless of the G-
proteins coupled to it, in this case melatonin (figure 11)28,29. The preferential 
activation of certain MT2-G-protein populations would provoke the activation 
on their coupled signaling pathways, and thus only their mediated effects 
would be observed. The decrease of cAMP levels subsequent to MT2 
stimulation is mediated by Gαi protein activation. Therefore, taking into 
account the lower binding of [35S]GTPγS relative to melatonin elicited by 1.21 
via MT2, and its full-agonistic properties at the same receptor subtype when 
the decrease of cAMP levels is measured,  our main hypothesis is that 1.21 
preferentially activate Gαi-coupled MT2 receptors. It remains to be determined 
whether the Gαi/cAMP pathway is responsible for the neurogenic effect 
observed. 
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Figure 11. Schematic representation of the functional selectivity hypothesis of 1.21 in 
MT2 receptor. (A) Melatonin (mel), the reference and natural ligand, binds to 
melatonergic receptors coupled to G-proteins, that upon activation bind [35S]GTPγS. 
The amount of G-protein activated is taken arbitrarily as 100%. The size of the G-
proteins and arrows represent the relative population of certain activated G-protein 
isoforms. (B) The low binding of [35S]GTPγS upon binding of 1.21 to melatonergic 
receptor could be indicating the preferential activation of certain populations of MTx-
Gx and thus, only certain signaling pathways are activated. 
 
Conclusions 
Herein, we have evaluated the ability of synthetic melatonin analogues 
potential as neurogenic agents in vitro. We have demonstrated that the 
efficiency at promoting this effect does not correlate with their potency at MT1 
and MT2 receptors even if both receptors are indeed implicated in mediating 
their neurogenic effect. This fact could be possibly related to a functional 
selectivity phenomenon, or to the interaction with additional pathways no 
directly related to the MT1 or MT2 activation but affected by their blockade. 
Being as it may, we can conclude that 1.21 and related neurogenic azole-
containing melatonin analogues are, in classical pharmacological terms, weak 
melatonergic agonists that, conversely, potentiate neurogenesis in vitro with 
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clear implication of MT1 and/or MT2 receptors. Moreover we have 
demonstrated the ability of 1.21 to potently increase the neurogenesis in mice 
hippocampus without significantly affecting the proliferation rate after 
chronic administration. In other words, in terms of orthodox bioisosterism, we 
can conclude that compound 1.21 that poorly substitutes for melatonin at 
melatonin receptors, conversely fully behaves as a bioisostere in the 
promotion of neurogenesis. Therefore, we propose 1.21 as a potential 
candidate for further development as therapeutic agent in the development of 
reparative agents for neurodegenerative diseases. 
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Experimental section 
Assays for MT1 and MT2 receptor subtypes 
The binding and intrinsic activity data was taken from chapter 1. Detailed 
description of the procedures can be found in the experimental section of the 
mentioned chapter. 
The effect of compound 1.21 on cAMP levels was measured in Chinese 
Hamster Ovary cells expressing human recombinant MT2 receptor in a 
homogeneous time resolved fluorescent assay. Melatonin was used as 
reference (100% agonist effect). Detailed information on the protocol can be 
found in www.cerep.fr.  
 
In vitro Blood–Brain Barrier Permeation Assay (PAMPA) 
 Prediction of the brain penetration was evaluated using a parallel artificial 
membrane permeation assay (PAMPA-BBB), in a similar manner as 
previously described30–32.  Pipetting was performed with a semi-automatic 
robot (CyBi®-SELMA) and UV reading with a microplate spectrophotometer 
(Multiskan Spectrum, Thermo Electron Co.). Commercial drugs, phosphate 
buffered saline solution at pH 7.4 (PBS), and dodecane were purchased from 
Sigma, Aldrich, Acros, and Fluka. Millex filter units (PVDF membrane, 
diameter 25 mm, pore size 0.45 μm) were acquired from Millipore. The 
porcine brain lipid (PBL) was obtained from Avanti Polar Lipids. The donor 
microplate was a 96-well filter plate (PVDF membrane, pore size 0.45 μm) and 
the acceptor microplate was an indented 96-well plate, both from Millipore. 
The acceptor 96-well microplate was filled with 200 μL of PBS : ethanol (70:30) 
and the filter surface of the donor microplate was impregnated with 4 μL of 
porcine brain lipid (PBL) in dodecane (20 mg mL-1). Compounds were 
dissolved in PBS: ethanol (70:30) at 100 μg mL-1, filtered through a Millex 
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filter, and then added to the donor wells (200 μL). The donor filter plate was 
carefully put on the acceptor plate to form a sandwich, which was left 
undisturbed for 240 min at 25 ºC. After incubation, the donor plate is carefully 
removed and the concentration of compounds in the acceptor wells was 
determined by UV-Vis spectroscopy. Every sample is analyzed at five 
wavelengths, in four wells and at least in three independent runs, and the 
results are given as the mean ± standard deviation. In each experiment, 11 
quality control standards of known BBB permeability were included to 
validate the analysis set. 
 
Neurogenesis studies in vitro in the presence of different melatonin 
analogues 
Animals. Adult (8-12 weeks old) male Wistar rats (n = 6 per group), housed in 
a 12 h light-dark cycle animal facility, were used in this study. All procedures 
with animals were specifically approved by the Ethics Committee for Animal 
Experimentation of the CSIC and carried out in accordance with National 
(normative 1201/2005) and International recommendations (Directive 2010/63 
from the European Communities Council). Special care was taken to minimize 
animal suffering. 
Neurosphere culture. Neurospheres (NS) were derived from the 
subventricular zone (SVZ) and subgranular zone (SGZ) of the dentate gyrus of 
the hippocampus of adult Wistar rats, which were induced to proliferate using 
established passaging methods to achieve optimal cellular expansion 
according to published protocols33. Rats were decapitated and brains 
dissected, obtaining the hippocampus and SVZ as described34. Briefly, cell 
suspension obtained after digestion was separated by centrifugation and later 
on seeded into 12-well dishes and cultured in Dubecco’s Modified Eagle’s 
Medium (DMEM)/F12 (1:1, Invitrogen) containing 10 ng/mL epidermal 
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growth factor (EGF, Peprotech, London, UK), 10 ng/mL fibroblast growth 
factor (FGF, Peprotech), and B27 medium (Gibco). After 3 days in culture, 
when neurospheres (NS) were visible, cultures were treated with the different 
compounds. Some cultures were pre-treated with luzindole for 2h prior to the 
addition of the tested compound addition. To determine the ability of 
compounds to induce differentiation, NS from 10-day old cultures were plated 
onto 100 μg/mL poly-L-lysine-coated coverslips for 48h in the presence of 
serum but in the absence of exogenous growth factors.  
 Immunocytochemistry. After treatment, cells were processed for 
immunocytochemistry with two types of neurogenesis-associated neuronal 
markers: anti-β-tubulin antibody (clone Tuj1), associated with early stages of 
neurogenesis, and MAP-2 (microtubule-associated protein 2), a marker of 
neuronal maturation. DAPI staining (4',6-diamidino-2-phenylindole) was used 
as a nuclear marker. Basal values were obtained under the same conditions, 
but in the absence of any product. Melatonin (endogenous ligand of the 
melatonergic receptors) and luzindole (melatonergic antagonist) were used as 
controls. The images were obtained using a Nikon fluorescence microscope 
90i that was coupled to a digital camera Qi. The microscope configuration was 
adjusted to produce the optimum signal-to-noise ratio. 
 
 Neurogenesis in vivo. MF316 treatment and labelling in adult mice 
Animals. Male C57BL/6 mice from our in-house colony (Instituto de 
Investigacion Hospital 12 de Octubre), were used. Age-matched mice not 
expressing the transgene were used as wild-type controls. 1.21 (500µg/kg), 
and BrdU (50 mg/kg) were injected intraperitoneally to each mouse once a 
day for 7 days, and mice were sacrificed, after deep anesthesia, 24 hours 
(group 1) or 21 days (group 2)after the last injection of BrdU. All animals were 
handled and cared for Council Directive 2010/63/UE of 22 September 2010. 
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Immunohistochemistry. Mice were deeply anesthetized with isoforane, 
transcardially perfused with 0.9% saline and brains were immediately 
removed. Next, tissues were fixed in phosphate-buffered 4% 
paraformaldehyde, pH 7.4, at 4ºC. Fixed brains were cut on a vibratome (Leica 
Microsystems) at 30 µm, and tissue sections were collected in cold PB 0.1 M, 
and incubated overnight at 4 °C with mouse anti-BrdU primary antibodies 
(1:20000, Hybridoma Bank). Additionally goat anti- doublecortin (DCX, 1:500, 
Santa Cruz Biotechnology) and NeuN (1:500, Millipore) were employed in 
group 1 (3 animals sacrificed 24h after the last injection of BrdU), and 2 (6 
animals sacrificed 21 days after the last injection of BrdU) respectively. After 
overnight incubation, primary antibody staining was revealed using donkey 
anti-mouse IgG 488 (FluoProbes®, Interchim) for BrdU, and Texas Red goat 
anti-rabbit IgG antibody (Jackson Immunoresearch, West Grove) for both DCX 
and NeuN.  
Quantification. The number of BrdU-positive cells in the granule cell and 
subgranular cell layer of the dentate gyrus were counted to estimate the total 
number of BrdU-positive cells in the entire dentate gyrus. BrdU-positive were 
counted in one of every six sections from rostral (2 mm from bregma) to 
caudal (-4.3 mm from bregma). To determine the fate of dividing cells 100-150 
BrdU-positive cells across 4-6 sections per mouse were analyzed by confocal 
microscopy for co-expressing with DCX (group 1) or NeuN (group 2). Those 
BrdU-positive nuclei with co-localization of DCX in the cytoplasm were 
considered as newly born immature neurons, and those BdrU-positive with 
NeuN co-localization were considered as newly born mature neurons. The 
number of double-positive cells was expressed as a percentage of BrdU-
positive cells in both cases. 
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Chapter 3 
 
Pinoline pharmacological characterization 
and development of rigid melatonin-
pinoline hybrids with neurogenic potential 
 
Introduction 
Pinoline was first isolated from pineal glands in 1978 by Schoemaker1,2. 
It was proposed to be the endogenous ligand of the [3H]imipramine binding 
site and the factor isolated by Farrell in 1960, named adrenoglomerulotropin, 
responsible for the pineal regulation of the adrenal gland3–9. Pinoline attracted 
a lot of attention until controversy arouse on its occurrence as an endogenous 
neurochemical of the pineal gland10. Ever since, its interest diminished and at 
the present time is mostly focused on the study of its antioxidant properties 
and as a probe for cytochrome activity11–15. In recent years, beyond its 
scientific interests, pinoline has also attracted attention of new age religious 
groups that ascribe enlightening properties to this molecule, probably due to 
its structural similarity to N,N-dimethyltryptamine,  nevertheless no reports of 
its exogenous administration to humans has ever been reported to the best of 
our knowledge15,16.  
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Both melatonin and pinoline are structurally related to serotonin. 
Pinoline is a methoxylated restricted-analogue of tryptamine. It has often been 
referred to as the endogenous pineal β-carboline from which it takes its name. 
According to its β-carboline structure, it is named 6-methoxy-1,2,3,4-
tetrahydro-β-carboline (6-MeO-THBC), but it can be also named as a 
tryptoline: 5-methoxy-tryptoline. The numbering for the methoxy group 
changes between both systems, and this can be misleading since both names 
can be found in the literature (figure 1).  
 
Figure 1. Numbering of the carboline (A) and tryptoline (B) structures. β-Carboline 
pyrido nitrogen is in position 2, γ-carboline in position 3. This nomenclature does not 
apply in the case of tryptolines. 
 
Numerous efforts were done during the 80s to determine the levels of 
pinoline in different tissues resulting in a wide variety of concentrations that 
ranged from few ng/g up to 1 µg/g, being the top scoring tissues: brain, 
pineal and adrenal gland5,19–22. Nevertheless criticism may apply in certain 
early determinations since the analytical procedures require a fine design of 
the protocol in order to avoid artifact formation21. Langer et al. 1985 reported 
the concentration of pinoline in the pineal gland to be as low as 2 ng/g in 
rats4. Since the synthesis of pinoline by pineal gland appears to be inexistent 
or at most scant, such levels question the relevance of the pineal production of 
pinoline. Even if there is no support for an active role of pineal gland in the 
synthesis of pinoline, however there are reports in the literature that suggest 
that spontaneous non-enzymatic generation of the β-carboline core could be 
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feasible from 5-methoxytryptamine in the presence of the superoxide anion in 
an oxidant environment, or via a spontaneous Pictet-Spengler condensation in 
the presence of glyoxylate in physiologic conditions followed by enzymatic 
decarboxylation22–26. 5-Methoxytryptamine is synthesized in the pineal gland 
as a precursor of melatonin, which would in principle support the pineal 
origin of pinoline27,28.  
Autoradiographic studies with tritiated pinoline reveal that it binds to 
neural membranes, mitochondria and cell nuclei. It is in nuclei where the 
largest amount of tracks was located. This intracellular location suggests that 
pinoline could act as an antioxidant in the nucleus as a direct scavenger, or 
perhaps exert direct interaction with nuclear receptors and transcription 
factors like melatonin does29,30.  
The synthesis of 1,2,3,4-tetrahydro-β-carbolines from tryptamines and 
aldehydes or ketones is straightforward via Pictet-Spengler reaction. This 
reaction was described as earlier as 1911 by the chemists A. Pictet and T. 
Spengler in the obtention of 1,2,3,4-tetrahydroisoquinolines31. Twenty years 
later Tatsui obtained 1,2,3,4-tetrahydro-β-carbolines from tryptamine32. This 
skeleton is found in numerous alkaloids and it has been widely studied in the 
total synthesis of natural products33. The importance of this reaction yields 
also in its occurrence in vivo, not only in the biosynthesis of numerous 
alkaloids by certain plants, but also of endogenous carbolines in superior 
animals26. As abovementioned, previous studies have demonstrated that the 
reaction is feasible under physiological conditions (buffered solution at 37 ºC 
and pH 7.4) without the presence of an enzymatic catalyst, especially in the 
case of 5-methoxytryptamine24. Enzymatic-catalysed Pictet-Spengler reactions 
are also involved in the biosynthesis of alkaloids, among them, morphine and 
ajmalicine. The enzymes implicated in this transformation are known as 
Pictet-Spenglerases, and can be found in different plant species33. 
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The β-carbolines family, to which pinoline belongs, includes several 
alkaloids isolated from different plant sources34–36. Harmala alkaloids are 
among them. They receive their name from the plant Peganum harmala in 
which seeds are found, but their occurrence is not limited to P. harmala, they 
are also present in other plant species, like the vine Banisteriopsis caapi, the 
main ingredient of the hallucinogenic beverage Ayahuasca used in 
Amazonian shamanism34,36. There is a wide variety of β-carbolines within the 
family of harmala alkaloids with different degrees of saturation, bearing or 
not a methoxy/hydroxy group (figure 2). The essential differences between 
pinoline and the harmala alkaloids are: the methyl in position 1, and the 
degree of saturation of the pyrido ring, with the exception of 
tetrahydroharmine which pyrido ring is fully saturated as well. In the case of 
harmala alkaloids numerous pharmacological and structure-activity 
relationship (SAR) studies have been conducted, and there are numerous 
examples showing how the degree of saturation of the pyrido ring greatly 
determines the pharmacological profile of these β-carbolines37–41. Harmala 
alkaloids have been more extensively studied than pinoline, therefore, being 
their structures so closely related, the advances achieved in the understanding 
of the pharmacology of harmala alkaloids provides hints on the putative role 
of the so-called pineal β-carboline. Some harmala alkaloids are known to be 
hallucinogenic per se; others act as coadjutant by inhibiting monoaminoxidase 
A (MAO-A)16,36,42,43. Whether pinoline is a hallucinogenic β-carboline in 
humans remains unknown.  
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Figure 2. Harmala alkaloids. The numbering on pyrido ring A has been assigned 
based on the carboline structure. 
 
Approach 
Pinoline and melatonin share the 5-methoxyindole ring in their 
structure, but there are two major structural differences between them: the 
nature of the non-aromatic nitrogen and the degree of flexibility. Pinoline, like 
serotonin, is an amine. The basicity of this secondary amine suggests a likely 
protonated ammonium state at physiologic pH with its corresponding 
positive charge. Melatonin is a primary amide; this carbamoyl moiety is able 
to intervene both as a donor and as acceptor in hydrogen bonds, but lacks any 
absolute charge. With regard on their flexibility, melatonin, like serotonin, has 
two free-rotation bonds separating the acetamido and heteroaromatic group, 
thus being able to adopt several energetically equivalent conformations by 
rotation around its sp3 carbons. Conversely, the additional methylene present 
in pinoline that configures the tetrahydropyrido ring limits the conformational 
freedom of the molecule being the relative spatial disposition constant. The 
approach employed in our study emerges from multiple ligand design 
strategies44. Taking into account the high structural similarity between 
pinoline and melatonin we based our design in the merging of the differential 
 
R Ring A saturation Common name 
-H Fully unsaturated Harmane 
-OMe Fully unsaturated Harmine 
-OH 3,4-dihydro Harmalol 
-OMe 3,4-dihydro Harmaline 
-OMe 1,2,3,4-tetrahydro Tetrahydroharmine 
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features of both pineal neurochemicals and thus, we aimed for the synthesis 
and pharmacological characterization of compound 3.3 (figure 3). 
 
Figure 3. Schematic representation of the approach employed. Filled arrows represent 
the common features of the depicted structures. Broken arrows represent the 
hybridization of pinoline and melatonin. 
 
Being 3.3 the target molecule of this project, we have further extended 
the synthesis to the obtention of position isomers 3.4 and 3.5 and its non-
acetylated counterparts 3.1 and 3.2 in order to establish a SAR in the receptors 
studied, and to compare it to their parent amino compounds (figure 4). The 
synthesis and characterization of these pinoline isomers (3.1 and 3.2) allowed 
us to gain insights into the structural determinants of the pharmacology and 
antioxidant properties of methoxy-tetrahydrocarbolines with special interest 
focused on pinoline. Moreover provided the neurogenic potential of 
melatonin and our interest in developing new potential brain-repairing 
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agents, we explored also the neurogenic potential of  3.3 in  neural  stem 
cells45–47. 
 
 
Compound Methoxy position 
Nitrogen 
position R 
pinoline 6 β H 
3.1 7 β H 
3.2 6 γ H 
3.3 6 β COCH3 
3.4 7 β COCH3 
3.5 6 γ COCH3 
 
Figure 4. Pinoline isomers, and melatonin – pinoline hybrids obtained in this work 
 
 
Chemistry 
For the synthesis of pinoline and 3.1 an acid-catalysed Pictec-Spengler 
procedure was employed48. The treatment of the appropriate tryptamine with 
paraformaldehyde in the presence of trifluoroacetic acid (TFA) afforded the 
corresponding β-carbolines as trifluoroacetate salts in fair yields. The 
synthesis of the acetylated tetrahydro-β-carbolines 3.3 and 3.4 from the 
corresponding free bases of the above-mentioned compounds and acetic 
anhydride proceeded smoothly with excellent yields (scheme 1). 
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Scheme 1. Synthesis of pinoline and related 1,2,3,4-tetrahydro-β-carbolines 3.1, 3.3 
and 3.4. Reagents and conditions. (a) paraformaldehyde, TFA, DCM, rt, 72h; (b) acetic 
anhydride, TEA, MeCN, rt, 1h. 
 
The acid-catalysed Pictet-Spengler reaction of tryptamines with keto-
derivatives starts with the condensation of the amine with the carbonyl group 
to form an iminium ion, followed by nucleophilic attack by the pyrrol core 
and cyclization (scheme 2).  
 
Scheme 2. Proposed mechanism for the synthesis of pinoline from 5-
methoxytryptamines via Pictet-Spengler reaction. There is evidence of the existence of 
a spiro intermediate ii, which formation is fast and reversible49. There is a debate on 
whether this specie takes part in the whole route as a precursor of the intermediate i 
or not50. 
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1,2,3,4-Tetrahydro-γ-carbolines 3.2 and 3.5 were obtained via Fischer 
indole synthesis starting from (4-methoxyphenyl)hydrazine hydrochloride 
and the corresponding 4-piperidone using two different methods (scheme 3). 
 
Scheme 3. Reagents and conditions. (c) 4-piperidone, EtOH, conc. HCl, 80 ºC; (d) 1-
acetyl-4-piperidinone, methylurea:tartartic acid (70:30), 80 ºC. 
 
In the case of 3.2 a traditional acid-catalysed method was employed: 
the starting hydrazine chlorhydrate was refluxed with 4-piperidone in a 
mixture of ethanol and aq. HCl, obtaining 3.2 in low yield51. In the synthesis of 
3.5 a different acid source was used. Deep eutectic mixtures have proven to be 
cheap and versatile solvents with similar properties to traditional ionic 
liquids, with the additional advantage of being greener media and much less 
toxic to environment and humans. To such extent, that in certain cases they 
can be employed as cosolvents in biocatalysis52. Moreover some natural 
occurring eutectic mixtures have been proposed to play a role in cell 
physiology and metabolism53,54. In this particular case, following the 
procedure described by Gore et al., a eutectic mixture of methylurea and 
tartaric acid (70:30) provided an acidic polar medium able to catalyse Fischer 
indole synthesis, and thus 3.5 was obtained from (4-
methoxyphenyl)hydrazine and 1-acetyl-4-piperidinone in very good yield55. 
The proposed mechanism leading to compounds 3.2 and 3.5 is shown in 
scheme 4. Condensation of the hydrazine and the corresponding piperidone 
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forms a hydrazone, that after a [3,3]-sigmatropic rearrangement, formation of 
a cyclic aminal, and irreversible elimination of ammonia, affords the 
corresponding γ-carboline. 
N
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Scheme 4. Adapted mechanism for the synthesis of 1,2,3,4-tetrahydro-γ-carbolines (3.2 
and 3.5) via Fischer indole synthesis. 
 
Pharmacology 
Serotonin receptors and transporter 
The binding affinities of the compounds for different serotonin 
receptors and transporter (5-HT and SERT, respectively) were determined in 
radioligand displacement studies in transfected cells stably or transiently 
expressing 5-HT receptors or SERT. The results are summarized in table 1.  
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Table 1. Binding profiles to 5-HT receptors, and SERT determined by radioligand displacement. Ki, µM (pKi ± SEM) 
 
Cpd 5-HT1A 5-HT1D 5-HT2A 5-HT2B 5-HT2C 5-HT3 5-HT6 5-HT7 SERT 
pinoline 4.335 (5.36±0.07) 
3.714 
(5.43±0.03) 
2.210 
(5.66±0.09) 
0.156 
(6.81±0.06) 
1.503 
(5.82±0.06) 
4.431 
(5.35±0.08) >10 
0.607 
(6.22±0.06) 
0.172 
(6.76±0.05) 
3.1 5.797 (5.24±0.08) >10 
2.919 
(5.53±0.08) 
0.385 
(6.41±0.05) 
1.258 
(5.90±0.07) >10 >10 
1.906 
(5.72±0.07) 
0.614 
(6.21±0.09) 
3.2 >10 >10 0.229 (6.64±0.07) 
0.194 
(6.71±0.08) 
0.219 
(6.66±0.06) >10 
4.748 
(5.32±0.05) 
0.938 
(6.03±0.06) >10 
3.3 7.305 (5.14±0.08) >10 
3.073 
(5.51±0.08) >10 >10 
1.842 
(5.73±0.07) 
3.063 
(5.51±0.06) >10 >10 
3.4 >10 >10 >10 >10 >10 >10 >10 >10 >10 
3.5 >10 >10 >10 2.555 (5.59±0.09) >10 >10 >10 >10 >10 
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Pinoline and compounds 3.1 and 3.2, bearing a protonatable amino 
group, showed more affinity for 5-HT receptors than their acetylated 
counterparts which lacked significant affinity for most of them. All three 
protonatable tetrahydrocarbolines showed, however, rather similar binding 
profiles: Ki values around the low or sub micromolar range for 5-HT1A, 5-HT2A, 
5-HT2B, 5-HT2C and 5-HT7. The similarities are even more obvious in the β-
carbolines pinoline and 3.1, where the relative position of the methoxy group 
does not appear to be relevant except for 5-HT1D and 5-HT7 receptors. The 
relative position of the protonatable nitrogen appears to be more relevant 
when comparing the γ-carboline 3.2 and pinoline. The nitrogen in γ-position 
abolishes the binding to 5-HT1A receptors, but increases the affinity for 5-HT2A 
and 5-HT2C receptors while maintaining the affinity for 5-HT2B and 5-HT7 
unchanged. In the case of the SERT the same SAR applies, being the affinity of 
the methoxy-regioisomers pinoline and 3.1 nearly identical, whereas the γ-
carboline 3.2 lacks significant affinity for this transporter. Among the 
acetamides, only derivative 3.3 seems to partially retain the affinity profile of 
its parent compound (pinoline) for the 5-HT1A, 5-HT2A and 5-HT3 with no 
significant affinity for any of the other 5-HT2 subtypes. Additionally it shows 
improved affinity for the 5-HT3 and modest affinity for the 5-HT6 receptor, not 
observed in any of the other tested compounds. Compound 3.4 showed no 
affinity for any receptor, and 3.5 only had some significant binding to 5-HT2B. 
The intrinsic activity of selected compounds was determined at 5-HT2 
receptors; the results are shown in table 2. The β-carboline derivatives pinoline 
and 3.1, showed a very similar qualitative pharmacological profile: partial 
agonism at the 5-HT2A, antagonism at the 5-HT2B (both in the low micromolar 
range) and full agonism at the 5-HT2C (in the sub-micromolar range). Pinoline 
is a relatively potent partial agonist at this subtype (EC50, 33 nM). γ-Carboline 
3.2 was unable to activate either receptor subtype. 
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Table 2. Functional characterization of non-acetylated compounds at 5-HT2 
receptors determined as intracellular calcium mobilizationa. 
 
 5-HT2A 5-HT2B 5-HT2C 
Cpd EC50  Emax n IC50  n EC50 Emax n 
pinoline 2.14±0.10 75 1.58 1.12±0.05 1.5 0.033±0.001 95 1.9 
3.1 3.28±0.15 57 1.35 3.63±0.17 1.3 0.120±0.005 100 1.7 
3.2 –b 19.8±0.9 1.4 –b 
 
a All EC50  or  IC50 values in µM with  ± SEM values. Emax is expressed as a percentage 
of the maximum reponse elicited by 5-HT. n represent the Hill coefficient. 
Experiments are run in duplicates. 
b 3.2 was unable to activate 5-HT2A nor 5-HT2C receptors.  
 
Inhibition of monoamine-oxidase isoforms A and B 
Table 3 summarizes the ability of tested compound to inhibit 
monoamineoxidase A (MAO-A) and B (MAO-B). Only basic tetrahydro-β-
carbolines showed significant inhibition of the MAO-A isoform, being the 
inhibition elicited by pinoline ~25-fold lower than that of 3.1. 
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Table 3. Pharmacological characterization of compounds: inhibition of the MAO 
isoforms, radioligand displacement studies at MT1 and MT2 receptors, and CNS 
predicted permeability determined by the PAMPA-BBB model 
 
 IC50, µM  ± SEM Ki, µM ± SEM PAMPA 
CNS 
perm. Cpd MAO-A MAO-B MT1 MT2 
pinoline 41.5 ± 6.3 >100 >10 >10 + 
3.1 1.3 ± 0.3 >100 >10 >10 + 
3.2 >100 >100 >10 >10 + 
3.3 >100 >100 0.685±0.025 0.330±0.010 + 
3.4 >100 >100 >10 >10 + 
3.5 >100 >100 >10 >10 + 
 
 
Affinity and intrinsic activity at melatonin receptors 
The affinity of the different compounds was determined by 
displacement of the radiolabelled ligand [125I]iodomelatonin; the results are 
summarized in table 3. Out of the six compounds tested only 3.3 showed 
significant binding activity for the melatonin receptors, being the affinity for 
MT2 two-fold higher than for MT1. None of its position isomers (3.5 or 3.4) 
showed any significant activity. Neither did any of the parent amino 
compounds: pinoline or its isomers (3.1 and 3.2).  
Compound 3.3 was functionally characterized at MT1 and MT2 receptor 
subtypes  in the [35S]GTPS binding assay (table 4). Derivative 3.3 is a partial 
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agonist at both receptor subtypes, being slightly more potent at the MT2 
subtype. 
Table 4. Functional characterization of compound 3.3 at MT1 and MT2 receptorsa. 
 
 MT1 MT2 
Cpd EC50 Emax EC50, Emax 
3.3 338±275 70% 141±70 77% 
 
a EC50   values in nM scale with ± SEM values. Emax is expressed as a percentage of the 
maximum reponse elicited by melatonin. Experiments are run in duplicates. 
 
Blood-brain barrier permeability 
According to the brain-blood barrier model PAMPA (parallel artificial 
membrane permeability assay), all tested compounds showed positive 
permeability in this model (table 3). In the case of pinoline, these results are in 
agreement with previous reports in which radiolabelled pinoline was able to 
reach the brain after intraperitoneal or intravenous administration to mice, 
even if its ability to do so was limited18,30. 
 
In vitro antioxidant potential  
Table 5 shows the antioxidant properties of all compounds determined 
in the oxygen radical absorbance capacity (ORAC) assay. Trolox, the aromatic 
part of vitamin E and the part that is responsible for radical capturing, was 
used as an internal standard to  which the unit value is arbitrarily given, 
ORAC (trolox) = 1. Thus, results were expressed as trolox equivalents 
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(micromoles of trolox/micromoles of tested compounds) on a comparative 
scale that shows if the products are better (ORAC > 1) or worse than trolox 
(ORAC < 1). Some indoles and indoleamines were included for comparison 
purposes to establish a subtractive structure-activity relationship between the 
different moieties. Among tested molecules, pinoline showed the highest 
antioxidant capacity equivalent to 3-fold trolox activity, followed by 3.1 with a 
value identical to that melatonin. γ-Carboline 3.2 showed the lowest value 
among the non-acetylated carbolines. On the other hand, its antioxidant 
potential is maintained when acetylated (3.5), unlike pinoline or 3.1. Amides 
3.3 and 3.4 antioxidant potential diminishes in up to one equivalent compared 
to parent compounds. Melatonin, equivalent to nearly 2.5 units of trolox, 
showed the highest ORAC value within the indoles and indoleamines 
included in the assay, followed by 5-methoxytryptamine (0.5 eq. difference) 
and 5-methoxyindole (1 eq. difference). Non-substituted indole showed 
significant antioxidant activity similar to that of trolox, whereas 1-
methylindole was totally devoid of it. 
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Table 5. Antioxidant properties of compounds and references determined in the 
ORAC assay. 
 
Cpd eq. trolox ±SEM 
melatonin 2.43±0.05 
5-methoxytryptamine 1.95±0.04 
5-methoxyindole 1.60±0.03 
indole 1.2±0.02 
1-methylindole Not antiox at 10μM 
pinoline 3.07±0.25 
3.1 2.39±0.26 
3.2 1.83±0.08 
3.3 2.07±0.19 
3.4 1.38±0.08 
3.5 1.67±0.12 
 
 
Neurogenesis studies in vitro 
The neurogenic potential of melatonin and 3.3 was determined in an in 
vitro model of neural stem cells from adult rat subventricular zone (SVZ). Both 
melatonin and 3.3 were able to promote neurogenesis in the model employed, 
whereas the melatonergic antagonist luzindole did not show any differences 
compared to control. 3.3-treated SVZ neurospheres appear to qualitatively 
express more Tuj1 (neuron-specific class III beta-tubulin, figure 5A) and 
MAP2 (microtubule-associated protein 2, figure 5B) than those treated with 
melatonin. Melatonin-promoted Tuj1 expression occurred mainly in the outer 
116 
 
part of the neurospheres in cells spreading out of the formation whereas the 
total expression of MAP2 was diffuse within the neurosphere, and occurred 
mostly surrounding the nuclei. Tuj1 expression pattern of 3.3-treated SVZ 
neurospheres seemed to correspond to that of melatonin, more abundant in 
the outer parts and in cells spreading out of the neurosphere, but the density 
of expression appeared to be comparatively higher. The expression of MAP2 
was dense and homogeneous both in the inner and the outer parts of the 
neurospheres treated with 3.3. Comparing the expression pattern of MAP2 
there were clear differences between melatonin and 3.3. The expression of 
MAP2 elicited by the latter was not limited to the surrounding of the nuclei 
but irradiated throughout the cell bodies.  
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 Overview Inner part Outer part   Overview Inner part Outer part 
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 control 
   
melatonin 
(10 μM) 
   
 melatonin (10 μM) 
   
luzindole 
(10 μM) 
   
 luzindole (10 μM) 
   
3.3 
(10 μM) 
   
 3.3 (10 μM) 
   
 
Figure 5. Immunostaining of neurogenic markers Tuj1 (green)  and MAP2 (red) in SVZ neurospheres in the presence of different 
compounds. DAPI (blue) was used as nuclear marker. Scale bar, 200 µm. 
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 In a second assay the neurogenic properties of pinoline were also 
evaluated in vitro in the same model. At 10 μM pinoline potently promotes the 
irradiated expression of both Tuj1 and MAP2 showing a pattern similar to that 
of 3.3 (figures 6). Pinoline was also evaluated at 10 nM as a preliminar study 
of its intrinsic neurogenic potential at a concentration comparable to the trace 
presence of pinoline reported by Langer et al. (1985)4. The expression of Tuj1 
appears unaffected by the concentration of pinoline, whereas the density of 
MAP2 clearly diminished at 10 nM being mostly located around the nuclei. 
 
The implication of melatonin receptors in the neurogenic properties of 
3.3 was studied in vitro. When SVZ neurospheres were preincubated in the 
presence of the non-selective melatonin antagonist luzindole, the expression of 
both Tuj1 and MAP2 was blocked. The blockade was complete in the case of 
MAP2, but some minor expression of Tuj1 remained despite the presence of 
the antagonist (figure 7). 
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 Overview Inner part Outer part   Overview Inner part Outer part 
control 
   
 control 
   
pinoline 
(10μM) 
   
 pinoline (10μM) 
   
pinoline 
(10nM) 
   
 pinoline (10nM) 
   
 
Figure 6.  Immunostaining of neurogenic markers Tuj1 (green) and MAP2 (red) in SVZ neurospheres in the presence of pinoline at 
different concentrations. DAPI (blue) was used as nuclear marker in all cases. Scale bar, 200 µm. 
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 Overview Inner part Outer part   Overview Inner part Outer part 
control 
   
 control 
   
luzindole 
(10 μM) 
   
 luzindole (10 μM) 
   
3.3  
(10μM) 
   
 3.3 (10μM) 
   
3.3  
(10μM)  
+ 
 luzindole 
(10μM)    
 
3.3  
(10μM)  
+ 
luzindole 
(10μM)    
 
Figure 7. Effect of luzindole on the expression of neurogenic markers promoted by 3.3 Tuj1 (green)  and MAP2 (red) in SVZ neurospheres. 
DAPI (blue) was used as nuclear marker. Scale bar, 200 µm. 
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Discussion 
To the best of our knowledge it is the first time that pinoline intrinsic 
activity has been characterized in 5-HT2 receptors even though direct 5-HT 
receptor stimulation has long been speculated18,56–58. Binding properties of 
pinoline and compound 3.1 were already studied by Glennon et al. (2000)38. 
The affinities of both compounds, together with other β-carbolines, were 
characterized in rat 5-HT1A, 5-HT2A and 5-HT2C receptors. Significant 
differences with their reported values were found only in the 5-HT2C receptor. 
[3H]Mesulergine was the radioligand employed in both cases but in our 
studies both pinoline and 3.1 showed more affinity for the human 5-HT2C 
receptor than for the rat receptor in Glennon’s report, being the difference 
around one order of magnitude.  
 It should be noted that binding properties of pinoline at the 5-HT2C 
were determined by displacement of the antagonist radioligand 
[3H]mesulergine. Being pinoline a full agonist at this receptor subtype, the 
differences found between the Ki and the EC50 obtained may be attributable to 
the difference between the intrinsic activities of radiolabelled ligand and 
tested compound. The same disparities are observed in the case of 3.1 at the 
same receptor subtype. Conversely, in the case of 5-HT2A, being the case 
analogous, no significant differences were observed between the values. 
Comparing pinoline and 3.1 we can conclude that the relative position of the 
methoxy group barely affects the affinity or the intrinsic activity of both β-
carbolines at 5-HT2 receptors whereas the relative position of the basic 
nitrogen does; γ-carboline 3.2 is an antagonist. 
Pinoline and 3.1 are both partial agonists at the 5-HT2A receptor within 
the low micromolar range what to the best of our knowledge represents the 
first time that direct agonism is reported at the 5-HT2A , not only for the 
particular case of this two compounds, but also for the whole family of β-
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carbolines including harmala alkaloids. Since Glennon et al. (2000) studied 
some selected hallucinogenic β-carbolines, among them harmaline and 
harmine, at the 5-HT2A receptor and found no IP3 (inositol-1,4,5-triphosphate) 
accumulation, the classification of harmala alkaloids as classical hallucinogens 
turned troublesome38. The inclusion in this category implies: hallucinogenic 
effect in humans, agonism or partial agonism at the 5-HT2A, and appropriate 
response in rats trained to discriminate DOM (2,5-dimethoxy-4-
methylamphetamine) or LSD (lysergic acid diethylamide) from vehicle59.  
Agonism or partial agonism at 5-HT2A is needed to elicit psychedelic effects 
exerted by classical hallucinogens; nevertheless not all agonists at this subtype 
possess hallucinogenic properties. The hallucinogenic effects of harmala 
alkaloids has been proved in humans, and even though they bind to 5-HT2A 
receptor with affinities ranging from good to modest, they were reported to be 
unable to activate the 5-HT2A16,38,42. The ability of hallucinogenic harmala 
alkaloids and pinoline to substitute for LSD in LSD-trained rats is rather low, 
however harmaline showed some similarity of effect with DOM in harmaline-
trained rat38,57,60–62. 
5-HT2A is a G-protein coupled receptor (GPCR) that activates 
phospholipase C (PLC). The activated PLC hydrolyses membrane lipids 
generating diacyl glycerol (DAG) and IP3, being the latter the responsible for 
the release of Ca2+ from intracellular stores. The lack of correlation between 
the IP3 production and subsequent Ca2+ release with the hallucinogenic 
potential arose doubts about the exclusivity of this signaling cascade and 
indeed 5-HT2A-activated additional pathways have been described: 
phospholipase A2-arachidonic acid (PLA2-AA) and phospholipase D 
(PLD)59,63. Interestingly, some hallucinogenic phenylalkylamine compounds, 
have demonstrated functional selectivity by differentially stimulating the 
PLC-IP3 or the PLA2-AA pathways64. In this report the ability of pinoline and 
3.1 to promote intracellular Ca2+ release via 5-HT2A has been studied, an effect 
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mediated by IP3 production. Both measurable components correspond to the 
same signaling cascade subsequent to PLC activation. To the best of our 
knowledge, the 5-HT2A-mediated activation of additional signaling cascades 
has never been studied in the case of pinoline or harmala alkaloids. Recently, 
Briereley and Davidson (2012) found that the increase in electrically-evoked 
dopamine efflux provoked by harmine was effectively blocked by ketanserin, 
a 5-HT2A antagonist, suggesting dependence on 5-HT2A agonism for such 
effect60. Our results with pinoline and 3.1 do not prove that the β-carbolines 
found in P. harmala are 5-HT2A agonists, however, the gathered data suggest 
that the pharmacology of harmala alkaloids at the 5-HT2A receptor might need 
an update and perhaps, other events, like additional signaling pathways or 
receptor heterodimerization should be considered65. Further studies would be 
needed to determine to what extent the tetrahydro-β-carbolines 3.1 and 
pinoline converge or diverge on their pharmacology profile with 
hallucinogenic harmala alkaloids in the central nervous system stimulation of 
5-HT2A receptors. The hallucinogenic properties of pinoline and 3.1 remain 
unknown to the best of our knowledge16. Even if its ability to substitute LSD 
in trained rats is scant, this is a shared feature with hallucinogenic harmala 
alkaloids57,58,66. Unlike other β-carbolines, pinoline toxicity is rather low (LD50 
112 mg/kg i.v. in mice) compared to harmala alkaloids like harmine (LD50 38 
mg/kg i.v. in mice), however it has never been reported to be tested in 
humans12,67. 
Pinoline is a weak MAO-A inhibitor. This inhibition could be of 
relevance at pharmacological doses but not if pinoline occurs in trace amounts 
under physiological conditions. The inhibitory effect in MAO-A is more 
pronounced in the nor-isomer of tetrahidroharmine: 3.1. Both 3.1 and 
tetrahidroharmine show a similar IC50 in the micromolar range40,68.  
With regard on MAO inhibition, a few words should be addressed to 
the imidazoline-2 binding site (I2-BS). There is evidence that the I2-BS is indeed 
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two different biding sites within the monoaminoxidase: a low affinity binding 
site involved in competitive inhibition, and a high affinity allosteric site. 
Potent I2-BS ligands like 2-(2-benzofuranyl)-2-imidazoline (2BFI; Ki, 10 nM) are 
known to inhibit the MAO-A (IC50, 12 µM) and MAO-B (IC50, 43 µM) with a 
much lower potency69. The same behavior is observed in the cases  of pinoline 
and 3.1 (Ki of 1.6 µM and 0.012 µM respectively for I2-BS), their potency at 
inhibiting MAO-A (IC50 41.5 µM and 1.3 µM respectively) compared to their 
binding affinities to rat I2-BS is 25 and 100 fold lower39. 
To what extent these results could be of relevance in endogenous 
occurring pinoline remains unknown, in the same way the presence of 
endogenous pinoline is still controversial. Exogenous origin cannot be 
excluded, several β-carbolines have been reported to be present in food stuff70. 
Regardless of the origin of the pinoline found on the pineal gland, such low 
levels could still be of a certain relevance in the stimulation of 5-HT2C receptor 
since its potency is close to the concentration found, at least, in the pineal 
gland (2 ng/g ≈ 10 nM pinoline in pineal gland, EC50(5-HT2C) = 33 nM)4,17. 
Previous studies revealed the presence of radiolabelled pinoline in neuronal 
membranes where 5-HT receptors and SERT are located30. The careful 
determination of pinoline concentration employed by Langer et al. (1985) in 
pineal gland has never been performed in adrenal gland to the best of our 
knowledge, but previous reports reveal a much higher concentration of 
pinoline in this gland than in the pineal body2,22. This fact allows us to 
speculate that, even if the concentration observed is above its real levels due to 
the formation of artifacts, accumulation could occur in the adrenal gland and 
the levels achieved to some degree could be of relevance in the endocrine 
system. The effect of exogenous administration of pinoline in the 
hypothalamic-pituitary-adrenal axis has already been previously studied, and 
this effect has been associated to the stimulation of 5-HT receptors.66,71,72 
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There are several reports that link the effects of pinoline to 
serotoninergic modulation73. Our results in the serotoninergic system call for a 
revision of the behavioral effects resulting from exogenous administration of 
pinoline; effects generally attributed to its inhibitory action of SERT and 
MAO-A74,75. The effects elicited by pinoline are more likely to be additive, if 
not synergic.   
The effects elicited by pinoline after intraperitoneal administration to 
rats resemble those of tricyclic antidepressants, together with some 
anxiogenic-like effects66. Some β-carboline compounds related to harmala 
alkaloids are antagonists or inverse agonists at the benzodiazepine (BZD) 
binding site producing anxiogenic effects. According to previous reports 
pinoline lacks any affinity for the BZD binding site or the convulsive potential 
associated to its antagonism37,41. Anxiogenic effects are also observed after 
stimulation of 5-HT2C receptors, what suggests that such anxiogenic-like 
effects mediated by pinoline could be elicited via 5-HT2C receptor76,77. Its 
activation could result both from direct interaction of pinoline with the 5-HT2C 
subtype and a net increase of serotonin levels in the synapse subsequent to 
SERT and MAO-A inhibition. 
 With regard on the radical scavenging properties of the studied 
compounds, the comparison between pinoline and its isomer 3.1 results in the 
ORAC assay reveals that the relative position of the methoxy group seems to 
play a key role in the antioxidant potential of tetrahydro-β-carbolines. The 
observed difference is probably due to the differential radical/charge 
stabilization contribution of the lone pairs of the methoxy group during the 
oxidation process. Comparing pinoline and 5-methoxytryptamine, the 
antioxidant potential of the latter is 1 trolox eq. lower. 5-Methoxytryptamine is 
essentially an open-ring pinoline what suggests that the plausible ring 
opening of the tetrahydropyrido cycle in the presence of oxidant species 
confers the tricyclic molecule added antioxidant potential compared to the 5-
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methoxytryptamine. The same structural analogy can be made between 
melatonin and 3.3, but with inverted results, being melatonin antioxidant 
potential slightly higher. This difference could be possibly related to the 
nature of the nitrogen in both pairs: amine, in the case of 5-
methoxytryptamine/pinoline; and amide, in the case of melatonin/3.3. The 
acetylation results in a dramatic reduction of the antioxidant potential of 
tetrahydro-β-carbolines (pinoline/3.3, 3.1/3.4) but not in the case tetrahydro-
γ-carbolines (3.2/3.5). The only amine-amide pair in which acetylation results 
in improved antioxidant potential is in the case of 5-methoxytryptamine-
melatonin. Kynuramines are metabolites formed as the result of oxidative 
degradation of melatonin78–81. Their structure suggests that melatonin’s 
antioxidant hotspot is located between position C2 and C3 within the 5-
methoxyindole (scheme 5). Even though it does not seem obvious looking at 
the structure of such compounds, these data suggest that the acetamido group 
of melatonin must play a role in the oxidative degradation, or in later phases 
of the scavenging cascade. Removal of the ethyl-acetamido group in 
melatonin or the tetrahydropyrido ring in pinoline leaves the bare 5-
methoxyindole, the common heteroaromatic core of both compounds. This 
small scaffold is able to retain a significant antioxidant potential, of which 
nearly one third is attributable to the 5-methoxy group substitution, by 
comparison with the non-substituted indole. The contribution of the proton in 
position 1 seems to be even greater, being the 1-methylindole totally devoid of 
any antioxidant activity at 10 μM. 
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Scheme 5. Structure of kynuramines resulting from the oxidative degradation of 
melatonin. 
Out of this subtractive antioxidant SAR no structural conclusions can 
be drawn to determine which fragments are best to enhance the reactivity in 
the presence of oxidant species. Acetylation clearly represents an upgrade in 
the case of melatonin compared to its precursor 5-methoxytryptamine, but not 
in the case of pinoline. Cyclization seems to be the key feature responsible for 
the high antioxidant potential of pinoline, but in the case of melatonin, when 
comparing it against 3.3, such cyclization penalizes the reactivity in nearly half 
an equivalent. Compound 3.3 seems to retain some of the pharmacological 
properties of the parent compounds, pinoline and melatonin, in the receptors 
tested in this study, but in this case, the returned value by this synthetic 
hybrid is not in between, but below both of them. Therefore, we could 
conclude that the antioxidant nature of pinoline and melatonin cannot be 
simply attributed to the reactivity of the 5-methoxyindole nucleus, nor 
envisioned as the result of a combination of chemical fragments that 
contribute separately to the whole antioxidant potential; instead, it suggests a 
more complex and optimized interaction between the moieties integrated in 
the heteroaromatic indole scaffold. 
ORAC assay is able to measure the reactivity of a certain molecule 
against reactive oxygen species (ROS), but it is important to mention that in 
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vivo other radicals are present as well, such as reactive nitrogen species (NOS) 
for which this model it is not valid. Moreover molecules like melatonin, and 
presumably pinoline, can mediate antioxidant responses within the cell via 
membrane receptors, interaction with transcription factors or by other 
mechanisms not directly related to the reactivity of the molecule. The 
contribution of melatonin’s chemical structure to the antioxidant properties 
observed in vivo is a controversial topic. High levels of the molecule would be 
needed, and these levels could only be achieved locally in certain tissues or at 
pharmacological doses82. In the case of pinoline, it has been proposed to have 
a direct role as DNA protecting agent against oxidative damage, and indeed 
some β-carbolines with antitumoral properties have demonstrated to bind to 
it12,37. As abovementioned, radiolabelled pinoline was found to bind 
significantly to mitochondria, where an eventual malfunction in the 
respiratory chain can result in the production of oxidative species. Here we 
have demonstrated that the chemical structures of both pinoline and 
melatonin intrinsically possess a certain degree of reactivity that in both cases 
confers them an optimized antioxidant profile when compared with their 
simplified structures (5-methoxytryptamine, 5-methoxyindole) or with 
structural isomers in the case of pinoline (3.1, 3.2).  
Derivatives 3.3, 3.4 and 3.5 are conformationally restricted melatonin 
analogues. The only compound that shows significant affinity and activity at 
the melatonin receptor is the structurally orthodox melatonin-pinoline hybrid 
3.3. Compared to melatonin’s subnanomolar affinity for MT1 and MT2 
receptors (table 1, chapter 1), 3.3 affinity is penalized by three orders of 
magnitude. Conformational restriction is an “all or nothing” approach. 
Freezing the conformation of a flexible ligand can greatly enhance the affinity 
since the entropic penalty associated to the accommodation of flexible ligands 
within the binding site decreases. However, the rigidified ligand ability to 
adapt itself to the receptor topography is extremely limited, and thus, the 
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relative spatial disposition of the functional groups involved in the molecular 
recognition by the receptor needs to be finely tuned. Unlike some previously 
reported melatonin restricted analogues, in our case the rigidification through 
a secondary amide renders impossible a captodative hydrogen bond (figure 
5)83,84. This interaction of the amide group with the receptor appears to be 
relevant at least for the MT1 subtype85. β-Carboline 3.3 is a partial agonist at 
both receptors; its ability to activate both MT1 and MT2 suggests in principle 
that the union of 3.3 to melatonin receptors should occur in an analogous way 
to that of melatonin. None of the other melatonin restricted analogues 
reported in this work showed any activity at the melatonergic receptors; thus 
it is important to stress out that the orthodox structural hybrid of pinoline and 
melatonin 3.3 should be the only compound able to exert agonism at 
MT1/MT2 receptors. 
 
Figure 5. Previously conformationally restrained melatonin analogues reported by 
Spadoni et al. (1997)84 and Zefirova et al. (2011)83 that display low nanomolar for 
melatonergic receptors. 
 
Compound 3.3 has also demonstrated its ability to stimulate early 
neurogenesis and maturation in adult rat SVZ neural stem cells. The blockade 
of the expression of neurogenic markers exerted by luzindole, together with 
its demonstrated agonistic properties at the melatonin receptors allow us to 
infer that the neurogenic effect of 3.3 is mediated by MT1 and MT2 receptors. 
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Taking into account its predicted ability to permeate through the blood-brain 
barrier, further studies in vivo will be required to determine if its potent 
neurogenic properties are also observed in the original cell niche. Both 
melatonin and pinoline, the two compounds embedded within the structural 
hybrid 3.3 demonstrated their in vitro neurogenic properties. In the case of 
melatonin its neurogenic effect can be effectively blocked likewise by 
luzindole (chapter 2, figures 5 and 6). Pinoline does not interact with MT1 or 
MT2 receptor, but is qualitative as potent as 3.3 and melatonin at the same 
concentration (10 μM). The stimulation of serotonin receptors 5-HT1A and 5-
HT2 is known to increase the neurogenesis rate in adult rat brain86. Pinoline is 
able to evoke agonistic response in the 5-HT2C subtype in the nanomolar 
concentration range, whether the sole stimulation of this subtype is able to 
elicit the neurogenic effect described at low concentrations of pinoline requires 
further studies, but so far taking into account the serotoninergic 
pharmacological profile of pinoline we hypothesize that its neurogenic effect 
could be at least partially mediated by serotonin receptors.  
 
Conclusions 
We have synthesized and studied the SAR of a series of pinoline 
isomers and pinoline-melatonin hybrids able to penetrate the central nervous 
system. We have characterized their pharmacological profile and compared it 
to their parent amino compounds in different enzymes and receptor systems. 
This systematic study has allowed us to identify 3.1 and pinoline as full 
agonists at the 5-HT2C and partial agonists at the 5-HT2A. To the best of our 
knowledge, this represent the first report of β-carbolines resembling 
hallucinogenic harmala alkaloids exerting direct agonism at the 5-HT2A. 
Pinoline has been long known to be both a SERT and MAO-A inhibitor; our 
results demonstrate that it indeed binds to the serotonin transporter, and that 
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it weakly inhibits MAO-A. Thus, the contribution of MAO-A inhibition to the 
observed behavioral effects of pinoline might have been overrated, and be 
more likely due to a broader interaction with the serotoninergic system. 
We have further studied the potential of melatonin and pinoline to act 
as direct radical scavengers in the presence of oxidant species. The results 
obtained reveal that both pinoline and melatonin are optimized antioxidant 
structures that cannot be envisioned as the sum of different moieties added 
over the 5-methoxyindole nucleus.  
We have synthesized and characterized 3.3 as a structural and 
pharmacological hybrid between melatonin and pinoline, able to partially 
retain the activity of melatonin over the MT1 and MT2, the affinity of pinoline 
for 5-HT1A and 5-HT2A receptors and to a lesser extent their direct scavenging 
properties in vitro.  Moreover we have demonstrated its neurogenic potential 
in vitro; an effect unequivocally mediated by melatonergic receptors and 
qualitatively superior to that of melatonin. Further studies will be required to 
establish whether its administration elicits the same effect in vivo. 
Additionally we have demonstrated that pinoline is able to stimulate 
neurogenesis in vitro at low nanomolar concentration; an effect that could be, 
at least partially, mediated by its agonistic properties at serotoninergic 
receptors. Be as it may, trace endogenous neurochemical, dietary β-carboline 
or myth, pinoline neurogenic properties underscore its ability to potently 
interact with biological systems at very low concentrations, and allows to this 
intriguing β-carboline to retain some of the research interest it once had. 
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Experimental section 
Chemistry. General Methods.  Equipment descriptions and general methods 
and are detailed in the experimental section of chapter 1. 
Pictect-Spengler reaction. General procedure. Trifluoroacetic acid (TFA, 60 
µL) and dichloromethane (DCM, 3 mL) were added to a mixture of the 
corresponding tryptamine (1 mmol)  and paraformaldehyde (1 mmol), and the 
mixture was stirred at room temperature (rt) for 72h. The TFA·salt of the 
corresponding β-carboline was collected by filtration. 
 
6-Methoxy-1,2,3,4-tetrahydro-β-carboline trifluoroacetate (pinoline).  
Obtained from 5-methoxytryptamine in 63% yield as 
a white-yellow powder of mp 180-185ºC. HPLC-MS 
(230-400nm) 100% (m/z) (MH+) 203.47. 1H NMR (500 
MHz, DMSO) δ 10.51 (s, 1H), 7.16 (d, J = 7.5 Hz, 1H), 6.80 (d, J = 1.5 Hz, 1H), 
6.78 (dd, J = 7.5, 1.5 Hz, 1H), 3.87 (s, 2H), 3.80 (s, 3H), 2.94 (t, J = 6.0 Hz, 2H), 
2.61 (t, J = 5.9 Hz, 2H). The compound was used as such for the next reaction. 
The compound employed for pharmacology assays was purchased from 
Sigma-Aldrich. 
 
7-Methoxy-1,2,3,4-tetrahydro-β-carboline trifluoroacetate (3.1).  
Obtained from 6-methoxytryptamine in 69% yield as 
a white fine powder of mp 171 – 173ºC. 1H NMR 
(300 MHz, DMSO) δ 10.84 (s, 1H), 7.32 (d, J = 8.6 Hz, 
1H), 6.88 (d, J = 2.0 Hz, 1H), 6.67 (dd, J = 8.5, 2.4 Hz, 
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1H), 4.28 (s, 2H), 3.76 (s, 3H), 3.41 (t, J = 6.0 Hz, 2H), 2.87 (t, J = 5.9 Hz, 2H). 13C 
NMR (75 MHz, DMSO) δ 156.13, 137.22, 125.84, 120.71, 118.73, 109.09, 105.77, 
95.10, 55.54, 42.03, 40.91, 18.74. Anal. (C14H15F3N2O3) C,H,N 
 
Acetylation. General procedure. The corresponding TFA salt (1 mmol) was 
disolved in acetonitrile (MeCN, 3 mL) and triethylamine (TEA, 2.2 mmol) was 
slowly added.  Finally acetic anhydride (1.1 mmol) is added. After 1 hour at rt 
the reaction is finished and forming a suspension. The TFA·TEA salt is filtered 
off and the filtrate evaporated. Washing the evaporated solid with water 
yielded the corresponding acetylated-β-carboline. 
 
2-Acetyl-6-methoxy-1,2,3,4-tetrahydro-β-carboline (3.3).  
Obtained from pinoline in 100% yield as a beige 
solid of mp: 183 – 187ºC. 1H NMR (300 MHz, DMSO) 
δ 10.66 (s, 1H), 7.17 (d, J = 8.7 Hz, 1H), 6.88 (d, J = 2.0 
Hz, 2H), 6.66 (dd, J = 8.7, 2.2 Hz, 2H), 4.62 (s, 3H), 3.86 – 3.61 (m, 9H), 2.71 (t, J 
= 5.4 Hz, 3H), 2.11 (s, 3H). 13C NMR (75 MHz, DMSO) δ 168.90, 153.07, 131.99, 
130.91, 126.88, 111.54, 110.28, 106.44, 99.81, 55.29, 44.09, 39.65, 21.52, 21.37. 
HRMS (ESI+): m/z calcd for C14H16N2O2 (M)+ 244.1212, found 244.1217. HPLC 
purity 100% (230 to 400 nm). 
 
2-Acetyl-7-methoxy-1,2,3,4-tetrahydro-β-carboline (3.4).  
Obtained from 3.1 in 94% yield as a white solid of 
mp: 169 – 173ºC. 1H NMR (400 MHz, DMSO) δ 10.65 
(s, 1H), 7.25 (d, J = 8.5 Hz, 1H), 6.82 (d, J = 2.2 Hz, 
1H), 6.62 (dd, J = 8.5, 2.3 Hz, 1H), 4.61 (s, 2H), 3.86 – 
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3.60 (m, 5H), 2.71 (t, J = 5.6 Hz, 2H), 2.12 (s, 3H). 13C NMR (101 MHz, DMSO) δ 
169.60, 155.92, 137.34, 130.48, 121.62, 118.67, 108.79, 107.10, 95.35, 55.83, 44.75, 
40.27, 22.20, 22.11.  HRMS (ESI+): m/z calcd for C14H16N2O2 (M)+ 244.1212, 
found 244.1212. HPLC purity 100% (230 to 400 nm). 
 
6-Methoxy-1,2,3,4-tetrahydro-γ-carboline (3.2).  
(4-methoxy-phenyl)hydrazine hydrochloride (150 mg, 
0.86 mmol) and 4-piperidone (85 mg, 0.86 mmol) were 
dissolved in ethanol (EtOH, 5 mL) and aq. HCl  (2M, 
150 µL) was added. The reaction was refluxed for 3h 
after which solvent was removed and the resulting solid chromatographed on 
silica (gradient DCM:MeOH, TEA 1%) to afford 3.2 (61 mg, 34%) as an off 
white solid of mp: 174 – 179ºC. 1H NMR (500 MHz, DMSO) δ 10.52 (s, 1H), 
7.13 (dd, J = 8.6, 0.6 Hz, 1H), 6.81 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.7, 2.5 Hz, 
1H), 3.83 (s, 2H), 3.72 (s, 3H), 3.02 (t, J = 5.7 Hz, 2H), 2.65 (t, J = 5.6 Hz, 2H). 13C 
NMR (126 MHz, DMSO) δ 152.87, 133.89, 130.42, 125.91, 111.18, 109.55, 107.82, 
99.57, 55.30, 42.97, 41.70, 24.06. Anal. (C12H14N2O) C,H,N. 
 
3-Acetyl-6-methoxy-1,2,3,4-tetrahydro-γ-carboline (3.5).  
A eutectic mixture of methylurea (MU) and tartaric 
acid (TA) was prepared (70:30) and melted at 80ºC. 
Over the heated mixture (4-methoxy-
phenyl)hydrazine hydrochloride (171 mg, 1 mmol) 
and 1-acetyl-4-piperidone (141 mg, 1 mmol) were added. After 1.5 h stirring at 
80ºC reaction reached completion. While still hot water was added and the 
mixture allowed cooling. A white precipitate formed that was filtered off and 
rinsed with water to afford 3.5 (204 mg, 84%) as a white solid of mp: 199 – 
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200ºC. 1H NMR (400 MHz, DMSO) δ 10.72 (s, 1H), 7.17 (d, J = 8.7 Hz, 1H), 6.93 
(d, J = 2.4 Hz, 1H), 6.66 (dd, J = 8.6, 2.5 Hz, 1H), 4.59 (s, 2H), 3.82 (t, J = 5.8 Hz, 
2H), 3.74 (s, 3H), 2.84 (d, J = 5.6 Hz, 2H), 2.12 (s, 3H). 13C NMR (101 MHz, 
cdcl3) δ 168.74, 153.09, 133.02, 130.81, 125.61, 111.50, 110.29, 105.79, 99.48, 55.28, 
43.46, 38.49, 23.79, 21.58. HRMS (ESI+): m/z calcd for C14H16N2O2 (M)+ 244.1212, 
found 244.1204. HPLC purity 97% (230 to 400 nm). 
 
Assays for 5-HT receptors and 5-HT transporter 
Ki determinations, agonist and antagonist functional data was generously 
provided by the National Institute of Mental Health's Psychoactive Drug 
Screening Program, Contract # HHSN-271-2013-00017-C (NIMH PDSP). The 
NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the University of North 
Carolina at Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda 
MD, USA.  
Radioligands and cell lines employed for determining binding affinities: 
[3H]8-OH-DPAT in CHO (chineses ovary hamster) cells stably expressing 5-
HT1A, [3H]GR125743 in HEKT (human embryonic kidney) cells transiently 
expressing 5-HT1D , [3H]Ketanserin in HEKT cells transiently expressing 5-
HT2A, [3H]LSD  in HEKT cells stably expressing 5-HT2B, [3H]Mesulergine in 
Flp-IN HEKT cells stably expressing 5-HT2C, [3H]LY278584 in HEKT cells 
stably expressing 5-HT3, [3H]LSD in HEKT cells stably expressing 5-HT6 or 5-
HT7 and [3H]Citalopram in HEKT cells stably expressing SERT. 
Functional characterization of compounds in 5-HT2A, 5-HT2B and 5-HT2C was 
performed in transfected Flp-In HEK cells stably expressing the corresponding 
receptor subtype in the calcium mobilization FLIPRTETRA assay. 
Detailed experimental protocols are described in the PDSP web site 
http://pdsp.med.unc.edu/. 
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Determination of MAO isoform activity 
 The potential effects of the test drugs on hMAO activity were investigated by 
measuring their effects on the production of hydrogen peroxide from p-
tyramine (a common substrate for both hMAO-A and hMAO-B), using the 
Amplex Red MAO assay kit (Molecular Probes, Inc., Eugene, Oregon, USA) 
and microsomal MAO isoforms prepared from insect cells (BTI-TN-5B1-4) 
infected with recombinant baculovirus containing cDNA inserts for hMAO-A 
or hMAO-B (Sigma-Aldrich Química S.A., Alcobendas, Spain). 
The production of H2O2 catalysed by MAO isoforms can be detected using 10-
acetyl-3,7-dihydroxyphenoxazine (Amplex Red reagent), a non-fluorescent, 
highly sensitive and stable probe that reacts with H2O2 in the presence of 
horseradish peroxidase to produce a fluorescent product: resorufin. In this 
study hMAO activity was evaluated using the above method following the 
general procedure described previously by us87. 
Briefly, 0.1 ml of sodium phosphate buffer (0.05 M, pH 7.4) containing various 
concentrations of the test drugs (new compounds or reference inhibitors) and 
adequate amounts of recombinant hMAO-A or hMAO-B required to obtain in 
our experimental conditions the same reaction velocity, i.e., to oxidize (in the 
control group) the same concentration of substrate: 165 pmol of p-
tyramine/min (hMAO-A: 1.1 g; specific activity: 150 nmol of p-tyramine 
oxidized to p-hydroxyphenylacetaldehyde/min/mg protein; hMAO-B: 7.5 g; 
specific activity: 22 nmol of p-tyramine transformed/min/mg protein) were 
incubated for 15 min at 37ºC in a flat-black-bottom 96-well microtiter 
(microtest plate, BD Biosciences,  Franklin Lakes, NJ, USA) placed in the dark 
fluorimeter chamber. After this incubation period, the reaction was started by 
adding (final concentrations) 200 μM Amplex Red reagent, 1 U/ml 
horseradish peroxidase and 1 mM p-tyramine. The production of H2O2 and, 
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consequently, of resorufin was quantified at 37 °C in a Multi-Detection 
microplate fluorescence reader (Fluostar Optima, BMG Labtech GmbH, 
Offenburg, Germany) based on the fluorescence generated (excitation, 545 nm, 
emission, 590 nm) over a 15 min period, in which the fluorescence increased 
linearly. 
Control experiments were carried out simultaneously by replacing the test 
drugs (new compounds and reference inhibitors) with appropriate dilutions 
of the vehicles. In addition, the possible capacity of the above test drugs to 
modify the fluorescence generated in the reaction mixture due to non-
enzymatic inhibition (e.g., for directly reacting with Amplex Red reagent) 
was determined by adding these drugs to solutions containing only the 
Amplex Red reagent in a sodium phosphate buffer. 
The specific fluorescence emission (used to obtain the final results) was 
calculated after subtraction of the background activity, which was determined 
from vials containing all components except the MAO isoforms, which were 
replaced by a sodium phosphate buffer solution. 
 
Assays for MT1 and MT2 Receptor Subtypes 
Detailed description of the affinity and intrinsic activity studies are included 
in the experimental section of chapter 1. 
 
In Vitro Blood–Brain Barrier Permeation Assay by PAMPA method 
 The PAMPA assay was carried out according to the procedures described in 
the experimental section of chapter 2. 
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Oxygen Radical Absorbance Capacity Assay. The ORAC-FL method was 
followed88, using a Polarstar Galaxy plate reader (BMG Labtechnologies 
GmbH, Offenburg, Germany) with 485-P excitation and 520-P emission filters. 
The equipment was controlled by Fluorostar Galaxy software (version 4.11-0) 
for fluorescence measurement. 2,2’-Azobis-(amidinopropane) dihydrochloride 
(AAPH), (±)-6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (trolox) 
and fluorescein (FL) were purchased from Sigma-Aldrich. The reaction was 
carried out in 75 mM phosphate buffer (pH 7.4) and the final reaction mixture 
was 200 L. Antioxidant (20 L) and FL (120 L; 70 mM, final concentration) 
solutions were placed in a black 96-well microplate (96F untreat, NuncTM). The 
mixture was pre-incubated for 15 min at 37 ºC and then, AAPH solution (60 
L, 12 mM, final concentration) was added rapidly using a multichannel 
pipette. The microplate was immediately placed in the reader and the 
fluorescence recorded every minute for 80 min. The microplate was 
automatically shaken prior each reading. Samples were measured at eight 
different concentrations (0.1-1M). A blank (FL + AAPH in phosphate buffer) 
instead of the sample solution and eight calibration solutions using trolox (1-8 
M) were also carried out in each assay. All the reaction mixtures were 
prepared in duplicate, and at least three independent assays were performed 
for each sample. Raw data were exported from the Fluostar Galaxy Software 
to an Excel sheet for further calculations. Antioxidant curves (fluorescence vs. 
time) were first normalized to the curve of the blank corresponding to the 
same assay, and the area under the fluorescence decay curve (AUC) was 
calculated. The net AUC corresponding to a sample was calculated by 
subtracting the AUC corresponding to the blank. Regression equations 
between net AUC and antioxidant concentration were calculated for all the 
samples. ORAC-FL values were expressed as trolox equivalents by using the 
standard curve calculated for each assay, where the ORAC-FL value of trolox 
was taken as 1.0. 
139 
 
 
Neurogenesis studies in vitro in the presence of different melatonin 
analogues.  
Detailed descriptions of the procedures employed for the evaluation of the 
expression of neurogenic markers in the presence of different compounds in 
the presence or absence of luzindole can be found in the experimental section 
of chapter 2. 
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Chapter 4 
 
Conformationally restrained 
carbamoylcholine analogues and bioisosteres. 
Design, synthesis and pharmacology at 
nicotinic acetylcholine receptors (nAChRs) 
 
Introduction 
Acetylcholine (ACh) is one of the most important neurotransmitters in 
the central nervous system (CNS) and peripheral nervous system (PNS). 
Presence of ACh is ubiquitous among all levels of life complexity, and has 
gained relevance along evolution1. In the nervous system its actions are 
mediated through two types of acetylcholine receptors (AChRs): the 
metabotropic G protein-coupled muscarinic AChRs (mAChRs) and the ligand-
gated ion channel nicotinic AChRs (nAChRs). Neuronal nAChR are located at 
presynaptic and postsynaptic neuron terminals where they modulate 
functions of major neurotransmitter systems, and thereby influence numerous 
brain functions2–4. There is wide evidence that nAChRs play a role in a broad 
range of neurodegenerative and psychiatric disorders such as Alzheimer’s 
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disease, Parkinson’s disease, epilepsy, schizophrenia, anxiety, and 
depression5–17. These implications provide support to the development of 
potential treatments for neurological and neurodegenerative diseases based 
on the direct intervention in the cholinergic system5–7,18. To date the only 
marketed drug targeting nAChR is varenicline, for smoking cessation19.  
The nAChR complex consists of five subunits embedded in the cell 
membrane symmetrically arranged forming the channel pore (figure 1A). The 
architecture of nAChRs is similar in CNS and PNS, but in contrast to muscle 
receptors, neuronal receptors only contain α (α2-α10) and β (β2-β4) subunits20. 
Among all the possible receptor combinations, in the CNS the vast majority of 
the nAChRs are heteromeric receptors containing α4 and β2 subunits and α7 
homomeric receptors, whereas in the PNS the most prevalent are α3 and β3 
heteromers (figure 1B)21. The orthosteric binding site of ACh binds is situated 
in the interface of neighboring α subunits and between α and β subunits in the 
heteromeric receptors22–24. 
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 A B 
Figure 1. (A) Structure of a generic nicotinic receptor embedded in the cell membrane; 
the five transmembrane domains configure the ion channel. (B) Schematic 
representation of the subunit arrangement in α7 and α4β2 nAChRs as examples of 
homomeric and heteromeric receptors. The drop-like coloured shape found in the 
interfaces of the subunits α7 and α4-β2 represents the ACh orthosteric binding site. 
Pictures adapted from Changeaux (2010)25. 
 
In order to achieve a better understanding of nAChR physiological and 
pathophysiological roles within the complexity of neurotransmission and 
neurological processes, and the eventual exploitation of their potential as 
therapeutic targets for the above-mentioned disorders, the development of 
tools capable to distinguish between the different nAChR subtype recognition 
is needed21,26. This process is not trivial since the orthosteric binding site is a 
highly conserved region within the family of nAChRs27.  
Recently Frølund’s group at University of Copenhagen synthesized 
and studied the structure-activity relationship (SAR) of a wide set of 
carbamoylcholine (CCh) analogues that led to the discovery of potent nAChR 
agonists with high affinity and very good selectivity for α4β2 subtypes. Some 
selected structures are depicted in figure 228–30. 
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Figure 2. Structures of CCh (carbamoylcholine), 4.1 (DMABC, 3-(dimethylamino)butyl 
dimethylcarbamate) and selected analogues in which the carbamate moiety has been 
modified: 4.2 (3-(dimethylamino)butyl methylcarbamate), 4.3 (3-
(dimethylamino)butyl azetidine-1-carboxylate), 4.4 [4-(1-methyl-1H-imidazol-2-
yloxy)but-2-yl]-N,N-dimethylamine and 4.5 [4-(1,4-dimethyl-1H-imidazol-2-
yloxy)but-2-yl]-N,N-dimethylamine. 
 
CCh analogues 4.1 and 4.2 exhibit a high degree of selectivity for 
nicotinic over muscarinic receptors28. Additionally, compounds 4.2-4.5 display 
a pronounced degree of selectivity towards nAChRs subtypes containing β2 
subunits when both their potencies and binding affinities for α4β2, α3β4, α4β4 
and α7 nAChRs are compared30,31. Initially, these CCh analogues were thought 
to bind to the nAChRs in a linear conformation similar to that determined by 
X-ray crystallography for acetylcholine ACh and CCh co-crystalised with 
Lymnaea stagnalis ACh binding protein (Ls-AChBP), a widely used nAChR 
model32. This putative binding pose was further supported by docking studies 
and the ability of compound 4.1 to superimpose to the epibatidine bound 
conformation in Ls-AChBP 30. Later crystallographic studies demonstrated 
that 4.1 and 4.4 bind to Ls-AChBP in a folded conformation favored by a likely 
intramolecular hydrogen bond established between the protonated 
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dimethylamino group and the ester-like oxygen of these compounds (figure 
3)31.  
 
Figure 3. Superimposition of the bound conformation of CCh (green, linear) and R-
DMABC (R)-4.1 (blue, folded), both determined by X-ray structure in Ls-AChBP 
binding site. The carbonyl of (R)-4.1 forms a hydrogen bond with a water molecule 
(red ball) in the binding site. The ester-like oxygen is within hydrogen bond distance 
to the presumably protonated dimethylamino group (3.0 Å). 
 
As abovementioned, the binding of ACh to the nAChRs occurs in the 
interface between two subunits, with at least one α subunit involved. The 
putative union of CCh, DMABC (4.1) and related compounds to the nAChRs 
is suggested to resemble that of ACh with the dimethyl ammonium group 
covered by the C-loop of the α subunit whilst the other end faces the 
complementary subunit. The most important interaction proposed with the 
complementary subunit is a hydrogen bond established between the carbonyl 
in the carbamate series or N3 in the imidazole, and a water molecule close to 
the subunit interface. This interaction has been observed in 4.1 and 4.4 bound 
to Ls-AChBP and it is considered a determinant contact for optimal binding to 
nAChR (figure 4)30,31,33.  
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Figure 4. Superimposition of (R)-4.1 (cyan), and (R)-4.4 (orange) co-crystalised in Ls-
AChBP. The alkyl-ammonium part of both molecules appears covered in the primary 
subunit (purple) by the C-loop (big purple loop on the right) whereas the carbamate of 
4.1, and the imidazole of 4.4 are found in the interface of both subunits interacting 
with a water molecule of the complementary subunit (blue and yellow ball). Relevant 
amino acid side-chains are shown. Figure adapted from Rohde et al. (2012)33.  
 
Besides this proposed hydrogen-bond interaction with the 
complementary subunit, the carbamate/azole part of the ligand is considered 
to be determinant for the observed subtype selectivity profiles. Plausible steric 
clashes against the complementary subunit are thought to be the most relevant 
interaction regarding nAChR subtype discrimination. To such extent in the 
case of imidazoles that α4β2 nAChRs subtype stoichiometry selectivity can be 
achieved31. 
 
Approach 
The carbamate moiety was extensively studied and high affinity 
selective ligands were developed. The alkyl-amino end of 4.1 was also studied 
by means of chain elongation, resolution of the enantiomers, alpha-methyl 
suppression or alkyl substitution, among others30. Some cyclic structures were 
also studied before but herein, we proposed the first systematic introduction 
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of different cycles representing various degrees of constriction within the 
structure of the flexible ligand 4.1 aiming to diminish the degrees of freedom 
of the original scaffold29,34. The main structural features of 4.1, the carbamoyl 
moiety and the protonatable amine at physiologic pH, were embedded in 
different cyclic structures (figure 5). The main purpose of this approach was to 
push the formation of the putative intramolecular hydrogen bond described 
above in the crystal structure of 4.1 in Ls-AChBP in order to verify the folded 
conformation of the bound ligand. For this purpose, a cyclopropyl moiety was 
included within the structure of 4.1 and 4.2. Additionally, the main structural 
features of 4.1 were progressively embedded in bigger synthetically-accessible 
cycles in order to gain insights on the ability of different scaffolds showing 
different degrees of bulkiness and flexibility to fit within the ACh binding site 
and presumably potentiate the ligand selectivity. Thus, several urea and 
thiourea analogues were prepared. Piperazine or homopiperazine have been 
widely exploited in the development of nicotinic ligands previously35.  
Additionally, in a continuation of Frølund’s group efforts to study the 
interactions of nicotinic ligands with the complementary subunit of the 
receptor, we utilized two oxadiazole isomers in the bioisosteric replacement of 
the carbamate moiety of compound 4.1 whilst the flexible amino-alkyl scaffold 
was kept intact (figure 5). 
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Figure 5. Schematic representation of the modifications performed in the structure of 
4.1. 
 
Chemistry 
Synthesis of restricted analogues of DMABC (4.1) 
The synthetic route that led to target compounds trans-4.17 - cis-4.20 is 
outlined in scheme 1. Trans-4.6 was synthesized via enzymatic hydrolysis of 
the meso diester diethyl trans-1,2-cyclopropanedicarboxylate by pig liver 
esterase (PLE)36,37. This procedure transformed the water-insoluble diethyl 
trans-1,2-cyclopropanedicarboxylate into the corresponding soluble mono-
hydrolysis product, which was easily extracted from the buffer with ethyl 
acetate, thus rendering trans-4.6 in excellent yield. This method is reportedly 
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also valid for diethyl cis-1,2-cyclopropanedicarboxylate, however for the 
synthesis of cis-4.7 alcoholysis of the inexpensive 1,2-
cyclopropanedicarboxylic anhydride was chosen instead affording the mono-
ester in very good yield38. 
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Cpd. R Yield(%)  Cpd. R Yield(%) 
trans-4.9 Me 83  cis-4.15 Me 65 
trans-4.10 H 78  cis-4.16 H 70 
cis-4.11 Me 76  trans-4.17 Me 65 
cis-4.12 H 75  trans-4.18 H 95 
trans-4.13 Me 77  cis-4.19 Me 94 
trans-4.14 H 56  cis-4.20 H 90 
 
Scheme 1. Reagents and conditions (a) PLE, pH 7, 0.1M K2HPO3 buffer, rt, 3h; (b) DPPA, 
TEA, tBuOH, toluene, 80ºC, 24h; (c) DIBAL, toluene, -78ºC, 4h; (d) (1) CDI, DMAP 
(cat.), toluene, rt, 3h; (2) RMeNH 33% EtOH, rt, 1h; (e) TFA, CH2Cl2, rt, 0.5h ; (f) 
NaCNBH3, CH2O, H2O-MeCN, rt, 1h.; (g) EtOH, pyr, reflux, 18h; (h) DPPA, TEA, 
tBuOH, toluene, 55ºC, 24h. 
 
The Curtius rearrangement of acids trans-4.6 and cis-4.6 mediated by 
diphenhylphosphoryl azide (DPPA) rendered both trans-4.7 and cis-4.7 in 
excellent yields. An adapted mechanism for the synthesis of cis-4.7 is shown in 
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scheme 2. DPPA transfers the azido group to the carboxylic acid thus forming 
an acyl azide stabilized by resonance. Upon heating, the acyl azide 
decomposes through a concerted mechanism releasing molecular nitrogen and 
forming an isocyanate. Finally, attack of tert-butanol over the electrophilic 
isocyanate forms the carbamate cis-4.7. The heating was milder in the 
synthesis of cis-4.6 in order to avoid isomerization. Nevertheless, unlike Csuk 
et al. reported previously, no isomerization of the cis-isomer was observed at 
all in NMR39–41.  
 
Scheme 2. Suggested mechanism for the DPPA-mediated Curtius rearrangement 
adapted to the synthesis of cis-4.7. 
 
Trans-4.7 and cis-4.7 were chemoselectively reduced to the 
corresponding alcohols trans-4.8 and cis-4.8 with diisobuthylaluminium 
hydride (DIBAL) in excellent yield. Different reducing agents (LiBH4, LiAlH4 
and DIBAL) were tested to selectively reduce the carbonyl group of the 
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ethylcarboxylate to the corresponding alcohol; out of the three tested reducing 
agents, DIBAL provided the best yields37.  
Boc-protected methyl- and dimethylcarbamates trans-4.9, trans-4.10, 
cis-4.11 and cis-4.12 were obtained in good yields in a two-step synthesis. First, 
addition of carbonyldiimidazole (CDI) over the corresponding alcohol (trans-
4.8 or cis-4.8) formed the corresponding imidazolylcarboxylate. Then, 
dimethylamine or methylamine was added. The nucleophilic amine attacked 
the electrophilic imidazolylcarboxylate forming the corresponding carbamate. 
In each step of the reaction imidazole was released to the medium (scheme 3). 
 
Scheme 3. Schematic representation of the two steps leading to the formation of 
carbamate trans-4.9 from trans-4.8 (Im: imidazole). 
 
The Boc group was cleaved from compounds trans-4.9, trans-4.10, cis-
4.11 and cis-4.12 using a mixture of trifluoroacetic acid and dichloromethane42. 
The yields of the free primary amines trans-4.13, trans-4.14, cis-4.15 and cis-4.16 
ranged from fair to good. During the work-up the process of extraction of the 
corresponding free amine from a basified solution of the salt was tedious and 
required continuous liquid-liquid extraction with dichloromethane. The 
reductive alkylation of the primary amines with formaline and sodium 
cyanoborohydride afforded the demethylated derivatives trans-4.17, trans-
4.18, cis-4.19 and cis-4.20 in excellent yields43. Both primary and dimethylated 
amines were tested as oxalate salts. 
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Addition of dimethylcarbamyl chloride to 3-dimethylaminopyrrolidine 
afforded compound 4.21 in fair yield. Compounds 4.22-4.24 were synthesised 
by addition of ethylisocyanate, methylisothiocyanate, or ethylisothiocyanate 
to a solution of 3-dimethylaminopyrrolidine in ether. The corresponding ureas 
and thioureas were obtained in various yields (scheme 4). Compounds 4.25-
4.27 were obtained from 1-methylpiperazine, 1-methylhomopiperazine and 1-
Boc-homopiperazine and dimethylcarbamyl chloride. Compounds 4.28-4.35 
were obtained by addition of the corresponding isocyanate or isothiocyanate 
to 1-methylpiperazine, 1-methylhomopiperazine and 1-Boc-homopiperazine. 
The ureas and thioureas generally precipitated off the solvent and were 
obtained in high yields and good purity (scheme 5). 
 
Cpd X R2 yield(%) 
4.21 - - 55 
4.22 O Et 62 
4.23 S Me 7 
4.24 S Et 63 
 
Scheme 4. Reagents and conditions. (i) Dimethylcarbamoyl chloride, TEA, THF (anh.) rt, 
2h; (j) Et2O, rt, 1h. 
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Cpd n X R1 R2 yield(%) 
4.25 1 - - Me 65 
4.26 2 - - Me 67 
4.27 2 - - Boc 100 
4.28 1 O Me Et 100 
4.29 2 O Me Et 98 
4.30 1 S Me Me 100 
4.31 2 S Me Me 100 
4.32 1 S Me Et 98 
4.33 2 S Me Et 98 
4.34 2 S Boc Me 98 
4.35 2 S Boc Et 99 
 
Scheme 5. Reagents and conditions. (i) Dimethylcarbamoyl chloride, TEA, THF (anh.) rt, 
2h; (j) Et2O, rt, 1h.  
 
Amide 4.36 was synthesized from 1-Boc piperidine-4-carboxylic acid 
via carbonyldiimidazole coupling with dimethylamine in good yield. Additon 
of bromhydric acid to amide 4.36 cleaved the protecting group and formed the 
hydrobromide salt 4.37 in fair yield after recrystallization. This procedure was 
also employed in the synthesis of compounds 4.38, 4.39 and 4.40 which 
hydrobromide salts were isolated in good and very good yield respectively 
(scheme 6). 
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Scheme 6. Reagents and conditions.(k) CDI, THF, TEA, DMA, 18h; (l) HBr (aq.), rt, 0.5h. 
 
Synthesis of oxadiazole-containing DMABC analogues. 
Compounds 4.42 and 4.45 were both synthesized starting from ethyl 
levulinate (scheme 7). Ethyl levulinate underwent a microwave-assisted 
cyclocondensation with acetamidoxime to afford 4.41 in very good yield. 
Reductive alkylation of 4.41 with dimethylamine and sodium 
cyanoborohydride afforded the 1,2,4 oxadiazole 4.42 in poor yield. Direct 
reductive alkylation of ethyl levulinate with dimethylamine and hydrogen in 
Pd/C afforded the aminoester 4.43 in fair yield. The microwave-irradiated 
hydrazinolisis of 4.43 quantitatively gave the corresponding hydrazide 4.44. 
Cyclocondensation of 4.44 with ethyl orthoacetate afforded the 1,3,4-
oxadiazole 4.45 in poor yield. 
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Scheme 7. Reagents and conditions. (a) Acetamidoxime, K2CO3, MeCN, 180ºC (mw), 1h; 
(b) dimethylamine hydrochloride, dimethylamine (aq.), MeOH, Na(CN)BH3, rt, 18h; 
(c) dimethylamine (aq.), EtOH, AcOH, H2, Pd/C, 1 atm, rt, 48h; (e) ethyl orthoacetate, 
125ºC (mw), 1h. 
 
Pharmacology 
Binding at recombinant nAChRs 
The binding affinities of the compounds were determined at 
recombinant heteromeric rat α4β2, α4β4 and α3β4 receptors. The summarized 
results of radioligand displacement binding studies of compounds showing 
significant affinity for either receptor are shown in table 2 and 3. None of the 
synthetic cyclic or oxadiazolic analogues of DMABC (4.1) was able to achieve 
its high affinity for α4β2 nAChR subtype (20 nM)28.  
 165 
 
Table 2. Competition binding, Ki (µM) [pKi ± S.E.M], of a selection of restricted 
analogues of DMABC at various nAChRs. 
Series Cpd α4β2 α4β4 α3β4 
 (S)nicotine 0.013 [7.85 ± 0.07] 0.072 [7.14 ± 0.09] 0.29 [6.54 ± 0.07] 
 4.130 0.02 [7.7 ± 0.04] 0.15 [7.7 ± 0.04] 0.42 [7.7 ± 0.04] 
 4.228 0.013 [7.9] 2.6 [5.0] 10 [5.0] 
 
trans-4.17 ~100 [~4.0] ~1000 [~3.0] ~1000 [~3.0] 
trans-4.18 ~300 [~3.5] ~1000 [~3.0] >1000 [<3.0] 
cis-4.19 1.5 [5.82 ± 0.08] 14 [4.84 ± 0.07] 14 [4.87 ± 0.08] 
cis-4.20 2.1 [5.67 ± 0.05] ~30 [~4.5]a ~50 [~4.3]a 
 
4.21 6.4 [5.19 ± 0.05] 2.3 [5.64 ± 0.07] 6.4 [5.19 ± 0.11] 
4.22 5.7 [5.25 ± 0.08] ~30 [~4.5]a ~30 [~4.5]a 
4.23 2.3 [5.63 ± 0.09] ~100 [~4.0]a ~300 [~3.5]a 
4.24 1.2 [5.93 ± 0.04] ~300 [~3.5]a >1000 [<3.0] 
 
4.25 ~30 [~4.5]a ~50 [~4.3]a ~50 [~4.3]a 
4.28 10 [5.00 ± 0.05] ~100 [~4.0]a ~100 [~4.0]a 
4.30 19 [4.72 ± 0.08] ~500 [~3.3]a >1000 [<3.0] 
4.32 5.8 [5.23 ± 0.07] ~300 [~3.5]a >1000 [<3.0] 
4.37 >1000 [<3.0] >1000 [<3.0] >1000 [<3.0] 
 
4.26 ~50 [~4.3]a ~300 [~3.5]a ~300 [~3.5]a 
4.38 11 [4.94 ± 0.11] ~50 [~4.3]a ~300 [~3.5]a 
a Since a complete concentration-inhibition curve could not be obtained for the 
compound in the concentration ranges tested the IC50 value given is an estimate. nd, 
not determined. 
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Table 3. Competition binding, Ki (µM) [pKi ± S.E.M], of oxadiazole analogues of 
DMABC at various nAChRs. 
Series Cpd α4β2 α4β4 α3β4 
 
4.42 1.7 [5.76 ± 0.06] ~50 [~4.3]a ~300 [~3.5]a 
 
4.45 18 [4.73 ± 0.05] ~100 [~4.0]a ~300 [~3.5]a 
a Since a complete concentration-inhibition curve could not be obtained for the 
compound in the concentration ranges tested the IC50 value given is an estimate. nd, 
not determined. 
 
Among the cyclopropane series the relative position of the substituents 
on the cycle is essential for receptor recognition, being the trans series totally 
devoid of affinity for any tested nAChRs. Conversely, the cis series, if still on a 
60-fold decrease in affinity constant compared to 4.1, showed a selectivity 
pattern similar to that of the reference compounds 4.1 and 4.2, being the 
dimethylaminocarbamate cis-4.19 slightly less selective than the 
monomethylcarbamate cis-4.20 for the α4β2 subtype than for the α3β4 or the 
α4β4. 
All dimethylaminopyrrolidine representatives showed similar low 
micromolar binding affinities. Dimethyl urea derivative 4.21 showed no 
selectivity for any of the tested nAChRs. Replacement for a monoethyl urea 
(4.22) slightly increased the degree of selectivity (both α4β4/α4β2, α3β4/α4β2 ~5 
fold). Monosubstituted thioureas 4.23 and 4.24 maintained the micromolar 
affinity with improved selectivity: ethylthiourea 4.24 was the most selective 
compound of the whole set (α4β4/α4β2  ~250 fold, α3β4/α4β2  >800 fold) with a 
selectivity profile identical to that of 4.2 (α4β4/α4β2  220 fold, α3β4/α4β2  770 
fold). In this series, N-mono-substituted ureas and thioureas showed a greater 
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ability to discriminate between the different tested nAChR with clear 
preference for the α4β2 subtype than the N,N-disubsituted 4.21. 
Very few urea and thiourea analogues with larger cycles reached 
affinity constant values below 10 μM for the α4β2 nAChR except for 
piperazines 4.28 and 4.32. A mild selectivity for α4β2 receptors was observed in 
all the N-monosubstituted ureas and thioureas that showed significant 
affinity. Even if a full displacement curve could not be obtained for the N,N-
dimethylurea 4.25, this compound appears to lack selectivity for any subtype. 
Deletion of the N-methyl substituent, and replacement of the sp2  nitrogen of 
4.25 for a sp3 carbon gave the inactive compound 4.37. The homopiperazine 
family was totally inactive, with the only exception of the secondary amine 
4.38. None of 1-methyl homopiperazines was able to significantly bind to the 
receptor.  
  The affinity of compound 4.42 for the α4β2 nAChR resulted 75-fold 
lower than that of compound 4.1. In the case of 4.45 the affinity drops an 
additional order of magnitude for the same receptor subtype (750-fold).  The 
carbamate substitution of 4.1 for either methyl-oxadiazole isomer (3-methyl-
1,2,4-oxadiazole and 2-methyl-1,3,4-oxadiazole) provoked a loss of affinity, 
more pronounced in the case of the 1,3,4-oxadiazole 4.45. It is worth noting 
that despite the penalty in affinity, the selectivity profile of compound 4.42 is 
similar to that of compound 4.1: greater ability to discriminate between the 
α3β4/α4β2 than the α4β4/α4β2 pair. 
 
Functional characterization at recombinant nAChRs 
Only selected compounds were functionally characterized in α4β2 and 
the α3β4 in the Fluorescent Imaging Plate Reader Membrane Potential Blue 
(FLIPR-FMP) assay (table 4).  Several cycle-containing compounds proved to 
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be agonists but unfortunately EC50 could not be determined due to its weak 
potency except for 4.21. This compound, as a racemic mixture, was as potent 
as other high affinity DMABC analogues like 4.3 (EC50 7.1 µM) at  the α4β2 
subtype but lacking any selectivity over α3β4 (only 3 fold)30. In the same assay 
the oxadiazole 4.42 was characterized as α4β2 antagonist (table 5). 
Table 4. Functional characteristics of the selected compounds at α4β2 and α3β4 nAChRs 
in the FMP agonist assay, EC50 (µM) [pEC50 ± S.E.M]. 
 
Series Cpd α4β2 α3β4 
 (S)nicotine 0.72 [6.14 ± 0.08] 1.5  [5.82 ± 0.07] 
 
cis-4.15 agonist
a agonista 
cis-4.19 agonist
a agonista 
cis-4.20 agonista agonista 
 
4.21 10 [5.01 ± 0.06] 32 [4.49 ± 0.08] 
4.22 agonista agonista 
4.23 agonista agonista 
4.24 agonista agonista 
 
4.28 agonista agonista 
4.32 agonista agonista 
a A complete concentration-inhibition curve could not be obtained for the compound 
in the concentration ranges. The compound elicited significant agonist responses at 
300 µM. b Weak agonist response at 1 mM. b n represents the number of members in 
the ring 
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Table 5. Functional characteristics of compound 4.42 at α4β2 and α3β4 nAChRs in the 
FMP antagonist assay, EC50 (µM) [pEC50 ± S.E.M]. 
Series Cpd α4β2 α3β4 
 
4.42 4.2 µM [5.37 ± 0.09] >300 µM [<3.5] 
 
 
Molecular modelling. Docking studies 
The compounds were docked into Ls-AChBP co-crystalised with (R)-
4.1 and the top-scoring poses visually evaluated based on its ability to 
superimpose to the crystal structure of (R)-4.1. In the case of cyclopropane-
containing compounds, the automated docking agreed with the binding 
results and clearly discriminated between the trans and cis-isomers. The 
binding conformation of compound cis-4.19 docked into the binding site of Ls-
AChBP corresponds with the folded crystalised structure of (R)-4.1 (figure 
6A). 
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Figure 6. (A) Superimposition of (R)-4.1 (blue) and compound cis-(1R,2S)-4.19 
(orange) and (B) compound (S)-4.21 (pink) docked into the same binding site (purple) 
with Schrödinger/Glide.  
 
The dimethylammonium moiety of cis-4.19 rightly overlaps with that 
of (R)-4.1, maintaining also the hydrogen-bond distance between the proton 
held over the charged nitrogen and the ester-like oxygen of the carbamate 
(figure 6B). Another important feature maintained is the distance between the 
carbonyl group and the water molecule buried in the binding pocket. Even if 
the main structural features of cis-4.19 spatially correspond with those of (R)-
4.1 crystal structure, the cyclopropyl edge is pointing in a different relative 
angle compared to the methyl substituent of (R)-4.1. The distinct geometry of 
cis-4.19 could involve steric clashes against the wall of the binding pocket and 
in turn, undermine its affinity. 
In the case of the docked conformation of dimethylaminopyrrolidine 
(S)-4.21, both the cationic center and the carbonyl group fairly overlap 
spatially with the folded structure of (R)-4.1, but the N,N-dimethyl 
substituents attached to ammonium nitrogen do not. The intramolecular 
hydrogen bond proposed in the case of both (R)-4.1 and cis-4.19, in the case of 
(S)-4.3 does not seem feasible due to the boat conformation of the pyrrolidine 
ring and the urea nature of the compound. The urea nitrogen that replaces for 
A B 
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the ester-like oxygen of compounds (R)-4.1 has a single lone pair in a p orbital 
conjugated with the urea carbonyl, what would weaken its availability for 
establishing hydrogen-bond interactions. 
None of the series of compounds synthesized in this work showed a 
selectivity profile attributable to the cycle used as scaffold. Conversely all 
series reinforced the hypothesis that the determinant feature for the selectivity 
displayed by 4.1 and its analogues is the substitution of the N-carbamoyl 
moiety regardless of the scaffold employed. The structural observations 
suggest that the interactions with the complementary subunit that putatively 
permit compound 4.2 to discriminate between different nAChR subtypes 
better than 4.1 are clearly present in the case of the cis-4.19 - cis-4.20 pair.  
The agreement found in the N-carbamate substitution-selectivity 
relationship between dimethylaminobutyl flexible ligands (4.1 and 4.2) and 
the cis-cyclopropane and dimethylaminopyrrolidine series further support 
that the binding to the nicotinic receptors of the latter should occur in a similar 
manner.   
Docking of compound (R)-4.42 revealed that the oxadiazole ring could 
virtually intervene in the same contacts as 4.1 does (figure 7). The alkyl-
ammonium ends of both compounds reasonably overlap. Additionally the 
oxygen within the oxadiazole ring is at hydrogen-bond distance from the 
dimethylammonium group. The nitrogen in position 4 within the oxadiazole 
ring replaces for the carbonyl oxygen in (R)-4.1 while keeping the methyl 
group in position 3 in a rather similar pose. Taking into account the 
importance of the N-carbamate substitution in subtype discrimination, the 
relative position of this methyl attached to the oxadiazole ring could justify 
the similar selectivity profile shared between 4.1 and 4.42. 
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Figure 7. Superimposition of (R)-4.1 (green) and compound 4.42 (gray) docked into Ls-
AChBP co-crystalised with (R)-4.1 with Schrödinger/Glide. 
 
 The structure-function relationship that determines the ability of 
nAChRs ligands to promote the activation of the receptor remains elusive. 
Numerous efforts have been made in order to rationalize the mechanistic 
determinants behind the effect of agonists. The closure of the C-loop of the 
primary subunit Ls-AChBP, as α4β2 surrogate, has been associated with the 
efficacy of partial agonists.44,45 More recently, it has been proposed that the C-
loop closure determines mostly the binding affinity whereas the efficacy of 
ligands relies on their ability to stabilize a strong intersubunit bridge between 
the interfaces of the α subunit and the complementary subunit33,46. 
Accordingly, even if an EC50 could not be obtained for most of the compounds 
prepared in this work, all cyclic-analogues of 4.1 which functional profile was 
characterized were agonists at the α4β2 subtype regardless of the cyclic 
scaffold employed. An agonism more likely to be attributable to the ureas and 
thioureas than to the amino-alkylic core. Following the same hypothesis, the 
substitution of the carbamate of 4.1 for 3-methyl-1,2,4-oxadiazole ring (4.42) 
could represent the opposite case. The original 3-dimethylaminobutyl scaffold 
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has been maintained intact, but the oxadiazole replacement possibly blocks 
the contacts that could lead to the activation of the α4β2 receptor. 
 
Conclusions 
A series of cyclic DMABC (4.1) analogues have been synthesized and 
pharmacologically characterized in different nAChRs subtypes. Summarizing 
the general results, in the context of this work, the smaller the cycle employed, 
the better affinity achieved. The conformational restriction approach used in 
this work has failed to provide potent and selective α4β2 nAChR ligands.  The 
compounds showing the highest affinity belong to the aminocyclopropane 
and aminopyrrolidine series, but the poor activity results obtained cannot 
clearly confirm the folded disposition of compound 4.1 as the preferred 
conformation upon binding to the α4β2 nAChR. Nevertheless the results 
obtained in this work reinforce the importance of the N-carbamate 
substitution in the structure-selectivity relationship of CCh derivatives, and 
show how substituted urea and thiourea can partially replace for such moiety. 
Derivative 4.21 proved to be functionally as potent as other studied ligands 
within the flexible analogues series. Further biostructural studies would be 
needed, and the pharmacology profile of both possible enantiomers 
established. Furthermore, our efforts to broaden up the family of DMABC 
azolic analogues have demonstrated how the bioisiosteric replacement of the 
carbamate of 4.1 for a 3-methyl-1,2,4-oxadiazole (4.42) leads to a reversion of 
the intrinsic activity while still maintaining the selectivity profile of the 
reference compound. Therefore, further exploitation of the bioisosteric 
replacement of the carbamate moiety could be an interesting strategy for the 
development of differential pharmacological profiles.  
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Experimental section 
Chemistry. General procedures.  All reactions involving air sensitive reagents 
were performed under a N2 atmosphere using syringe-septum cap techniques 
and glassware was flame-dried in vacuo prior to use. Unless otherwise noted, 
all materials were obtained from commercial suppliers and used without 
further purification. When dry solvents were used, THF was distilled and 
stored over molecular sieves (4Å and toluene was purchased from a 
commercial source and stored over molecular sieves (4Å). 1H NMR and 13C 
NMR spectra were obtained on a Varian Gemini 2000 (300 MHz) or Varian 
Mercury Plus (300 MHz). Analytical thin-layer chromatography (TLC) was 
carried out using Merck silica gel 60 F254 plates, and the compounds were 
visualized using either KMnO4 spraying reagent or phosphomolybdic acid 
10% wt. in ethanol. Elemental analyses were performed by J. Theiner at 
Department of Physical Chemistry, University of Vienna, Austria. Melting 
points were determined in open capillary tubes and are uncorrected. Liquid 
chromatography was performed on a Waters analytical LC-MS  equipped 
with a SunFire C18 4.6 x 50 mm column and a cuadrupole mass spectrometer 
(Micromass ZQ). 
 
General procedure for oxalate salt formation: To the free base of the amine (1 
equiv.) was added a solution of oxalic acid (1.0 – 1.3 equiv.) dissolved in warm 
acetone, the mixture was cooled to force crystallization. In the cases were this 
was not sufficient, after the evaporation of the solvent, the mixture was 
recrystallized from EtOH:Et2O. 
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Method A. N,N,4-Trimethylpiperazine-1-carboxamide oxalate (4.25). 
 1-methylpiperazine (221 mg, 2.21 mmol) was added carefully 
over a solution of dimethylcarbamyl chloride (236 mg, 2.21 mmol) 
and triethylamine (637 µL, 4.42 mmol) dissolved in anhydrous 
THF (10 mL). The evolution was followed by TLC. After 2 h 
stirring at room temperature a fine white precipitate was formed 
that was filtered off, and the filtrate was evaporated to give a light brown oil 
that was resuspended in water made basic with NaOH 2M (pH 11-12). The 
aqueous suspension was subjected to liquid-liquid continuous extraction with 
EtOAc that after, drying over MgSO4, and evaporation of the solvent gave the 
free base (4.25) (245 mg, 65%) as a slightly yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 3.26 (t, J = 5.0 Hz, 4H), 2.76 (s, 6H), 2.42 (t, J = 4.8 Hz, 4H), 2.29 (s, 
3H). The free base was crystalised as an oxalate according to the general 
method and thus (4.25) was obtained as a white solid. Mp: 112-114ºC. 1H NMR 
(400 MHz, D2O) δ 3.83 (d, J = 13.2 Hz, 2H), 3.55 (d, J = 11.0 Hz, 2H), 3.27 – 3.11 
(m, 4H), 2.95 (s, 3H), 2.90 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 167.14, 55.54, 
46.17, 45.50, 40.20. HPLCMS (m/z) [MH+] 172.1 (free base). Anal. 
(C8H117N3O·1.3 C2H2O4) C, H, N. 
 
Method B. N,N-Dimethylpiperidine-4-carboxamide hydrobromide (4.37). 
 4.36 was dissolved in EtOH  (4 mL) and a solution of  HBr 62% 
aq. (0.3 mL) was added. The mixture was kept stirring 
overnight, solvent removed and the resulting solid was 
recrystalised from EtOH:Et2O to yield 4.37 (81 mg, 50%) as a 
white solid. Mp: 178-180ºC. 1H NMR (400 MHz, DMSO) δ 8.38 (s, 1H), 8.04 (s, 
1H), 3.27 (d, J = 12.5 Hz, 2H), 3.02 (s, 3H), 3.00 – 2.93 (m, 3H), 2.80 (s, 3H), 1.82 
– 1.62 (m, 4H). 13C NMR (101 MHz, DMSO) δ 172.74, 42.42, 36.58, 34.96, 34.70, 
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24.88. HPLCMS (m/z) [MH+] 157.2 (free base). Anal. (C8H16N2O·1.6HBr) C, H, 
N. 
 
Method C. N-Ethyl-4-methylpiperazine-1-carboxamide oxalate (4.28).  
1-homopiperazine (79 mg, 0.78 mmol) was dissolved in 1 mL 
of Et2O and ethyl isocyanate (68 µL, 0.86 mmol) was then 
added. The evolution of the reaction was followed by TLC. 
After 0.5 h stirring at room temperature, the solvent was 
removed and the free base 4.28 (134 mg, 100%) was recovered 
as an oil that crystalised upon standing. 1H NMR (400 MHz, CDCl3) δ 4.39 (s, 
1H), 3.34 (t, J = 5.1 Hz, 4H), 3.20 (qd, J = 7.2, 5.3 Hz, 2H), 2.37 (t, J = 5.1 Hz, 
4H), 2.27 (s, 3H), 1.07 (t, J = 7.2 Hz, 3H).The free base was converted to the 
oxalate salt according to the general procedure to obtain a white solid. Mp: 
164-165ºC. 1H NMR (400 MHz, D2O) δ 4.05 (d, J = 14.5 Hz, 2H), 3.47 (d, J = 12.4 
Hz, 2H), 3.20 – 3.14 (m, 2H), 3.11 (q, J = 7.3 Hz, 2H), 3.00 (td, J = 12.4, 2.9 Hz, 
2H), 2.86 (s, 3H), 1.02 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, D2O) δ 165.76, 
52.85, 42.89, 40.90, 35.56, 14.39.LCMS (m/z) [MH+] 172.2 (free base). Anal. 
(C8H17N3O·C2H2O4)  C, H, N. 
 
 trans-2-(Ethoxycarbonyl)cyclopropanecarboxylic acid (trans-4.6). 
 A suspension of trans-1,2-cyclopropanedicarboxylate ( 
8.33 g, 44.7 mmol) in K2HPO4 buffer at pH 7.0 (250 mL) 
and room temperature is stirred gently and a suspension of PLE (412 mg, 7000 
units, Sigma Aldrich) previously soaked for 2 h at room temperature in the 
same buffer (250 mL) is added over the mixture. The pH is maintained at pH 
7.0 – 7.2 by manual addition of NaOH 35% wt dropwise. No pH change was 
observed after 1 hour, nevertheless the stirring was maintained for 16 h. The 
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mixture was filtrated to remove the protein aggregates, acidified (pH 1-2) by 
addition of HCl 4M and extracted with diethyl ether (4 x 100 mL). The 
combined organic phases were dried (MgSO4) and the solvent removed. The 
remaining oil crystallized upon standing at room temperature to afford trans-
4.6 (6.4 g, 90%) as brownish crystals. Mp: 49.8-52.3ºC. 1H NMR (300 MHz, 
CDCl3) δ 4.23 – 4.08 (q, J = 7.1 Hz, 2H), 2.29 – 2.08 (dddd, J = 17.8, 8.6, 6.0, 3.8 
Hz, 2H), 1.56 – 1.41 (m, 2H), 1.33 – 1.23 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 178.04, 171.49, 61.52, 23.30, 22.34, 16.13, 14.45.  
 
trans-Ethyl-2-((tert-butoxycarbonyl)amino)cyclopropanecarboxylate (trans-
4.7). 
 To a stirred solution of trans-4.6 (5.59 g, 32.5 mmol) in 
dry toluene (50 mL), dry triethylamine (3.49 g, 34.6 
mmol) and dry tert-butanol (13.27 g, 179 mmol) diphenyl-phosphorylazide 
(8.94 g, 32.5 mmol) is added. The solution is heated to 80ºC under nitrogen 
and stirred for 20 h.  After cooling to room temperature the solvent and the 
excess of tert-butanol were removed under reduced pressure and the 
remaining oil resuspended in citric acid 10% (50 mL) and extracted with 
EtOAc (20 mL x 4). The combined organics were then washed with NaHCO3 
sat. (40 mL) and brine (40 mL), dried (MgSO4) and solvent evaporated to 
afford trans-4.7 (6.9 g, 92%) as a brownish oil that crystallized upon standing 
at room temperature and that was used as such for the next step. Mp: 58.5-
59.5ºC. 1H NMR (300 MHz, CDCl3) δ 4.76 – 4.67 (br s, 1H), 4.23 – 4.07 (m, 2H), 
3.15 – 2.90 (m, 1H), 1.78 – 1.68 (ddd, J = 8.8, 5.7, 2.7 Hz, 1H), 1.49 – 1.43 (s, 9H), 
1.44 – 1.35 (dt, J = 7.7, 5.7 Hz, 1H), 1.33 – 1.22 (t, J = 7.1 Hz, 3H), 1.15 – 1.06 (dt, 
J = 9.1, 5.1 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 172.34, 155.93, 80.20, 60.94, 
32.19, 28.57, 22.79, 15.99, 14.53. IR( cm-1): 3337, 2980, 2930, 1721, 1688, 1514, 
1163.  
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cis-2-(Ethoxycarbonyl)cyclopropanecarboxylic acid (cis-4.6).  
1,2-Cyclopropanedicarboxylic anhydride (4 g, 35 mmol) 
was dissolved in a mixture of EtOH (7 mL) and pyridine 
(4.5 mL) and heated  to 100ºC. The mixture was stirred for 18 h after which the 
solvents were evaporated at reduced pressure. The remaining oil was 
resuspended in H2O (30 mL), acidified with conc. aqueous HCl (pH 1-2) and 
extracted with Et2O (20 mL x 5). The combined ethereal extracts were dried 
(MgSO4) and solvent evaporated to afford cis-4.6 (4.4 g, 80%) as white crystals. 
1H NMR (300 MHz, CDCl3) δ 8.50 – 7.94 (br s, 1H), 4.42 – 3.88 (q, J = 7.1 Hz, 
2H), 2.17 – 2.00 (m, 2H), 1.73 – 1.61 (td, J = 6.7, 5.0 Hz, 1H), 1.36 – 1.27 (td, J = 
8.5, 5.1 Hz, 1H), 1.27 – 1.21 (m,1H; t, J = 7.1 3H), 1.19 – 1.11 (q, J = 5.9 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 175.62, 170.18, 61.61, 22.77, 21.63, 14.34, 12.77. 
 
cis-Ethyl 2-((tert-butoxycarbonyl)amino)cyclopropanecarboxylate (cis-4.7).  
To a stirred solution of cis-4.6 (4.3 g, 27.4 mmol) in dry 
toluene (30 mL), dry triethylamine (2.7 g, 27.4mmol) 
and dry tert-butanol (25.7 g, 347 mmol) diphenyl-phosphorylazide (7.52 g, 27.4 
mmol) is added. The solution is heated to 55ºC under nitrogen and stirred for 
24 h. After cooling to room temperature the solvent and the excess of tert-
butanol were removed under reduced pressure, the remaining oil 
resuspended in EtOAc (40 mL) and washed with citric acid 10% (2 x 30 mL). 
The acidic washings were extracted with EtOAc (20 mL). The combined 
organics were then washed with NaHCO3 sat. (30 mL) and brine (30 mL), 
dried (MgSO4) and solvent evaporated to afford cis-4.7 (5.71 g, 91%) as a white 
crystals. Mp: 53-55ºC. 1H NMR (300 MHz, CDCl3) δ 5.55 – 5.08 (s, 1H), 4.30 – 
3.98 (qd, J = 7.1, 1.1 Hz, 2H), 3.45 – 3.20 (m, 1H), 1.93 – 1.76 (q, J = 7.7 Hz, 1H), 
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1.46 – 1.39 (s, 9H), 1.31 – 1.24 (t, J = 7.1 Hz, 4H), 1.19 – 1.11 (q, J = 5.9 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 172.12, 156.19, 79.85, 61.05, 31.70, 28.70, 19.36, 
14.57, 14.31. IR ( cm-1): 3361, 2980, 2935, 1710, 1512, 1183, 1155. 
 
 trans-tert-Butyl (2-(hydroxymethyl)cyclopropyl)carbamate (trans-4.8).  
DIBAL (30.5 mL, 1M in toluene) was cooled to -78ºC 
under nitrogen. A solution of trans-4.7 (2 g, 8.73 mmol) 
was slowly added in THF with an automated system over 40 min. Stirring at -
78ºC was kept for 4 h, after which the reaction was quenched by slow addition 
of Na2SO4 soaked in H2O. The mixture was allowed to reach room 
temperature and stirred for 1 h after which the precipitate was filtered off and 
washed with EtOAc (4 x 20 mL). The filtrate and the washings were 
combined, washed with brine (30 mL), dried (MgSO4) and solvent removed to 
afford trans-4.8 (1.45g, 88%) as a dark yellow oil. 1H NMR (300 MHz, CDCl3) δ 
4.92 – 4.83 (br s, 1H), 3.91 – 3.72 (m, 1H), 3.21 – 3.01 (t, J = 9.8 Hz, 1H), 2.96 – 
2.84 (s, 1H), 2.33 – 2.30 (dd, J = 4.5, 2.8 Hz, 1H), 1.51 – 1.41 (s, 9H), 1.36 – 1.14 
(td, J = 9.2, 5.9 Hz, 1H), 0.87 – 0.76 (td, J = 9.5, 4.6 Hz, 1H), 0.76 – 0.66 (dt, J = 
7.5, 5.9 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 156.71, 80.16, 65.07, 29.96, 28.61, 
24.24, 11.55. IR ( cm-1): 3330, 2925, 2854, 1686, 1513, 1165. 
 
 cis-tert-Butyl (2-(hydroxymethyl)cyclopropyl)carbamate (cis-4.8).  
According to the preparation  of trans-4.8, from cis-4.7 
(3.22 g, 14.06 mmol) cis-4.8 (2.10 g, 81%) was obtained as 
colorless oil that crystallized upon standing. Mp: 63.5-64.8. 1H NMR (300 
MHz, CDCl3) δ 4.90 – 4.82 (br s, 1H), 3.98 – 3.89 (td, J = 11.5, 3.7 Hz, 1H), 3.52 – 
3.48 (d, J = 11.2 Hz, 1H), 3.19 – 3.09 (t, J = 11.1 Hz, 1H), 2.65 – 2.58 (td, J = 6.9, 
4.2 Hz, 1H), 1.47 – 1.46 (s, 9H), 1.42 – 1.32 (m, 1H), 0.96 – 0.88 (ddd, J = 9.2, 7.2, 
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5.7 Hz, 1H), 0.27 – 0.20 (td, J = 6.2, 4.3 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 
158.52, 80.83, 61.74, 28.58, 26.94, 21.31, 9.43. IR ( cm-1): 3370, 2951, 1689, 1508, 
1163. 
 
trans-(2-((tert-Butoxycarbonyl)amino)cyclopropyl)methyl 
dimethylcarbamate (trans-4.9).  
To a solution of trans-4.8 (704 mg, 3.76 mmol) in a 
mixture anhydrous toluene (11 mL) and 
anhydrous THF (3 mL) carbonyldiimizadole (914 
mg, 5.64 mmol) and a catalytic amount of 4-dimethylaminopyridine were 
added. After stirring at room temperature for 2.5 h a solution of 
dimethylamine 33% in EtOH was added (18.8 mL) and stirred for an 
additional hour. The reaction was monitored on TLC. The solvent was 
eliminated under vacuum and the resulting oil dissolved in EtOAc (30 mL). 
The solution was washed with citric acid 10% in H2O until the pH stays acidic 
after washing, then NaOH 1 M (2 x 10 mL), brine (10mL), dried (MgSO4) and 
solvent evaporated to afford trans-4.9 (800 mg, 83%) as a colorless oil. 1H NMR 
(300 MHz, CDCl3) δ 4.88 – 4.75 (br s, 1H), 3.99 – 3.90 (m, 2H), 2.88 – 2.85 (d, J = 
0.9 Hz, 6H), 2.48 – 2.41 (m, 1H), 1.42 – 1.38 (s, 9H), 1.31 – 1.16 (m, 1H), 0.77 – 
0.70 (dd, J = 8.1, 5.2 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 156.61, 156.34, 79.61, 
66.95, 36.61, 36.13, 28.60, 28.33, 19.81, 12.37. IR (cm-1): 3332, 2976, 2932, 1686, 
1498, 1163. 
 
trans-tert-Butyl (2-((methylcarbamoyl)oxy)methyl)cyclopropyl)carbamate 
(trans-4.10). 
 According to the preparation of trans-4.9, from 
trans-4.8 (1.45 g, 7.75 mmol), employing 
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methylamine 33% in EtOH instead (3.6 mL), trans-4.10 (1.48 g, 78%) was 
obtained as a white solid. Mp: 94.7-95.2ºC. 1H NMR (300 MHz, CDCl3) δ 4.70 – 
4.64 (br s, 2H), 4.00 – 3.90 (d, J = 8.3 Hz, 2H), 2.82 – 2.77 (d, J = 4.2 Hz, 3H), 2.50 
– 2.45 (s, 1H), 1.47 – 1.42 (s, 9H), 1.30 – 1.22 (m, 1H), 0.82 – 0.72 (m, 1H). 13C 
NMR (75 MHz, CDCl3) δ 157.24, 156.37, 79.81, 66.72, 28.66, 28.47, 27.82, 19.87, 
12.43. IR (cm-1): 3338, 2977, 1693, 1524, 1253, 1167. 
 
(2-((tert-Butoxycarbonyl)amino)cyclopropyl)methyl dimethylcarbamate (cis-
4.11). 
 According to the preparation  of trans-4.9, from 
cis-4.8 (1.12 g, 6.01 mmol) cis-4.11 (1.19 g, 76%) 
was obtained as white crystal. Mp: 84.5-87.0ºC.1H 
NMR (300 MHz, CDCl3) δ 5.72 – 5.67 (br s, 1H), 
4.30 – 4.22 (dd, J = 11.9, 4.6 Hz, 1H), 4.01 – 3.92 (dd, J = 11.9, 9.4 Hz, 1H), 2.92 – 
2.90 (s, 6H), 2.70 – 2.57 (m, 1H), 1.44 – 1.43 (s, 9H), 1.30 – 1.17 (m, 1H), 1.04 – 
0.96 (dt, J = 12.4, 5.8 Hz, 1H), 0.43 – 0.36 (td, J = 6.1, 4.2 Hz, 1H). 13C NMR (75 
MHz, CDCl3) δ 157.52, 157.13, 79.48, 64.40, 36.80, 36.28, 28.67, 27.58, 17.01, 
11.02. IR(cm-1): 3326, 2977, 2933, 1685, 1500, 1387, 1365, 1165. 
 
cis-tert-Butyl(2-(((methylcarbamoyl)oxy)methyl)cyclopropyl)carbamate (cis-
4.12). 
 According to the preparation  of trans-4.9, from 
cis-4.8 (885 mg, 4.73 mmol), employing 
methylamine 33% in EtOH (3.4 mL) cis-4.12 (866 
mg, 75%) was obtained as white crystal. Mp: 92.8-95.2ºC. IR(cm-1): 3327, 2977, 
1689, 1514, 1253, 1164. 1H NMR (300 MHz, CDCl3) δ 5.60 – 5.49 (br s, 1H), 4.81 
– 4.72 (br s, 1H), 4.29 – 4.19 (dd, J = 11.8, 4.9 Hz, 2H), 4.01 – 3.89 (t, J = 10.6 Hz, 
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1H), 2.83 – 2.76 (d, J = 5.4 Hz, 3H), 2.67 – 2.59 (m, 1H), 1.45 – 1.43 (s, 9H), 1.30 – 
1.17 (m, 1H), 1.04 – 0.96 (m, 1H), 0.44 – 0.38 (td, J = 6.1, 4.2 Hz, 1H). 13C NMR 
(75 MHz, CDCl3) δ 157.50, 157.09, 79.59, 64.13, 28.70, 27.84, 27.53, 16.89, 11.16. 
 
trans-(2-Aminocyclopropyl)methyl dimethylcarbamate oxalate (trans-4.13 
oxalate). 
 A solution of trans-4.9 (688 mg, 2.68 mmol) in 
CH2Cl2 (10 mL) and TFA (10 mL) was stirred at room 
temperature for 30 min after which solvent was 
evaporated to afford the corresponding trifluoroacetic salt as a crude. 1H NMR 
(300 MHz, D2O) δ 3.85 – 3.78 (dd, J=12.2, 6.6 Hz, 1H), 3.69 – 3.62 (dd, J=12.2, 
8.1 Hz, 1H), 2.66 – 2.65 (s, 6H), 2.48 – 2.41 (dt, J = 7.6, 3.6 Hz, 1H), 1.47 – 1.34 
(dddd, J = 13.6, 9.8, 6.4, 3.2 Hz, 1H), 0.89 – 0.81 (ddd, J = 9.9, 6.9, 4.2 Hz, 1H), 
0.76 – 0.69 (q, J=9.3 Hz, 1H). The reaction crude was dissolved in H2O (20 mL) 
and basified with conc. NaOH. The free amine was extracted from the solution 
through continuous liquid-liquid extraction with CH2Cl2. The solvent was 
dried (MgSO4) and evaporated to afford trans-4.13 (326 mg, 77%) as a yellow 
oil. 1H NMR (300 MHz, CDCl3) δ 3.95 – 3.79 (qd, J = 11.5, 7.2 Hz, 2H), 2.91 – 
2.89 (s, 6H), 2.71 – 2.68 (s, 2H), 2.34 – 2.29 (m, 1H), 1.27 – 1.12 (m, 1H), 0.71 – 
0.62 (ddd, J = 9.2, 5.3, 4.0 Hz, 1H), 0.59 – 0.49 (dt, J = 7.1, 5.4 Hz, 1H).  13C NMR 
(75 MHz, CDCl3) δ 156.83, 67.75, 36.66, 36.19, 30.04, 20.58, 12.80. IR(cm-1): 3393, 
2941, 1698,1459, 1390, 1185. The oxalate salt was formed according to the 
general method and thus from trans-4.13  (131 mg, 0.83 mmol), trans-4.13 
oxalate (97 mg, 47%) was obtained as white crystals. Mp: 129.1-130.2ºC 1H 
NMR (300 MHz, D2O) δ 3.96 – 3.83 (dd, J = 11.6, 6.2 Hz, 1H), 3.83 – 3.69 (dd, J 
= 11.6, 7.4 Hz, 1H), 2.84 – 2.63 (s, 6H), 2.60 – 2.47 (dt, J = 7.4, 3.6 Hz, 1H), 1.56 – 
1.41 (dtt, J = 13.8, 7.1, 3.6 Hz, 1H), 1.00 – 0.88 (ddd, J = 10.1, 6.8, 4.2 Hz, 1H), 
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0.88 – 0.75 (q, J = 7.0 Hz, 1H). HPLCMS (m/z) [MH+] 159.32 (free base). Anal. 
(C7H14N2O2 · 1.25 C2H2O4) C, H, N.  
 
trans-(2-Aminocyclopropyl)methyl methylcarbamate oxalate (trans-4.14 
oxalate). 
According to the preparation  of trans-4.13, from 
trans-4.10 (1.32 g, 5.4 mmol) trans-4.14 (432 mg, 56%) 
was obtained as a colourless oil. 1H NMR (300 MHz, 
CDCl3) δ 4.72 – 4.56 (br s, 1H), 3.95 – 3.77 (m, 2H), 2.83 – 2.76 (d, J = 4.9 Hz, 
3H), 2.32 – 2.25 (dt, J = 6.9, 3.4 Hz, 1H), 1.74 – 1.71 (s, 2H), 1.16 – 1.06 (m, 1H), 
0.66 – 0.57 (ddd, J = 9.0, 5.1, 3.9 Hz, 1H), 0.54 – 0.46 (dt, J = 6.9, 5.3 Hz, 1H). 13C 
NMR (75 MHz, CDCl3) δ 157.83, 66.75, 29.05, 27.82, 19.95, 12.24. IR (cm-1): 3350, 
2956, 1693, 1536, 1265, 1139. The oxalate salt was formed according to the 
general method and thus from trans-4.14 (180 mg, 1.25 mmol) trans-4.14 
oxalate (175 mg, 57%) was obtained as white crystals. Mp: 115.8-116.5ºC. 1H 
NMR (300 MHz, D2O) δ 3.91 – 3.82 (dd, J = 11.9, 6.6 Hz, 1H), 3.73 – 3.65 (dd, J 
= 11.9, 8.0 Hz, 1H), 2.54 – 2.45 (s, 3H; m 1H), 1.49 – 1.37 (m, 1H), 0.94 – 0.86 
(ddd, J = 10.1, 6.9, 4.5 Hz, 1H), 0.81 – 0.73 (q, J = 7.1 Hz, 1H).  HPLCMS (m/z) 
[MH+] 145.29 (free base). Anal. (C6H12N2O2 · 1.3 C2H2O4) C found 38.78, calcd 
39.54; H found, 6.15 calcd 5.63; N found 11.71, calcd 10.72. 
 
cis-(2-Aminocyclopropyl)methyl dimethylcarbamate oxalate (cis-4.15 
oxalate). 
 According to the preparation  of trans-4.13, from cis-
4.11 (1.15 g, 4.5 mmol) cis-4.15 (460 mg, 65%) was 
obtained as an orange oil. 1H NMR (300 MHz, CDCl3) 
δ 4.43 – 4.34 (dd, J = 11.4, 5.5 Hz, 1H), 4.16 – 4.05 (dd, J = 11.3, 9.2 Hz, 1H), 2.94 
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– 2.90 (s, 6H), 2.55 – 2.46 (td, J = 6.9, 4.1 Hz, 1H), 1.77 – 1.69 (s, 2H), 1.17 – 1.01 
(ddd, 12.5, 6.3, 3.4 Hz, 1H), 0.82 – 0.71 (ddd, J = 9.1, 6.8, 5.2 Hz, 1H), 0.31 – 0.22 
(dt, J = 5.7, 4.2 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 156.99, 64.82, 36.64, 36.24, 
28.59, 17.31, 12.32. IR (cm-1): 3378, 2937, 1686, 1408, 1187. The oxalate salt was 
formed according to the general method and thus from cis-4.15 (138 mg, 0.87 
mmol) cis-4.15 oxalate (88 mg, 40%) was obtained as white crystals. Mp: 117.2-
118.5ºC. 1H NMR (300 MHz, D2O) δ 4.33 – 4.26 (dd, J = 12.5, 5.5 Hz, 1H), 3.85 – 
3.74 (dd, J = 12.5, 9.9 Hz, 1H), 2.77 – 2.69 (d, J = 11.4 Hz, 8H), 2.66 – 2.56 (td, J = 
7.3, 4.6 Hz, 1H), 1.47 – 1.31 (qd, J = 9.7, 4.2 Hz, 1H), 1.05 – 0.95 (dt, J = 10.7, 7.8 
Hz, 1H), 0.67 – 0.58 (dt, J = 6.8, 4.6 Hz, 1H). HPLCMS (m/z) [MH+] 159.20 (free 
base). Anal. (C7H14N2O2 · 1 C2H2O4) N found 11.89, calcd 11.29. 
 
cis-(2-Aminocyclopropyl)methyl methylcarbamate (cis-4.16). 
 According to the preparation  of trans-4.13, from cis-
4.12 (826 mg, 3.38 mmol) cis-4.16 (340 mg, 70%) was 
obtained as a colourless oil. 1H NMR (300 MHz, 
CDCl3) δ 4.72 – 4.63 (br s, 1H), 4.43 – 4.35 (dd, J = 11.3, 5.5 Hz, 1H), 4.12 – 4.03 
(dd, J = 11.3, 9.1 Hz, 1H), 2.81 – 2.78 (d, J = 4.9 Hz, 3H), 2.53 – 2.46 (td, J = 6.8, 
4.1 Hz, 1H), 1.73 – 1.69 (s, 2H), 1.17 – 0.99 (m, 1H), 0.80 – 0.71 (ddd, J = 9.0, 6.8, 
5.2 Hz, 1H), 0.28 – 0.21 (td, J = 5.6, 4.1 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 
157.51, 64.42, 28.55, 27.85, 17.22, 12.25. IR (cm-1): 3341, 2924, 1692, 1535, 1259, 
1135. All the attempts to precipitate cis-4.16 oxalate according to the general 
method previously described  were unsuccessful. 
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trans-(2-(Dimethylamino)cyclopropyl)methyl dimethylcarbamate oxalate 
(trans-4.17 oxalate)).  
To a solution of trans-4.13 (133 mg, 0.85 mmol) in H2O 
(4 mL) AcCN (5 mL) formaldehyde 37% in H2O (670 
µL) NaCNBH3 (165 mg, 2.66 mmol) was added. The 
pH was adjusted and maintained at 6 by addition of glacial AcOH and the 
mixture stirred at room temperature for 1 h. The reaction mixture was 
quenched with few drops of conc. HCl and washed with EtOAc (2 x 10 mL). 
The pH was then turned basic by addition of conc. NaOH and extracted with 
CH2Cl2 (4 x 10 mL). The organic layer was dried (MgSO4) and solvent 
evaporated to afford trans-4.17 (127 mg, 65%) as a colourless oil. 1H NMR (300 
MHz, CDCl3) δ 4.13 – 4.05 (dd, J = 11.4, 6.1 Hz, 1H), 3.72 – 3.63 (dd, J = 11.4, 8.7 
Hz, 1H), 2.94 – 2.91 (s, 6H), 2.36 – 2.33 (s, 6H), 1.60 – 1.54 (dt, J = 6.9, 3.5 Hz, 
1H), 1.25 – 1.17 (ddd, J = 8.8, 5.9, 3.0 Hz, 1H), 0.78 – 0.70 (dt, J = 9.2, 4.5 Hz, 
1H), 0.58 – 0.50 (dt, J = 6.8, 5.3 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 156.75, 
67.76, 45.87, 45.15, 36.65, 36.13, 19.85, 12.21. IR (cm-1): 3393, 2940, 1908, 1459, 
1390, 1185. The oxalate salt was formed according to the general method and 
thus from trans-4.17 (103 mg, 0.55 mmol) trans-4.17 oxalate (101 mg, 66%) was 
obtained as white crystals. Mp: 109.6 -110.5ºC. 1H NMR (300 MHz, D2O) δ 4.07 
– 3.99 (dd, J = 11.6, 5.8 Hz, 1H), 3.63 – 3.55 (dd, J = 11.6, 8.3 Hz, 1H), 2.81 – 2.79 
(s, 6H), 2.76 – 2.70 (m, 6H; dd, J = 7.6, 3.5 Hz, 1H), 1.69 – 1.55 (ttd, J = 11.7, 6.2, 
3.5 Hz, 1H), 1.14 – 1.06 (ddd, J = 10.5, 7.3, 4.3 Hz, 1H), 0.98 – 0.90 (dd, J = 7.3, 
7.5 Hz, 1H). HPLCMS (m/z) [MH+] 187.32 (free base). Anal. (C9H18N2O2 · 0.95 
C2H2O4) C, H, N.  
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trans-(2-(Dimethylamino)cyclopropyl)methyl methylcarbamate oxalate  ((±)-
trans-4.18 oxalate). 
According to the preparation  of trans-4.17, from trans-
4.14 (250 mg, 3.38 mmol) trans-4.18 (284 mg, 95%) was 
obtained as a colourless oil. 1H NMR (300 MHz, 
CDCl3) δ 4.72 – 4.54 (br s, 1H), 4.03 – 3.91 (dd, J = 11.5, 6.6 Hz, 1H), 3.84 – 3.72 
(dd, J = 11.3, 8.1 Hz, 1H), 2.84 – 2.76 (d, J = 4.9 Hz, 3H), 2.42 – 2.32 (s, 6H), 1.68 
– 1.57 (dt, J = 6.7, 3.3 Hz, 1H), 1.32 – 1.16 (m, 1H), 0.83 – 0.74 (m, 1H), 0.60 – 
0.50 (q, J = 5.7 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 156.84, 67.23, 45.88, 45.15, 
27.86, 19.72, 12.01. IR (cm-1): 3336, 2949, 1694, 1534, 1421, 1263, 1059. The 
oxalate salt was formed according to the general method and thus from trans-
4.18 (299 mg, 1.74 mmol) trans-4.18 oxalate (324 mg, 71%) was obtained as 
white crystals. Mp: 125.4-126.4ºC. 1H NMR (300 MHz, D2O) δ 4.02 – 3.88 (dd, J 
= 11.7, 6.0 Hz, 1H), 3.63 – 3.55 (dd, J = 11.8, 8.1 Hz, 1H), 2.79 – 2.78 (s, 6H; m, 
1H), 2.53 – 2.51 (s, 3H), 1.66 – 1.49 (m, 1H), 1.14 – 1.00 (m, 1H), 0.98 – 0.82 (m, 
1H). HPLCMS (m/z) [MH+] 173.29 (free base). Anal. (C8H16N2O2 · 1.1 C2H2O4) 
C found 44.28, calcd 45.16; N found 11.13, calcd 10.33. 
 
 cis-(2-(Dimethylamino)cyclopropyl)methyl dimethylcarbamate oxalate (cis-
4.19 oxalate). 
 According to the preparation  of trans-4.17, from cis-
4.15 (293 mg, 1.85 mmol) cis-4.19 (325 mg, 94%) was 
obtained as a bright yellow oil. 1H NMR (300 MHz, 
CDCl3) δ 4.73 – 4.62 (s, 1H), 4.40 – 4.33 (dd, J = 11.2, 6.6 Hz, 1H), 4.11 – 3.94 
(dd, J = 11.2, 8.8 Hz, 1H), 2.92 (s, 6H), 2.33 – 2.33 (s, 6H), 1.77 – 1.70 (td, J = 6.8, 
4.4 Hz, 1H), 1.27 – 1.14 (tdd, J = 12.6, 7.5, 4.6 Hz, 1H), 0.78 – 0.68 (ddd, J = 9.0, 
6.8, 5.2 Hz, 1H), 0.36 – 0.28 (dt, J = 5.7, 4.7 Hz, 1H). 13C NMR (75 MHz, CDCl3) 
δ 156.39, 65.20, 45.87, 44.90, 36.71, 36.31, 18.24, 10.26. IR (cm-1): 3372, 2942, 
N
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1681, 1457, 1190, 1056. The oxalate salt was formed according to the general 
method and thus from cis-4.19 (320 mg, 1.72 mmol) cis-4.19 oxalate (233 mg, 
84%) was obtained as white crystals. Mp: 84.7-85.6. 1H NMR (300 MHz, D2O) δ 
4.53 – 4.44 (dd, J = 12.6, 5.6 Hz, 1H), 3.74 – 3.65 (dd, J = 12.4, 10.6 Hz, 1H), 2.89 
– 2.85 (s, 6H), 2.82 – 2.70 (m, 1H; m 6H), 1.66 – 1.52 (dtd, J = 13.2, 9.9, 6.9 Hz, 
1H), 1.17 – 1.07 (qd, J = 7.5, 3.8 Hz, 1H), 0.77 – 0.69 (td, J = 7.1, 5.0 Hz, 1H). 
HPLCMS (m/z) [MH+] 187.39 (free base).  Anal. (C9H18N2O2 · 1.55 C2H2O4) C 
found 42.46, calcd 44.61; N found 10.93 calcd 8.6. 
 
 cis-(2-(Dimethylamino)cyclopropyl)methyl methylcarbamate oxalate (cis-
4.20 oxalate). 
According to the preparation  of trans-4.17, from cis-
4.15 (199 mg, 1.38 mmol) cis-4.20 (211 mg, 90%) was 
obtained as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 
4.72 – 4.62 (s, 1H), 4.32 – 4.23 (dd, J = 11.0, 6.3 Hz, 1H), 4.13 – 4.06 (dd, J = 11.1, 
8.3 Hz, 1H), 2.82 – 2.77 (d, J = 4.9 Hz, 3H), 2.30 – 2.28 (s, 6H), 1.74 – 1.65 (td, J = 
6.8, 4.3 Hz, 1H), 1.21 – 1.09 (m, 1H), 0.77 – 0.65 (ddd, J = 8.9, 6.8, 5.1 Hz, 1H), 
0.32 – 0.23 (dt, J = 6.0, 4.6 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 157.57, 64.86, 
45.91, 44.71, 27.84, 18.14, 10.50. IR (cm-1): 3339, 2945, 1694, 1534, 1459, 1260, 
1139. The oxalate salt was formed according to the general method and thus 
from cis-4.20 (210 mg, 1.28 mmol) cis-4.20 oxalate (187 mg, 56%) was obtained 
as white crystals. Mp: 103.5-104.8ºC. 1H NMR (300 MHz, D2O) δ 4.53 – 4.45 
(dd, J = 12.6, 5.4 Hz, 1H), 3.75 – 3.65 (dd, J = 12.5, 10.0 Hz, 1H), 2.90 – 2.83 (s, 
6H; m, 1H), 2.55 – 2.50 (s, 3H), 1.63 – 1.48 (m, 1H), 1.16 – 1.06 (dt, J = 9.3, 7.3 
Hz, 1H), 0.78 – 0.69 (td, J = 7.2, 4.9 Hz, 1H). HPLCMS (m/z) [MH+] 173.17 (free 
base). Anal. (C8H16N2O2 · 1.15 C2H2O4) C found 43.71, calcd 44.86; H found 
6.72, calcd 6.69; N found 38.42, calcd 38.29. 
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3-(Dimethylamino)-N,N-dimethylpyrrolidine-1-carboxamide oxalate (4.21). 
 Following method A, from 3-(dimethylamino)pyrrolidine (89 
mg, 0.78 mmol), the free base 4.21. 1H NMR (400 MHz, CDCl3) δ 
3.58 – 3.39 (m, 3H), 3.22 (dd, J = 10.0, 8.7 Hz, 1H), 2.82 (s, 6H), 2.63 
(tt, J = 8.7, 6.3 Hz, 1H), 2.27 (s, 6H), 2.12 – 2.00 (m, 1H), 1.74 (dtd, J 
= 11.9, 10.3, 8.6 Hz, 1H). was obtained as an orange oil that was 
converted to the oxalate salt according to the general procedure to yield  a 
white powder (153 mg, 55%, two steps). Mp: 113-116ºC. 1H NMR (400 MHz, 
D2O) δ 3.93 (p, J = 7.5, 7.0 Hz, 1H), 3.83 (dd, J = 11.3, 7.2 Hz, 1H), 3.63 (dt, J = 
10.6, 5.9 Hz, 2H), 3.59 – 3.48 (m, 1H), 2.97 (s, 3H), 2.96 (s, 3H), 2.89 (s, 6H), 2.52 
– 2.40 (m, 1H), 2.15 (dq, J = 13.1, 8.4 Hz, 1H). 13C NMR (101 MHz, D2O) δ 
165.62, 163.62, 64.62, 48.80, 46.62, 42.00, 41.54, 37.62, 26.94. HPLCMS (m/z) 
[MH+] 186.2. Anal. (C9H19N3O·1.05 C2H2O4) C, H, N. 
 
3-(Dimethylamino)-N-ethylpyrrolidine-1-carboxamide (4.22). 
 Following method B, from 3- (dimethylamino)pyrrolidine (89 
mg, 0.78 mmol), and ethyl isocyanate (71 µL, 0.87 mmol), 4.22 
precipitated as a white solid that was filtered off and washed 
with cold Et2O (91 mg, 62%). Mp: 74-76ºC. 1H NMR (400 MHz, 
CDCl3) δ 4.07 (dd, J = 11.0, 4.9 Hz, 1H), 3.56 (t, J = 9.0 Hz, 1H), 
3.45 (td, J = 9.4, 1.7 Hz, 1H), 3.28 – 3.15 (m, 3H), 3.03 (t, J = 8.9 Hz, 1H), 2.63 
(dtd, J = 10.0, 8.5, 6.8 Hz, 1H), 2.20 (s, 6H), 2.13 – 1.99 (m, 1H), 1.75 (dtd, J = 
12.1, 10.2, 8.8 Hz, 1H), 1.07 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
156.83, 65.51, 50.09, 44.76, 44.42, 35.57, 30.55, 15.97. HPLCMS (m/z) [MH+] 
186.2. Anal. (C9H19N3O) H calcd 10.34, found 9.52; N calcd 22.68, found 21.80. 
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3-(Dimethylamino)-N-methylpyrrolidine-1-carbothioamide (4.23). 
 Following method B, from 3- (dimethylamino)pyrrolidine (89 
mg, 0.78 mmol), and methyl isothiocyanate (63 mg, 0.87 mmol), 
4.23  precipitated as a white solid that was filtered off and 
washed with cold Et2O (recovered 11 mg, 7%.). Mp: 97-99ºC. 1H 
NMR (400 MHz, CDCl3) δ 5.32 – 5.09 (m, 1H), 4.00 – 3.81 (m, 1H), 
3.81 – 3.61 (m, 1H), 3.52 – 3.36 (m, 1H), 3.36 – 3.19 (m, 1H), 3.08 (d, J = 4.5 Hz, 
3H), 2.73 (p, J = 7.6 Hz, 1H), 2.22 (s, 6H), 2.17 – 2.09 (m, 1H), 1.86 (q, J = 10.4 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 179.98, 65.20 53.63, 48.10, 44.07, 32.40, 
30.21. HPLCMS (m/z) [MH+] 188.1.  Anal. (C8H17N3S) C; H; N found 21.69, 
calcd 22.43; S found 15.55 calcd 17.12. 
 
3-(Dimethylamino)-N-ethylpyrrolidine-1-carbothioamide oxalate (4.24). 
 Following method B, from 3-(dimethylamino)pyrrolidine (89 mg, 
0.78 mmol), and ethyl isothiocyanate (77 µL, 0.89 mmol), the free 
base 4.24.  1H NMR (400 MHz, CDCl3) δ 5.05 (s, 1H), 4.00 – 3.66 
(m, 2H), 3.61 (qd, J = 7.2, 5.2 Hz, 2H), 3.33 – 3.20 (m, 1H), 2.71 (dt, 
J = 15.7, 7.2 Hz, 1H), 2.22 (s, 6H), 2.12 (dt, J = 11.7, 5.8 Hz, 2H), 
1.83 (p, J = 10.3 Hz, 1H), 1.17 (t, J = 7.2 Hz, 3H) was obtained as a yellowish oil 
that was converted to the oxalate salt according to the general procedure to 
yield a white powder (184 mg, 63%, two steps). Mp: 175-177ºC. 1H NMR (400 
MHz, D2O) δ 4.18 (dd, J = 11.6, 7.4 Hz, 1H), 4.05 (p, J = 7.1 Hz, 1H), 3.96 – 3.76 
(m, 2H), 3.62 – 3.53 (m, 3H), 2.97 (s, 6H), 2.61 (ddd, J = 19.1, 7.4, 4.4 Hz, 1H), 
2.33 (dq, J = 16.6, 8.3 Hz, 1H), 1.18 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, D2O) 
δ 176.21, 165.56, 63.91, 50.78, 46.87, 41.95, 41.27, 40.39, 26.66, 13.91. HPLCMS 
(m/z) [MH+] 202.2 (free base). Anal. (C9H19N3S·1.05 C2H2O4) C, H, N, S. 
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N,N,4-Trimethylpiperazine-1-carboxamide oxalate (4.25). The synthesis and 
characterization of compound 4.25 is described in Method A. 
 
N,N,4-Trimethyl-1,4-diazepane-1-carboxamide oxalate (4.26). 
 Following method A, starting from 1-methylhomopiperazine 
(180 mg, 1.6 mmol), the free base 4.26 (200 mg, 67%) was 
obtained as a yellowish oil. 1H NMR (400 MHz, CDCl3) δ 3.42 (t, 
J = 4.8 Hz, 1H), 3.37 (t, J = 6.1 Hz, 1H), 2.71 (s, 6H), 2.67 (t, J = 4.8 
Hz, 1H), 2.57 (t, J = 5.2 Hz, 1H), 2.33 (s, 1H), 1.90 (q, J = 6.0 Hz, 
1H). The free base was converted to the oxalate salt according to the general 
procedure to obtain white crystals. Mp: 84-87ºC. 1H NMR (400 MHz, D2O) δ 
3.65 (dd, J = 15.9, 4.7 Hz, 1H), 3.57 – 3.24 (m, 8H), 3.16 (t, J = 11.8 Hz, 1H), 2.86 
(s, 3H), 2.75 (s, 6H), 2.21 – 1.99 (m, 2H). 13C NMR (101 MHz, D2O) δ 164.29, 
56.82, 55.82, 47.51, 43.96, 42.85, 38.10, 24.39. HPLCMS (m/z) [MH+] 186.2 (free 
base). Anal. (C9H19N3O·1.6 C2H2O4) C, H, N. 
 
tert-Butyl 4-(dimethylcarbamoyl)-1,4-diazepane-1-carboxylate (4.27). 
 Following method A, starting from 1-tert-butoxycarbonyl-
homopiperazine (200 mg, 1 mmol), 4.27 (206 mg, 100%) was 
obtained as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 
3.55 – 3.39 (m, 6H), 3.34 (t, J = 5.8 Hz, 2H), 2.81 (s, 6H), 1.90 
(m, 2H), 1.46 (s, 9H). 
 
N-Ethyl-4-methylpiperazine-1-carboxamide oxalate (4.28). The synthesis and 
characterization of compound 4.28 is described in Method C. 
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N-Ethyl-4-methyl-1,4-diazepane-1-carboxamide (4.29). 
 Following method C, starting from 1-methyl-
homopiperazine (100 µL, 0.80 mmol) and ethyl isocyanate 
(68 µL, 0.86 mmol), 4.29 (146 mg, 98%) as a white powder. 
Mp: 69-70ºC. 1H NMR (400 MHz, CDCl3) δ 4.29 (s, 1H), 3.59 
(t, J = 4.7 Hz, 2H), 3.43 (t, J = 6.2 Hz, 2H), 3.26 (qd, J = 7.2, 5.4 Hz, 2H), 2.67 – 
2.57 (m, 4H), 2.38 (s, 3H), 1.95 (dt, J = 11.4, 6.1 Hz, 2H), 1.13 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.95, 59.10, 57.80, 46.71, 45.47, 44.94, 35.85, 
27.88, 15.80. HPLCMS (m/z) [MH+] 186.2 (free base). Anal. (C9H19N3O) C calcd 
58.35, found 59.85; H calcd 10.34, found 9.41; N. 
 
N,4-Dimethylpiperazine-1-carbothioamide oxalate (4.30). 
Following method C, from 1-methyl piperazine (97 µL, 0.87 
mmol), and methyl isothiocyanate (70 mg, 0.96 mmol) the free 
base 4.30 (140 mg, 100%) was obtained as a yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 5.52 (s, 1H), 3.76 (t, J = 5.3 Hz, 4H), 3.10 (d, J 
= 4.5 Hz, 3H), 2.38 (t, J = 4.8 Hz, 4H), 2.25 (s, 3H). The free base 
was converted to the oxalate salt according to the general procedure to obtain 
the oxalate salt as a white solid. Mp: 157-158ºC. 1H NMR (400 MHz, D2O) δ 
4.70 – 4.59 (m, 2H), 3.53 (d, J = 12.5 Hz, 2H), 3.38 (t, J = 13.5 Hz, 2H), 3.08 (t, J = 
12.4 Hz, 2H), 2.99 (s, 3H), 2.88 (s, 3H). 13C NMR (101 MHz, D2O) δ 181.19, 
165.54, 52.58, 44.40, 42.76, 32.59. HPLCMS (m/z) [MH+] 174.1 (free base). Anal. 
(C7H15N3S · C2H2O4·0.1H2O) C, H, N, S. 
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N,4-Dimethyl-1,4-diazepane-1-carbothioamide fumarate (4.31). 
 Following method C, from 1-methyl-homopiperazine (100 µL, 
0.80 mmol), and methyl isothiocyanate (64 mg, 0.88 mmol), the 
free base 4.31 (158 mg, 100%) was obtained as a yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 5.48 (s, 1H), 4.16 – 4.08 (m, 2H), 3.74 
(t, J = 5.9 Hz, 2H), 3.17 (d, J = 4.4 Hz, 3H), 2.76 (t, J = 4.6 Hz, 
2H), 2.62 (t, J = 5.6 Hz, 2H), 2.40 (s, 3H), 2.04 (q, J = 6.1, 5.7 Hz, 2H). Attempts 
to convert the free base 4.31 (110 mg, 0.58 mmol) to its oxalate salt failed and 
the fumarate was formed instead by the same procedure (122 mg, 62%, white 
solid). Mp: 148-150ºC. 1H NMR (400 MHz, D2O) δ 6.67 (s, 2H), 4.68 – 4.58 (m, 
1H), 3.86 – 3.71 (m, 1H), 3.71 – 3.45 (m, 4H), 3.32 – 3.13 (m, 2H), 2.98 (s, 3H), 
2.88 (s, 3H), 2.31 – 2.14 (m, 2H). 13C NMR (101 MHz, D2O) δ 180.74, 170.79, 
134.52, 56.89, 55.86, 47.50, 45.20, 43.91, 32.57, 23.74. HPLCMS (m/z) [MH+] 168.2 
(free base). Anal. (C8H17N3S·1.55 C4H4O4) C; H; N calcd 11.44, found 11.94; S 
calcd 8.73, found 9.25.  
 
N-Ethyl-4-methylpiperazine-1-carbothioamide oxalate (4.32). 
 Following method C, from 1-methyl-piperazine (100 µL, 0.90 
mmol), and ethyl isothiocyanate (87 µL, 1 mmol), the free base 
4.32 (165 mg, 98%) was obtained as a yellowish oil. 1H NMR 
(400 MHz, CDCl3) δ 5.55 (s, 1H), 3.88 (t, J = 4.9 Hz, 4H), 3.70 
(qd, J = 7.2, 4.9 Hz, 2H), 2.53 (t, J = 5.3 Hz, 4H), 2.37 (s, 3H), 1.24 (t, J = 7.3 Hz, 
3H). The free base was converted to the oxalate salt according to the general 
procedure to obtain a white solid. Mp: 166-167ºC. 1H NMR (400 MHz, D2O) δ 
4.90 – 4.82 (m, 2H), 3.71 – 3.55 (m, 4H), 3.46 (t, J = 13.6 Hz, 2H), 3.17 (dd, J = 
17.5, 7.4 Hz, 2H), 2.97 (s, 3H), 1.20 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, D2O) 
δ 180.10, 165.55, 52.61, 44.42, 42.75, 41.20, 13.46. HPLCMS (m/z) [MH+] 188.1 
(free base). Anal. (C8H17N3S·1.05 C2H2O4) C, H, N, S. 
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N-Ethyl-4-methyl-1,4-diazepane-1-carbothioamide oxalate (4.33). 
 Following method C, from 1-methyl-homopiperazine 
(100 µL, 0.80 mmol), and ethyl isothiocyanate (77 µL, 0.88 
mmol), the free base 4.33 (159 mg, 98%) was obtained as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 5.34 (s, 1H), 4.18 
– 4.05 (m, 2H), 3.78 – 3.60 (m, 4H), 2.78 (t, J = 4.7 Hz, 2H), 2.65 (t, J = 5.3 Hz, 
2H), 2.41 (s, 3H), 2.07 (dt, J = 11.2, 6.0 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H). The free 
base was converted to the oxalate salt according to the general procedure to 
obtain a white solid. Mp: 131-133ºC. 1H NMR (400 MHz, D2O) δ 4.69 – 4.61 (m, 
1H), 3.77 (dd, J = 16.9, 9.4 Hz, 1H), 3.72 – 3.47 (m, 6H), 3.32 – 3.13 (m, 2H), 2.88 
(s, 3H), 2.34 – 2.11 (m, 2H), 1.11 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, D2O) δ 
179.63, 165.69, 56.95, 55.85, 47.50, 45.15, 43.91, 41.05, 23.73, 13.77. HPLCMS 
(m/z) [MH+] 202.1 (free base).  Anal. (C9H19N3S·1.05 C2H2O4) C, H, N, S. 
 
tert-Butyl 4-(methylcarbamothioyl)-1,4-diazepane-1-carboxylate (4.34). 
 Following method C, from 1-tert-butoxycarbonyl-
homopiperazine (200 mg, 1 mmol) and methyl 
isothiocyanate (74 mg, 1 mmol), 4.34 (268 mg, 98%) was 
obtained as a yellowish oil. 1H NMR (400 MHz, CDCl3) δ 
5.48 (s, 1H), 4.03 – 3.94 (m, 1H), 3.90 – 3.74 (m, 2H), 3.60 (t, J 
= 6.1 Hz, 1H), 3.57 – 3.47 (m, 2H), 3.37 – 3.23 (m, 2H), 3.08 (s, 3H), 1.88 (dt, J = 
13.8, 6.4 Hz, 2H), 1.39 (s, 9H). 
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tert-Butyl 4-(ethylcarbamothioyl)-1,4-diazepane-1-carboxylate (4.35). 
Following method C, from 1-tert-butoxycarbonyl-
homopiperazine (200 mg, 1 mmol) and ethyl isothiocyanate 
(87 µL, 1 mmol), 4.35 (281 mg, 99%) was obtained as a 
yellowish oil. 1H NMR (400 MHz, CDCl3) δ 5.30 (s, 1H), 4.02 
– 3.94 (m, 1H), 3.88 – 3.74 (m, 2H), 3.69 – 3.56 (m, 3H), 3.56 – 3.48 (m, 2H), 3.37 
– 3.22 (m, 2H), 1.88 (p, J = 6.3, 5.8 Hz, 2H), 1.39 (s, 9H), 1.17 (t, J = 7.2 Hz, 3H).  
 
tert-Butyl 4-(dimethylcarbamoyl)piperidine-1-carboxylate (4.36). 
 1-(tert-butoxycarbonyl) piperidine-4-carboxylic acid (4.27) 
(229 mg, 1 mmol) was dissolved in anhydrous THF (4 mL), 
1,1’-carbonyldiimidazole (190 mg, 1.10 mmol) and 
triethylamine (154 µL, 1.10 mmol) were added to the 
solution. After 0.5 h at 50ºC a solution of dimethylamine 2M 
in THF (802 µL) were added. The reaction was kept at room temperature 
overnight. In order to remove the imidazole NaOH 2M was added to the 
mixture and then extracted with EtOAc , the organic extracts were pooled 
together, dried over MgSO4, and evaporated to give 4.36 (128 mg, 77%) as a 
clear oil. 1H NMR (400 MHz, CDCl3) δ 4.08 (dt, J = 14.3, 3.6 Hz, 2H), 2.97 (s, 
3H), 2.90 (s, 3H), 2.69 (ddd, J = 13.3, 11.1, 4.0 Hz, 2H), 2.57 (td, J = 10.3, 4.8 Hz, 
1H), 1.73 – 1.56 (m, 4H), 1.39 (s, 9H). 
 
N,N-Dimethylpiperidine-4-carboxamide hydrobromide (4.37).The synthesis 
and characterization of compound 4.37 is described in Method B. 
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N,N-Dimethyl-1,4-diazepane-1-carboxamide dihydrobromide (4.38). 
 Following method B, starting from 4.26 (206 mg, 0.76 mmol), 
4.38 (128 mg, 50%)  was obtained as a white solid. Mp: 174-
175ºC. 1H NMR (400 MHz, DMSO) δ 8.77 (s, 2H), 3.48 – 3.44 (m, 
2H), 3.35 (t, J = 6.0 Hz, 2H), 3.21 (p, J = 4.9 Hz, 2H), 3.13 (dt, J = 
8.9, 5.2 Hz, 2H), 2.70 (s, 3H), 1.99 (dt, J = 11.4, 6.0 Hz, 2H). 13C NMR (101 MHz, 
DMSO) δ 163.96, 47.26, 45.79, 44.67, 43.87, 38.50, 25.19.HPLCMS (m/z) [MH+] 
172.2 (free base). Anal. (C8H17N3O·2HBr·0.5H2O) C, H, N. 
 
N-Methyl-1,4-diazepane-1-carbothioamide hydrobromide (4.39). 
 Following method B, from 4.34 (268 mg, 0.98 mmol), 4.39 
(190 mg, 75%) was obtained as a white powder. Mp: 200-
201ºC. 1H NMR (400 MHz, DMSO) δ 4.25 (t, J = 5.5 Hz, 
2H), 3.80 (t, J = 6.2 Hz, 2H), 3.39 (t, J = 5.3 Hz, 2H), 3.29 
(ddd, J = 5.9, 3.9, 2.2 Hz, 2H), 3.04 (s, 3H), 2.23 – 2.12 (m, 
2H).  13C NMR (101 MHz, DMSO) δ 181.35, 46.28, 45.15, 44.77, 43.97, 30.67, 
23.43. HPLCMS (m/z) [MH+] 174.24 (free base). Anal. (C7H15N3S · 1.35 HBr · 
0.25 C2H7O) C, H, N, S. 
 
N-Ethyl-1,4-diazepane-1-carbothioamide hydrobromide (4.40). 
 Following method B, from 4.35 (281 mg, 0.99 mmol), 4.40 
(224 mg, 83%) was obtained as a white powder. Mp: 154-
155ºC. 1H NMR (400 MHz, DMSO) δ 4.24 (t, J = 5.2 Hz, 
2H), 3.80 (t, J = 6.2 Hz, 2H), 3.63 (q, J = 7.2 Hz, 2H), 3.39 (t, 
J = 5.2 Hz, 2H), 3.32 – 3.24 (m, 2H), 2.23 – 2.12 (m, 2H), 1.17 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 180.40, 46.20, 45.10, 44.87, 44.00, 39.23, 23.40, 
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12.14. HPLCMS (m/z) [MH+] 188.33 (free base). Anal. (C8H17N3S ·1.2 HBr · 0.2 
C2H7O) C, H, N, S. 
 
4-(3-Methyl-1,2,4-oxadiazol-5-yl)butan-2-one (4.41). 
 ethyl levulinate (494 µL, 4.0 mmol), acetamidoxime 
(354 mg, 4.8 mmol), K2CO3 (552 mg , 4.0 mmol) were 
suspended in 2 mL of MeCN, and the mixture was 
heated to 180ºC for 1h under microwave irradiation.  The mixture was filtered 
through a short silica plug, washed with EtOAc and thus 4.41 (520 mg, 84%) 
was recovered as a brown oil.1H NMR (300 MHz, CDCl3) δ 3.16 – 3.08 (m, 2H), 
3.07 – 2.98 (m, 2H), 2.37 (s, 3H), 2.25 (s, 3H). HPLCMS (m/z) [MH+] 155.25. 
 
N,N-Dimethyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)butan-2-amine oxalate (4.42).  
Na(CN)BH3  (130 mg, 2.1 mmol) was added over a 
solution of 4.41 (107 mg, 0.69 mmol), an aq. solution of 
dimethylamine 33% (0.3 mL),  dimethylamine 
hydrochloride (562 mg, 6.9 mmol) in MeOH (3 mL). The 
mixture is kept at rt. for 18 h, then solvent removed. The evaporated mass is 
resuspended in a sat. aq. K2CO3 solution and extracted with EtOAc  (x2) and 
the free base 4.42 (61 mg, 48%) is obtained as a brownish oil, 1H NMR (400 
MHz, CDCl3) δ 2.90 – 2.69 (m, 2H), 2.54 (dq, J = 13.0, 6.3 Hz, 1H), 2.42 (s, 3H), 
2.15 (s, 6H), 1.92 – 1.80 (m, 1H), 1.76 – 1.63 (m, 1H), 0.91 (d, J = 6.5 Hz, 3H), 
HPLCMS (m/z) [MH+] 184.33,  that was converted to the oxalate salt 
according to the general  procedure to give 4.42 (53 mg, 28% both steps) as a 
yellow powder.Mp: 124-125ºC. 1H NMR (400 MHz, DMSO) δ 3.35 (dqd, J = 
10.4, 6.6, 3.9 Hz, 1H), 3.08 – 2.90 (m, 2H), 2.66 (s, 6H), 2.31 (s, 3H), 2.20 (dddd, J 
= 13.6, 10.2, 6.6, 3.9 Hz, 1H), 1.88 (dtd, J = 13.3, 9.7, 5.8 Hz, 1H), 1.23 (d, J = 6.6 
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Hz, 3H). 13C NMR (101 MHz, DMSO) δ 179.20, 167.42, 165.14, 165.13, 60.19, 
27.40, 23.00, 13.26, 11.78. HPLCMS (m/z) [MH+] 184.30 (free base. Anal. 
(C11H19N3O5) C, H, N. 
 
Ethyl 4-(dimethylamino)pentanoate (4.43). 
 ethyl levulinate (1 mL, 9.87 mmol) is dissolved in EtOH (4 
mL), glacial AcOH (1.2 mL)  and hydrogenated (Pd/C, 
10%, 300 mg) at 1 atm H2 and rt. for 48h. Then Pd/C was 
filtered off, the solvent was evaporated and the residue resuspended in H2O, 
acidified to pH 2 with HCl 2 M and the water phase was washed with DCM 
(x2). The aqueous solution was then basified to pH 10 with NaOH 2M and 
extracted with DCM (x3). The extracts were dried over MgSO4, and solvent 
evaporated, to give 4.43 (857 mg, 50%) of a yellowish oil.1H NMR (400 MHz, 
CDCl3) δ 4.06 (q, J = 7.1 Hz, 2H), 2.52 (p, J = 6.8 Hz, 1H), 2.29 (t, J = 7.6 Hz, 2H), 
2.19 (s, 6H), 1.78 (ddd, J = 14.3, 7.9, 6.6 Hz, 1H), 1.53 (dq, J = 13.8, 7.4 Hz, 1H), 
1.19 (t, J = 7.1 Hz, 3H), 0.92 (d, J = 6.5 Hz, 3H). 
 
4-(Dimethylamino)pentanehydrazide (4.44). 
4.43 (121 mg, 0.7 mmol) was subjected to 
hydrazinolysis with microwave heating with 
hydrazine hydrate (0.52 mL, 10 mmol), and EtOH (1 
mL) at 155ºC for 45 min. Then the solvent and hydrazine excess was 
evaporated to give 4.44 (95 mg, 85%) as a colourless oil, 1H NMR (400 MHz, 
D2O) δ 2.49 (dqd, J = 13.2, 6.6, 3.9 Hz, 1H), 2.27 – 2.07 (m, 9H), 1.80 (dddd, J = 
13.4, 10.5, 7.0, 4.2 Hz, 2H), 1.51 (ddt, J = 13.2, 9.0, 4.6 Hz, 2H), 0.96 (d, J = 6.6 
Hz, 3H). 
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N,N-Dimethyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)butan-2-amine oxalate (4.45). 
 4.44 (95 mg, 0.60 mmol) were suspended in ethyl 
orthoacetate (1.5 mL) and the mixture heated to 125ºC for 
1h. The excess of ethyl orthoacetate was removed by 
evaporation and the residue suspended  in H2O, acidified to pH 2 with HCl 2 
M and the water phase was washed with DCM (x2). The aqueous solution was 
then basified to pH 10 with NaOH 2M and extracted with EtOAc several 
times.The EtOAc extracts were dried over MgSO4, and solvent evaporated to 
give the free base 4.45 (30 mg, 27%) as a yellow oil 1H NMR (400 MHz, CDCl3) 
δ 2.94 – 2.70 (m, 2H), 2.59 (dq, J = 13.0, 6.3 Hz, 1H), 2.46 (s, 3H), 2.19 (s, 6H), 
1.96 – 1.84 (m, 1H), 1.82 – 1.66 (m, 1H), 0.95 (d, J = 6.5 Hz, 3H)  that was then 
converted to the oxalate salt according to the general procedure to give 4.45 
(31 mg, 11% both steps) as a white powder. Mp: 118-119ºC. 1H NMR (400 
MHz, DMSO) δ 3.47 (dtt, J = 10.1, 6.4, 3.2 Hz, 1H), 3.04 – 2.84 (m, 2H), 2.79 (s, 
6H), 2.46 (s, 3H), 2.31 – 2.20 (m, 1H), 2.04 – 1.90 (m, 1H), 1.33 (d, J = 6.7 Hz, 
3H). 13C NMR (101 MHz, DMSO) δ 164.78, 163.65, 163.51, 59.50, 36.97, 25.50, 
19.86, 10.30, 7.85.  HPLCMS (m/z) [MH+] 184.30 (free base). Anal. (C11H19N3O5 
· 0.25 C2H2O4) C, H, N. 
 
Radioligand binding assays. 
The [3H]epibatidine binding experiments using membranes from HEK293 cell 
lines stably expressing rat α4β2, α3β4, and α4β4 nAChRs.  
In the [3H]epibatidine binding experiments, the stable HEK293 cell lines were 
harvested at 80–90% confluency and scraped into assay buffer [140 mM NaCl, 
1.5 mM KCl, 2 mM CaCl2, 1 mM Mg2SO4, 25 mM HEPES (pH 7.4)], 
homogenized using a Polytron for 10 s, and centrifuged for 20 min at 50000g. 
Cell pellets were resuspended in fresh assay buffer, homogenized, and 
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centrifuged at 50000g for another 20 min. Then the cell pellets were 
resuspended in the assay buffer, and the cell membranes were incubated with 
25 pM [3H]epibatidine in the presence of various concentrations of 
compounds in a total assay volume of 1500 μL. Nonspecific binding was 
determined in reactions with 5 mM (S)-nicotine. The mixtures were incubated 
for 4 h at room temperature while shaking.  
 
FLIPR membrane potential (FMP) blue assay. 
Selected compounds were characterized functionally at the α4β2 and α3β4-
HEK293 cell lines in the FMP assay essentially as previously described28,29. In 
brief, cells were split into poly-D-lysine-coated 96-well black Opti-plates (BD 
Biosciences, Bedford, MA) in Dulbecco’s modified Eagle medium 
supplemented with penicillin (100 U/mL), streptomycin (100 μg/mL), and 
10% fetal calf serum, supplemented with 0.7 mg/mL G-418. At 16–24 h later 
the medium was aspirated, and the cells were washed with 100 μL of Krebs 
buffer [140 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 11 mM 
HEPES, 10 mM D-glucose, pH 7.4]. Then 50 μL of Krebs buffer was added to 
the wells (in the antagonist experiments, various concentrations of the 
antagonist were dissolved in the buffer), and then an additional 50 μL of 
Krebs buffer supplemented with the FMP assay dye (1 mg/mL) was added to 
each well. Then the plate was incubated at 37 °C in a humidified 5% 
CO2 incubator for 30 min and assayed in a NOVOstar plate reader (BMG 
Labtechnologies, Offenburg, Germany) measuring emission (in fluorescence 
units, FU) at 560 nm caused by excitation at 530 nm before and up to 1 min 
after addition of 33 μL of agonist solution. The experiments were performed in 
duplicate at least three times for each compound at the receptor. 
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Molecular modelling. Docking studies. 
The Ls-AChBP structure co-crystalized with compound 4.1 was obtained from 
the PDB (3ZDG)31. The structure was imported into the Schrödinger Maestro 
Version 9.3.026 and processed with the Protein Preparation Wizard module. 
The tested ligands were processed with the program Epik prior to docking 
with Glide. Post-docking minimization was carried out and the most relevant 
contacts of the docked ligands measured and visually studied.  
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Epilogue 
 
 
Concluding remarks 
 
In each chapter detailed discussions have been made and prospective analysis 
and specific conclusions have been drawn. Being interrelated in some aspects and 
divergent in others this epilogue may serve as the common juncture of the chapters 
contained in this thesis. The purpose of this epilogue is to offer a general overview on 
how this work was elaborated, why, what was learnt along the way, and thus, 
somehow, place this thesis work within the context of the current academic practice of 
medicinal chemistry, and prospectively, in drug discovery. In the previous pages it 
has been shown what the PhD candidate has done for medicinal chemistry. In this 
section, it will be presented how medicinal chemistry has been approached by the 
student, but more importantly, it will be outlined what such approach has taught to 
the trainee beyond the practice of the discipline. The ideas that appear in the 
forthcoming paragraphs might sound obvious to a senior investigator, but the 
learning and realization of most of them have been determining milestones in the 
course of this work. 
 
Bibliographic review and synthetic ease have been the main driving forces in 
the design of target compounds. Extensive review of previous reports on the 
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development of synthetic analogues was the key tool that provided the starting point 
for the design of compounds. Bibliographic research was what shaped the project and 
provided the context:  which were the main challenges and what gaps were missing in 
the field of study, what strategies and approaches were attempted before, continued 
or abandoned in order to fill in those gaps. It was during this process where the main 
structural clues are revealed: how a new molecular entity should look, “fit”, and 
behave.  
 
Both conformational restriction and bioisosteric replacement are old-school 
medicinal chemistry strategies within every beginner’s reach. With the exception of 
the synthesis of DMABC restricted analogues in chapter four, no computional-aided 
design was initially made. Only traditional ligand-based approaches intervened in the 
design of target molecules for the melatoninergic system and the bioisosteres of 
DMABC (chapter 4, compound 4.1).  
 
With regard on the chemical approach, very few reactions were optimized 
and the obtaining of pure products in sufficient quantities was prioritized over the 
neatness of the reactions. More products than those described in this thesis were 
synthesised, some just as reactivity tests, some were just the result of a why-not? 
approach. Nevertheless, in order to keep this work consistent and systematic they 
were excluded in this report. As abovementioned, synthetic ease was a major wheel in 
the design.  Being organic synthesis the source for novel molecular entities, in this 
thesis it was utilized in the most pragmatic way. In order to maximise the synthetic 
output in the minimum time, we prioritized the generation of as many analogues as a 
synthetic route could afford over the preparation of complex entities through long 
synthetic routes. Thus, the pharmacological feedback readily available from a good set 
of compounds provided a good starting point for rationalization and re-design. The 
application of chemistry to biological systems is where organic chemistry turns into 
medicinal chemistry, and therefore pharmacology was what has defined the course of 
the projects and subprojects included in this manuscript. All synthesised compounds 
were characterized in as many systems as they could be rationally addressed. 
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Those were the means employed that yielded the results described and 
discussed in the different chapters. Nevertheless, during the course of their 
application a lot of personal reflections and additional insights, not necessarily 
scientific, came along. It is likely that these revelations would not have been possible 
without an essential factor: the freedom I have enjoyed throughout the course of this 
thesis project, from the early design to the rationalization of the results. I am 
extremely grateful to my supervisor, María Isabel Rodríguez Franco, for letting me 
take over the whole project. Both for good and bad. Getting deeply involved 
provoked an exacerbated perception of both the small achievements and the slap-in-
the-face results could get to be sometimes. Additionally, it greatly increased the 
feeling of empowerment and control over the project, what triggered the necessity of 
finding my very own solutions to the problems that appeared along the way, and 
turned out to be the most gratifying and fruitful experience of the whole work. It may 
serve as an example the evolution of this thesis project right from its beginning. In its 
genesis it was initially conceived for the development of novel positive allosteric 
modulators of the α7 nicotinic receptor, but the issues that appeared along the way, 
little by little, reshaped till it became what it is contained in these pages. 
 
And with regard on the nicotinic receptor, it has been of major importance my 
time in Copenhagen under the supervision of Bente Frølund, both professionally and 
personally. Even if the synthesis has not been able to return super potent and selective 
ligands for the α4β2-nicotinic receptor, the nearly-year I spent in the department of 
Drug Design and Pharmacology of Copenhagen University, offered me much more 
than a lab bench. Loads of ideas for new projects not directly related with cholinergic 
system and upgrades for the previous ones, emerged there. A side-project in the 
synthesis of fluorescent analogues of melatonin that is not contained in this work for 
intellectual property issues was born during that time. I also had the chance to share 
and witness how medicinal chemistry is envisioned from different perspectives, and 
somehow maturate what it is contained in these lines.  
 
In my opinion a thesis in medicinal chemistry not only represents an attempt 
to apply the scientific method to broaden up knowledge in the field, but it also implies 
a responsibility. Acquisition of knowledge does not need a justification or revenue. 
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Knowledge is a goal by itself. And that shall be the main driving force in the design of 
an academic PhD project. Beyond epistemological considerations, pragmatism applies 
in medicinal chemistry as well. Independently of the approach employed or the stage 
of development, the ultimate goal of the whole process is to, at least try, to acquire 
new knowledge that could be useful from a preventive, therapeutic or diagnostic 
point of view.  
 
There are different ways to envision the therapeutic potential from a PhD 
student. The naïve impression of a beginner fresh out of pre-grad school, as I was at 
the time this thesis period started, is somehow a pipeline that “just” needs to be 
fulfilled --knowledge is in the books, so putting the things in order and some labwork 
will do the rest--. The goals seem to be around the corner. But reality little by little 
slowly puts things in place, and unrest emerges together with the realization that the 
pipeline to reach the market is infinite. Beyond the everlasting chemical pursuit of the 
highest affinity/potency/selectivity and novelty there are a million issues i.e. 
solubility, ADME properties, cardiovascular effects, toxicity, expensive production, 
lack of venture capitalist… that can lead a hit to nowhere.  
 
Another great feeling of despair comes from the let’s-play-like-big-pharma-
does pretention. This delusion of grandeur is rather common in academia but in my 
opinion, academia and industry use the same ball, but they play different games. The 
tiniest contact with the industry will let you guess how much of a nothing most 
academic research groups are compared to the gigantic proportions of the industry, in 
terms of amount of information and data management, efficiency and productivity. 
Someone that attempts to play the “big pharma” game on its own it is not a David 
seeking to defeat Goliath, it is a fool. The pharma giant is busy with its own stuff. The 
stuff that sounds relevant, ultimately, where the money is. But the giant is extremely 
annoyed, because despite its gigantic proportions is unable to find the panacea. 
Moreover, it is spending loads of money in the pursuit, and gets nothing back. Upon 
attendance to any mid-to-large sized medicinal chemistry congress, it is common to 
find within the programme a certain guy, or several, from a certain pharmaceutical 
company (which slogan repeats the word “innovation” as a mantra) giving a lecture 
on how a brand-new translational-multidisciplinary-high-throughput-integrated 
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approach, developed by them of course, is going to take drug discovery out of the 
draught. And we all hope they will. Because they are the people who have the money 
and the means to care about the enormous pipeline. That pipeline is not suitable for 
an academic PhD. In my opinion an academic PhD must forget about the pipeline, 
recall the pursuit of knowledge, and focus on all those fields the big pharma is not 
interested in. Not because they are not interesting, relevant or important, but hard to 
trade with. Briefly, more medicinal chemistry and less drug discovery, but of course, 
keeping them both present. 
 
My PhD thesis is professionally the most thrilling project I ever embarked on. 
And as a project, I consider that it should be envisioned from a holistic point of view, 
always keeping in mind which are the sole points in you can actually intervene in. 
These might be seen as a limitation but those points are the actual mines where your 
gold, the knowledge, is. Bioisosterism and conformational restriction are very classical 
strategies within every medicinal chemist reach. What defines how conservative or 
ground-breaking the approach is depends on its application not in the strategy itself. 
Pharmacological assays are in most cases the scales that are going to weight the 
relevance of your outputs. And that is a big point, because novelty shall be sought at 
all possible levels. Biological systems are not just mysterious black boxes. 
Pharmacology works much differently than organic chemistry does, but there is a lot 
more than just nanomolar constants. An obsessive seeking of a certain selectivity or 
pharmacological profile will probably make you miss loads of interesting roads that 
might appear along the way. If your beloved target feels nausea of your compounds, 
that is a clear clue that something failed. And that of course should be the first issue to 
address in the following steps… But it might not be your compounds last word; there 
is nothing embarrassing in rationally seeking for a different target your failed 
compounds can fit in. That is what medicinal chemistry is about, not about telling if 
the chicken or the egg came first.  The “medicinal chemist” that invented the 
superpowerful “utopiate”1 soma, Aldoux Huxley, stated “we can only love what we 
know, and we can never know completely what we do not love”2. In the present case 
reconciling with pharmacology provided a higher feeling of control in the research, 
and aroused questions we felt eager to answer. Medicinal chemistry is nothing 
without chemistry and pharmacology. The cleft between both is perfectly exemplified 
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by the nature of the matter chemistry and pharmacology work with: inert matter and 
alive matter.  That qualitative leap is what results fascinating in the practice of 
medicinal chemistry. The more one gets to know about either world, the more likely it 
will be to feel haunted by the intersection between them. And the broadening of that 
intersection will be the greatest achievement.  
 
For an organic chemist an amide coupling is for “kids”, but if it leads to the 
ligand you were looking for... who cares? There are loads of clichés that should be 
disregarded. Click chemistry is “cool”, but is it really useful for your purposes or just 
a pointless way to move away the mainstream? There are plenty of questions that 
should be answered to decide whether “the trends” represent an added value in your 
project, or if they are just buzz-words. We went for two humble traditional 
approaches just because we considered them potentially useful. One should question 
everything. Science cannot be dogmatic. Most of the paradigms that were well 
established a decade ago in medicinal chemistry and drug discovery have been 
challenged; a lot of concepts have been proved wrong whereas others have evolved. 
Neat selectivity, potency and specificity have been long pursued as “guarantee” of 
efficacy and safety in the development of drug candidates. That pursuit has lost a 
great share of support if we take into account phenomena, like compensatory effects, 
that challenge the reductionism of focusing on a single node within the complexity of 
biological systems3.  Phenomena that could also explain the high degree of attrition in 
clinical trials. Most of old and new marketed drugs interact with dozens of receptors, 
a fact has been commercially exploited for drug repurposing4. Even the very concept 
of target-based Drug Discovery has been questioned5. Old principles are renewed and 
complemented by emerging ones or by other concepts that regain relevance. The 
traditional pharmacological ligand-receptor-response paradigm is continuously being  
enriched with concepts like residence time6, functional selectivity7, receptor homo- 
and heterodimerization8. 
 
Medicinal chemistry is alive, it is continuously evolving, and the only way to 
keep track of its constant update is reading.  In my opinion, it cannot be emphasised 
enough how important reading is. Not only to keep oneself updated but also to avoid 
dead-end alley hidden right behind a certain line. A clear example of this could be 
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found in this thesis. During the development of the pinoline-melatonin hybrids 
project, that intriguing and putatively endogenous neurochemical named pinoline 
evoked into me not only a scientific interest but some kind of fascination too. 
Especially as an endogenous neurochemical --melatonin’s ignored little brother--. 
There were many hypothesis surrounding the role and relevance of this β-carboline: 
schizophrenia, the visual content of the dreams9… some of them bordering 
esotericism. This fascination lasted for quite a while, until the molecule revealed itself 
as nearly a myth according to the studies of Langer and Barbaccia in the 80s10,11. 
Perhaps not even the pineal-relating name of the molecule is justified. Those papers 
were found when the project was already ongoing, and the report had to be rewritten 
and the perspective totally redirected. Notwithstanding with that blow, further 
reading revealed that the agonistic properties of pinoline and its isomer 3.1 at the 5-
HT2A receptor could be of relevance, not as an endogenous chemical anymore, but in 
the pharmacology of harmala alkaloids. A topic, we are currently working on, as 
fascinating, or even more than pinoline was at the beginning. Reading is the only way 
a dead-end can turn into a new road stretching to the horizon. In the particular case of 
the synthetic melatonin analogue 1.21 there are good perspectives for this candidate 
for further development of its potential. Nevertheless, careful and well-founded 
observations during its development have arisen many intriguing questions on its 
mechanism of action, that could result even more intriguing than its development as a 
therapeutically tool for neurodegenerative diseases. 
 
These are hard times for drug development in neurodegenerative diseases. 
Loads of clinical trials have been carried out, billions spent, and no candidates have 
become approved drugs for curing or disease-modifying treatments. There are several 
clinical trials ongoing in the field, but there is little support for optimism. Several 
pharmaceutical companies are giving up in such unfruitful field and closing up their 
Alzheimer disease (AD) drug discovery programmes, a company seeks benefit an 
perhaps, from an economical point of view, “it is just not worth it”12. Current 
treatments are merely palliative and only effective during early stages of clinically 
manifested AD. Disease-modifying treatments have been long sought, but none of the 
candidates have succeeded13. The underlying reasons that have led to such awful 
scenario are found in the very nature of the disease. When AD becomes clinically 
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manifested, its pathogenic mechanisms have been previously ongoing for a long time. 
The loss of neuronal tissue is enormous before the AD can be clinically diagnosed. 
Therefore potential effectiveness of a disease-modifying therapy is compromised by 
the great degree deterioration present in the patient brain when the treatment starts. 
Hope rests upon early detection of the disease14. Detection of AD on its earlier stages 
would permit a better comprehension of the declining process and therefore, would 
open up doors to intervention with conservative and restorative therapies at that 
pathophysiological level, like for instance, the ambitious neurogenesis potentiation 
approach. This approach not only attempts to stop the progression of the disease, but 
also to restore the cognitive functions. It is important to note that neurogenesis is not 
just restricted to the appearance of new neurons; its relevance relies in the ability of 
the new neurons to become integrated in the neural circuitry15.  If we compare the 
neurogenesis rate of sharks and humans, settling in of new neurons in the most 
evolved brains of then the animal kingdom during adult stages appears to be 
manifestly unfavourable. Evolution is clearly discouraging at this point and the 
remaining neurogenesis in adults appears to be a just a vestigial process. The precise 
role of naturally occurring hippocampal neurogenesis in adult mammals is unclear, 
and the contribution of the natural-occurring process to cognitive performance in 
adults limited15,16. Neural renewal might sound as a conceptually science-fictional 
approach in drug discovery, and additionally, it deserves careful handling, since 
uncontrolled potentiation of the neural proliferation could easily lead to a neuroma, 
but it definitely needs to be given a chance. Moreover the characterization of the 
process should be compelling enough to justify the time and money spent. There are 
loads of questions surrounding the process in terms of relevance, function, 
contribution to the cognitive processes, and ultimately therapeutical potential, which 
deserve to be answered. 
 
The future of neurodegenerative diseases is grim. AD prevalence grows to 
such extent that it is predicted to become epidemic in some years, but as 
abovementioned, the biggest issue is that we do not have effective weapons against 
it17.  Is it a fair war we are in attempting to defeat it? The classical medical paradigm 
and the common perception establish that behind the pathology there must be an 
etiology. This may not be as simplistic in the case of many highly prevalent metabolic 
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and neurodegenerative diseases like AD. Numerous longitudinal studies have 
determined what risk and protective factors contribute to a greater or lesser incidence 
of AD18. Some genes have been identified as determinant in certain cases of familial 
AD but the greatest known risk for developing AD is age19. It sounds as strikingly 
obvious and despairing as saying that the main risk factor for dying is ageing. The 
older a population gets, the more likely it is to develop AD. We could fantasize with 
the idea of diminishing the deterioration associated to the process of ageing, but we 
cannot just simply fight against ageing. Therefore it would be a huge leap in medicine 
just to be able to slow down the progression of the disease but, as abovementioned, 
that recalls for early detection of the disease. Furthermore taking into account the 
characteristics of the disease one might wonder if the pursuit of a cure for AD is not 
just a chimera. 
 
The nature of AD is revealing. Post-mortem histologic analysis of the patient 
brains shows that the main affected area by this dementia is the cortex, the structure 
responsible for superior cognitive functions20. If something characterizes the Homo 
sapiens is the ability to perform complex cognitive processes, and this ability is 
inherently related to the high degree of development achieved by its brain; the most 
evolved brain in the course of evolution. This machinery is enormously complex and 
precise; it has been adapted and optimized by evolution throughout hundreds of 
thousands of years. A robust and reliable machine set up to last, at least, as much as 
the individual would stay alive. That meant, on average, 31 years globally and less 
than 50 years in developed countries in the beginning of the 20th century21. But the 20th 
century did make a difference in the course of history. Last century witnessed the 
greatest technological and scientific progress made by humanity ever since the dawn 
of civilization. Progress that permeated throughout all levels, and that permitted 
during the turn of the millennium to witness the achievement of the highest degree of 
development humanity ever knew. As a result, many indicator boosted, among them, 
life expectancy22. And one might wonder how the organism can adapt itself to such 
sudden changes. Evolutionary changes occur in periods of hundreds of thousands of 
years and during a single century humanity has globally nearly doubled its life 
expectancy, surpassing the 80 years in many developed countries23. And such 
extension of the life expectancy cannot be explained without assuming that such 
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sudden changes have had an enormous impact in our physiology and 
pathophysiology. The causes of death and disease have greatly changed along the 
past century, and nowadays metabolic and neurodegenerative diseases are peaking at 
both.  
 
And people die, and always will. It could be seen as death and disease always 
finding its way despite the great progresses made by humanity in hygiene, surgery, 
medicine… but it is precisely the other way around. Longer lifespan permits certain 
pathologies to become visible. Pathologies, like AD, that are rather common these 
days were rare in the old times, just because a 19th century average lifetime would not 
generally be enough for it to show up. Taking into account these type of dementia 
mostly appear in populations at stages of life in which their reproductive period is 
over, not even natural selection would make a strong effort in eradicating them24. The 
homeostatic-guarantee period of the soma has been extended, but it has an expiring 
date, and that expiring date in the case of the central nervous system, the most 
complex system in our physiology, is manifested as neurodegenerative diseases. 
When looked from that point of view, it results extremely pretentious, nearly foolish, 
to embark on the pursuit of a small molecule able to re-adapt a system that would 
need thousands of lifetimes to do so. But again, just finding out a way to slow down 
the progression of the disease would be a ground-breaking therapeutical revolution. 
 
If ask whether I am confident that in the near future a treatment for AD will be 
discovered, I would say no, not at all. But I am looking forward to taking part in 
whatever comes next to defeat it. 
 
❦ 
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Abstract 
 
Bioisosterism and conformational restriction: 
ligand-based design in the development of 
nicotinic ligands and melatonin analogues 
with neurogenic properties 
 
Introduction 
Neurodegenerative diseases lack determinant causes or specific conditions 
for their onset. Therefore, the most intuitive approach, the targeting of an 
etiological agent, is not suitable in their case. Another common characteristic of 
these widespread diseases is the complexity of their neuropathophysiology. From 
the very molecular basis of the disease to the cognitive abilities of the patient 
there are several pathognomonic abnormalities interrelated at all biological levels. 
In the case of Alzheimer’s disease (AD), addressing such complex scenario led to 
a scientific consensus that required several hypothesis to cover all the 
characteristic signs of this neurodegenerative process. The most accepted 
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hypotheses in the case of AD are: the cholinergic deficit, the β-amiloid 
accumulation and the τ-protein hyperphosporilation. The cholinergic hypothesis, 
the oldest of the three, has as therapeutic potential merely palliative. Despite this 
limited potential it is the only therapeutic approach that has been able to provide 
effective drugs for the treatment of AD with the sole exception of the N-methyl-
D-aspartate receptor inhibitor memantine. The pharmacodynamics of approved 
cholinergic based-treatments are essentially based on the inhibiton of the enzyme 
acetylcholinesterase. This inhibiton results in an indiscriminate net increase of the 
levels of acetycholine in the central nervous system. This increase compensates 
for the loss of cholinergic neurons resulting from the neurodegenerative process. 
During the last two decades, efforts were made in order to achieve a more precise 
and specific stimulation of the cholinergic system via direct stimulation of 
acetylcholine receptors, specially nicotinic receptors, by synthetic ligands. This 
unfinished work requires new pharmacological tools are needed both for a better 
understanding of the cholinergic system, and for exploiting its therapeutic 
potential. 
Melatonin is a neurohormone secreted by the pineal gland in the absence 
of light whose main role in the body is the control of the circadian cycles. Recent 
studies ascribe many other physiological functions to this intriguing molecule. 
Melatonin modulates the immune system, protects mitochondria from oxidative 
damage, acts as a neuroprotective agent and interestingly participates in the 
development of nicotinic receptor. Experiments in mice revealed that chronic 
treatment with melatonin did not extend the lifespan of the individuals; however, 
the treated group enjoyed a much healthier aging that includes better 
performance at cognitive tests. Beyond melatonin neuroprotective properties, in 
the recent years, melatonin has also demonstrated its ability to stimulate 
neurogenesis in rodents. Taking into account the neural death that occurs in 
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neurodegenerative processes this ability could be of special interest in the field of 
regenerative medicine applied to these types of dementia. 
 
Objectives 
 In this thesis work we aimed to develop new ligands for both the 
melatonergic and cholinergic system. For this purpose, we have systematically 
applied two traditional ligand-based design approaches, bioisosterism and 
conformational restriction. The compounds thus designed were synthesized and 
their structures and pharmacological profile characterized. Preliminar studies in 
biological assays in order to assess their potential as therapeutic tools were 
carried out for selected compounds. 
 
Results 
The N-acetyl group of melatonin was replaced for different azolic 
heterocycles and reversed amides following the principles of bioisosterism. We 
have set up an efficient synthetic method that permits the generation of a wide 
variety of azolic compounds that were unequivocally characterized. Those 
compounds that could exist in a tautomeric equilibrium were found to be present 
in a single tautomeric form in DMSO. The acidic nature of some of these azoles 
was confirmed indirectly in a solubility assay at different pH. The ability of the 
analogues to bioisosterically substitute for melatonin was measured in functional 
and radioligand displacement experiments in melatonergic receptors. The results 
obtained revealed that the retroamides and azoles utilized in this work can 
partially replace for the N-acetyl group of melatonin in terms of MT1 and MT2 
receptor recognition. We have rationalized the results based on the ability of 
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active compounds to superimpose to the bioactive conformation of melatonin 
(chapter 1). 
 Selected melatonin analogues demonstrated their ability to promote the 
expression of neurogenic markers in neurospheres cultured from rat neural 
precursors. Their ability to cross the brain-blood barrier was determined in vitro. 
The in vitro neurogenic effect of the most potent compounds was effectively 
blocked by the melatonin antagonist luzindole, and in the case of compound 1.21 
the neurogenic results were confirmed in vivo (chapter 2). 
 The putatively pineal β-carboline pinoline was chosen as the skeletal 
structure in the design of melatonin restricted analogues. A small series of 
tricyclic compounds with varying relative positions of their amines or amides and 
methoxy substituent was synthesized and their pharmacological profiles studied 
in several receptors. Additionally, a structure-antioxidant activity relationship 
study was carried out, and the neurogenic potential of selected compounds was 
studied in vitro. The fusion of the structures of pinoline and melatonin in the 
development of conformationally restrained analogues of melatonin was clearly 
detrimental in terms of melatonergic receptor recognition. Only one compound, 
3.3, retained significant activity at the melatoninergic receptors. With regard on 
the neurogenesis assay, both compound 3.3 and pinoline demonstrated their 
ability to stimulate neurogenesis in vitro. In the case of compound 3.3 its 
neurogenic effect was counteracted by luzindole. Pinoline proved to be rather 
potent at eliciting the expression of neurogenic markers even at nanomolar 
concentrations (chapter 3). 
 The structure of DMABC (3-dimethylaminobutyl dimethylcarbamate), an 
analogue of carbamylcholine with an interesting selectivity profile in nicotinic 
receptors was embedded in different cycles with varying degrees of 
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conformational restriction. Out of the four families of compounds prepared only 
cis-dimethylaminocyclopropyl and dimethylaminopyrrolidine series displayed 
significant affinity for the tested nicotinic receptors. The bioisosteric replacement 
of the carbamate of DMABC for oxadiazole retained some affinity for some 
nicotinic receptors, but resulted in antagonism (chapter 4).  
Conclusions 
 We have systematically applied and re-validated two ligand-based drug 
design strategies in the genesis of novel melatonin and DMABC analogues. The 
molecular entities resulting from the application of both approaches have been 
pharmacologically characterized.  Beyond their reported activity in the 
corresponding receptors, this work has also provided several structures suitable 
to be employed as pharmacological tools in the study of the mechanisms behind 
the melatoninergic-driven neurogenesis process. 
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Resumen 
 
Bioisosterismo y restricción conformacional: 
diseño basado en el ligando aplicado al 
estudio de la selectividad en receptores 
nicotínicos y al desarrollo de análogos de 
melatonina con propiedades neurogénicas 
 
Introducción 
 Las enfermedades neurodegenerativas carecen de causas o condiciones 
específicas que desencadenen la instauración de la patología. Por tanto, la 
estrategia terapéutica más intuitiva consistente en neutralizar  los agentes 
etiológicos no es aplicable en su caso. Otra de las características comunes de estas 
enfermedades es la complejidad de su neurofisiopatología. Desde la base 
molecular de la enfermedad hasta el cuadro clínico cognitivo del paciente hay un 
buen número de signos patognomónicos interrelacionados a todos los niveles 
biológicos. En el caso de la enfermedad de Alzheimer (EA), entre otras, 
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enfrentarse a este escenario tan complejo requirió de un consenso científico que 
necesariamente incluía varias hipótesis para poder así cubrir todos los signos 
característicos de este proceso neurodegenerativo. Las hipótesis más aceptadas en 
el caso de la EA son: el déficit colinérgico, la acumulación del péptido β-amiloide 
y la hiperfosforilación de la proteína τ. La hipótesis colinérgica, la más antigua de 
las tres, tiene la limitación de que su potencial terapéutico es meramente 
paliativo. A pesar de ello, es la única aproximación terapéutica capaz de producir 
fármacos efectivos en el tratamiento de la EA con la única excepción de la 
memantina (inhibidor del receptor de N-metil-D-aspartato). La farmacodinamia 
de los tratamientos vigentes basados en el sistema colinérgico se basa 
esencialmente en la inhibición de la enzima acetilcolinesterasa.  Dicha inhibición 
produce un aumento indiscriminado de los niveles de acetilcolina en el sistema 
nervioso central. Este incremento compensa la pérdida de neuronas colinérgicas 
que se produce como resultado del proceso neurodegenerativo. En las dos 
últimas décadas se han realizado grandes esfuerzos con el objetivo de alcanzar 
una estimulación más precisa y específica del sistema colinérgico mediante 
ligandos sintéticos, especialmente de los receptores nicotínicos. Este trabajo 
inacabado requiere de nuevas herramientas farmacológicas tanto para alcanzar 
un mayor conocimiento del sistema colinérgico, como para explorar su potencial 
terapéutico. 
 La melatonina es una neurohormona secretada por la glándula pineal en 
ausencia de luz cuyo rol principal en el organismo es el control de los ciclos 
circadianos. Estudios recientes atribuyen a esta fascinante molécula muchas otras 
funciones fisiológicas. La melatonina modula el sistema inmune, protege a la 
mitocondria frente al daño oxidativo, actúa como agente neuroprotector y 
curiosamente también contribuye al desarrollo de los receptores nicotínicos. 
Experimentos realizados con ratones tratados con melatonina de forma crónica 
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demostraron que, si bien no se consiguió aumentar la esperanza de vida de los 
individuos, los animales tratados disfrutaron de un proceso de envejecimiento en 
mejores condiciones de salud, incluyendo mejores resultados en pruebas 
cognitivas. Más allá de las propiedades neuroprotectoras de la melatonina, en los 
últimos años, la melatonina también ha demostrado su capacidad de estimular la 
neurogénesis en roedores. Teniendo en cuenta la muerte neuronal que se produce 
como consecuencia de los procesos neurodegenerativos, esta capacidad puede ser 
de especial interés en el campo de la medicina regenerativa aplicada a este tipo de 
demencias. 
 
Objetivos  
 En esta tesis se ha propuesto el desarrollo de nuevos ligandos para los 
sistemas melatonérgico y colinérgico. Para este propósito se han aplicado de 
forma sistemática dos aproximaciones tradicionales en el diseño basado en el 
ligando: bioisosterismo y restricción conformacional. Los compuestos así 
diseñados fueron sintetizados, y sus estructuras y farmacología caracterizadas. 
Algunos compuestos fueron seleccionados para el estudio en diferentes ensayos 
biológicos de su potencial como herramientas terapéuticas.  
Resultados 
 El grupo N-acetilo de la melatonina fue reemplazado por diferentes 
heterociclos azólicos y retro-amidas siguiendo los principios del bioisosterismo. 
Se puso a punto un método sintético que permitió la generación de una gran 
variedad de análogos azólicos de forma eficiente. Compuestos que una vez 
sintetizados fueron caracterizados de forma inequívoca, especialmente en el caso 
de aquellos susceptibles de existir en un equilibrio tautomérico. Se determinó que 
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solo uno de los posibles tautómeros estaba presente en disolución en DMSO. La 
naturaleza acídica de algunos compuestos azólicos se confirmó de forma indirecta 
en un ensayo de solubilidad a diferentes pH. La capacidad de dichos análogos 
para sustituir como bioisósteros a la melatonina se evaluó en ensayos funcionales 
y de desplazamiento de radioligando en receptores melatonérgicos. Los 
resultados obtenidos revelan que las retroamidas y azoles preparados en este 
trabajo pueden ser parcialmente reconocidos por los receptores MT1 y MT2  de 
forma análoga al grupo N-acetilo de la melatonina. Dichos resultados se 
racionalizaron basándose en la capacidad de los compuestos activos para ser 
superpuestos sobre la conformación bioactiva de la melatonina (capítulo 1). 
 Algunos análogos de melatonina seleccionados demostraron su capacidad 
para promover la expresión de marcadores neurogénicos en neuroesferas 
cultivadas de precursores neurales de cerebro de rata. Se determinó su habilidad 
para permear a través de la barrera hematoencefálica por difusión pasiva in vitro. 
El antagonista de melatonina luzindol bloqueó de forma efectiva el efecto 
neurogénico de los compuestos más potentes in vitro; y en el caso del compuesto 
1.21 los resultados de neurogénesis fueron confirmados in vivo (capítulo 2). 
 La pinolina, una β-carbolina supuestamente producida por la glándula 
pineal, se eligió como esqueleto estructural en el diseño de análogos rígidos de 
melatonina. Se sintetizó y estudió en diferentes receptores una serie de 
compuestos tricíclicos con diferentes posiciones relativas de sus grupos amida o 
amina y metoxilo. Además se llevó a cabo un análisis relacionando la estructura 
de los compuestos con su actividad antioxidante, y se estudió su potencial 
neurogénico in vitro. La fusión de las estructuras de pinolina y melatonina no 
resultó favorable para la interacción con los receptores de melatonina. Solo el 
compuesto 3.3 fue capaz de mantener una actividad significativa en los receptores 
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melatonérgicos. En el ensayo de neurogénesis, tanto la pinolina como el 
compuesto 3.3 demostraron su capacidad para promover la neurogénesis in vitro. 
En el caso del compuesto 3.3 su efecto neurogénico fue neutralizado en presencia 
de luzindol. La pinolina demostró ser capaz de promover la expresión de 
marcadores neurogénicos incluso a concentraciones en el rango nanomolar 
(capítulo 3). 
 La estructura de DMABC (3-dimetilaminobutil dimetilcarbamato), un 
agonista análogo de carbamilcolina con un interesante perfil de selectividad en 
receptores nicotínicos, fue integrada en diferentes ciclos con diversos grados de 
restricción conformacional. De las cuatro familias de compuestos que se 
prepararon, tan solo la series de cis-dimetilamnociclopropilo y 
dimetilaminopirrolidina mostraron una afinidad significativa por los receptores 
nicotínicos en los que fueron ensayados. El reemplazo del carbamato de DMABC 
por oxadiazol también mantuvo una cierta afinidad por los receptores nicotínicos, 
pero en este caso el compuesto resulto ser un antagonista. 
 
Conclusiones 
 En este trabajo se han aplicado de forma sistemática, y revalidado, dos 
estrategias de diseño basado en el ligando para la génesis de nuevos análogos de 
melatonina y DMABC. Se han caracterizado las propiedades farmacológicas de 
las entidades moleculares resultantes de la aplicación de ambas aproximaciones. 
Y más allá de las actividades descritas en sus correspondientes receptores, este 
trabajo ha proporcionado diversas estructuras susceptibles de ser empleadas 
como herramientas farmacológicas en el estudio de los mecanismos subyacentes 
en la capacidad de promoción de la neurogénesis de la melatonina. 
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